



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a safety and feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022862
Article Type:	Research
Date Submitted by the Author:	22-Mar-2018
Complete List of Authors:	Islam, Md Badrul; International Centre for Diarrhoeal Disease Research Bangladesh, LSSD Islam, Zhahirul; The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) , Laboratory Sciences and Services Division (LSSD) Rahman, Shafiqur; Uttara Adhunik Medical College, Anaesthesia and Intensive Care Endtz, Hubert; Erasmus University Medical Center, Department of Medical Microbiology and Infectious Diseases; Fondation Merieux Vos, Margreet; Erasmus MC Medical Center Rotterdam, Department of Medical Microbiology and Infectious diseases van der Jagt, Mathieu; Erasmus MC, Department of Intensive Care Van Doorn, Peter; Erasmus University Medical Center, Department of Neurology Jacobs, BC; Erasmus University Medical Center, Departments of Neurology and Immunology Mohammad, Quazi; National Institute of Neuroscience
Keywords:	Guillain-Barré syndrome, Small volume plasma exchange, Safety, Feasibility
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.	
SUPPLEMENTARY VIDEO.mp4	

SCHOLARONE™
Manuscripts

1 Title:

2 Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings:
3 a safety and feasibility study

4 Authors

5 1. Badrul Islam

6 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
7 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
8 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)

9 E-mail: badrul.islam@icddr.org
10 bislamdmch@gmail.com

11 2. Zhahirul Islam

12 Laboratory Sciences and Services Division (LSSD)
13 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

14 E-mail: zislam@icddr.org

15 3. Shafiqur Rahman

16 Department of Intensive Care Medicine, Uttara Adhunik Medical College & Hospital.

17 E-mail: drshafiqk23@yahoo.com

18 4. Hubert P. Endtz

19 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
20 Center, Rotterdam, The Netherlands, and Fondation Mérieux, Lyon, France.

21 Email: hubert.endtz@fondation-merieux.org

22 5. Margreet C. Vos

23 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
24 Center, Rotterdam, The Netherlands.

25 Email: m.vos@erasmusmc.nl

6. Mathieu van der Jagt

Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands.

Email: m.vanderjagt@erasmusmc.nl

7. Pieter A. van Doorn

Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.

E-mail: p.a.vandoorn@erasmusmc.nl

8. Bart C. Jacobs

Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.

E-mail: b.jacobs@erasmusmc.nl

9. Quazi D. Mohammad

National Institute of Neuroscience (NINS), Dhaka, Bangladesh.

E-mail: quazideenmohammad@gmail.com

Corresponding author

Badrul Islam

Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD), International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

E-mail: bislamdmch@gmail.com

Word count: 4382 (Excluding abstract, reference, table and figures)

50 **ABSTRACT**

51 **OBJECTIVE**

52 To assess the safety and feasibility of small volume plasma exchange (SVPE) as an alternative to
53 standard plasma exchange (PE) or intravenous immunoglobulin (IVIg) for Guillain-Barré
54 syndrome (GBS) patients.

55 **DESIGN**

56 Non-randomized, single arm, interventional trial.

57 **SETTING**

58 National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.

59 **PARTICIPANTS**

60 Twenty adult (>18 years) patients with GBS presented within 2 weeks of onset of weakness who
61 were unable to walk unaided for more than 10 meters.

62 **INTERVENTIONS**

63 SVPE involves blood cell sedimentation in a blood bag and removal of supernatant plasma after
64 blood cells are re-transfused. This procedure was repeated three to six times a day, for eight
65 consecutive days.

66 **OUTCOME MEASURES**

67 Serious adverse events (SAE) were defined as severe sepsis and deep venous thrombosis related
68 to the central vein catheter (CVC) used during SVPE. SVPE was considered safe if less than 5/20
69 patients experienced a SAE, and feasible if 8 L plasma could be removed within 8 days in at least
70 15/20 patients.

71 **RESULTS**

72 Median patient age 33 years (IQR 23-46; range 18-55); 13 (65%) were male. Median MRC sum
73 score was 20 (IQR 0-29; range 0-36); three (15%) patients required mechanical ventilation. One
74 patient developed SAE (severe sepsis, possibly related to CVC). Minor adverse effects were

transient hypotension in 10 (50%) patients; CVC-associated bleeding in 10 (50%); transfusion reaction to fresh frozen plasma in 4 (20%); and hypo-albuminemia, anaemia or electrolyte imbalance in 4 (20%). Removal of 8 L plasma was possible in 15 (75%) patients. GBS disability score improved by at least one grade in 14 (70%) patients four weeks after SVPE started. No patients died.

CONCLUSION

SVPE seems a safe and feasible alternative treatment to standard PE or IVIg for GBS; further studies of clinical efficacy in low-resource developing countries are warranted.

TRIAL REGISTRATION

Clinicaltrials.gov NCT02780570 on May 23, 2016

94 **Strength and limitations of the study:**

95

- 96 1. The strength of this study underlies the novel and simple technique of SVPE, which is
- 97 much less expensive than conventional immunotherapies (plasma exchange and
- 98 intravenous immunoglobulin)
- 99 2. SVPE is corroborated as safe and feasible for the first time in a prospective and
- 100 standardized cohort of patients with Guillain-Barré syndrome (GBS).
- 101 3. The intrinsic limitations of this study are its non-randomized, single arm nature, which is
- 102 conducted in a single center with a limited sample size of GBS patients.
- 103 4. Clinical efficacy of SVPE on patients with GBS was a secondary end-point assessment
- 104 and therefore deserves a randomized controlled trial in future to assess the clinical
- 105 efficacy of SVPE for the patients with GBS.

106

107 Introduction

108 Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a
109 yearly incidence of 1.2 to 2.3 cases per 100,000 per year¹. GBS is characterized by rapidly
110 progressive limb weakness and, in a proportion of cases, respiratory failure (25%) or severe
111 autonomic dysfunction (10%). Plasma exchange (PE) was the first treatment proven to be
112 effective for GBS, if given within 4 weeks of the onset of weakness²⁻¹⁰. Later studies showed
113 treatment with intravenous immunoglobulin (IVIg) (0.4 g/kg per day for 5 days) has a similar
114 efficacy as PE in patients with GBS who are unable to walk, if started within 2 weeks of the onset
115 of weakness^{11, 12}.

116
117 Unfortunately, most patients in low-income countries cannot afford expensive treatment with
118 either PE or IVIg¹³. In Bangladesh, a full course of IVIg for a 60 kg adult costs approximately
119 12,000-16,000 US\$ and treatment with conventional PE for 5 days costs approximately 4,500-
120 5,000 US\$. The mean income in Bangladesh was 4 US\$ per day in 2016 (World Bank and
121 Bangladesh Bureau of Statistics 2016); IVIg and PE cost the equivalent of 3,000 and 1,250 mean
122 income days, respectively. At present, the majority (92%) of patients with GBS in Bangladesh
123 receive supportive care only¹³. In addition, mobile PE equipment is not available in Bangladesh;
124 therefore, patients admitted to the intensive care unit (ICU) cannot receive PE. We previously
125 reported the mortality rates for GBS in Bangladesh range from 12 to 14% and observed 29% of
126 patients with GBS in Bangladesh are unable to walk at 6 months after onset; these poor outcomes
127 are undoubtedly due to the low rates of specific treatment with PE or IVIg^{14, 15}.

128
129 Small volume plasma exchange (SVPE) may represent a cheap, effective alternative treatment for
130 GBS. SVPE is based on the same principle as conventional PE (selective removal of plasma) but
131 uses a novel, simple technique with much lower costs (approximately 500 US\$). The current non-

1
2
3 132 randomized trial was designed to investigate the safety and feasibility of SVPE in 20 patients
4
5 133 with GBS admitted to the National Institute of Neurosciences Hospital in Dhaka, Bangladesh.
6
7 134

8
9 135 **Methods/Design**

10
11 136 Study design

12
13 137 For this non-randomized, single arm, interventional safety and feasibility trial, 20 adult patients
14
15 138 with GBS were enrolled between March 2016 and December 2016 for SVPE at the National
16
17 139 Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh. A detailed study protocol
18
19 140 was published previously and includes definitions of all variables used in this study ¹⁶.
20
21 141

22
23 142 Four to six daily sessions of whole blood sedimentation and removal of supernatant plasma after
24
25 143 re-transfusion of the sedimented blood cells was planned for the 20 patients with GBS, with a
26
27 144 target of removing an overall volume of at least 8 litres (L) of plasma over a total of 8 days ¹⁶.
28
29 145 (See supplementary video for SVPE procedure)
30
31 146

32
33 147 Patients with GBS were monitored according to a standard protocol throughout the course of
34
35 148 SVPE until the second day after withdrawal of the central venous catheter (CVC) in order to
36
37 149 assess predefined measures of safety and feasibility and followed up for six months to assess
38
39 150 neurological outcome. The protocol was reviewed and approved by the institutional research and
40
41 151 ethics review committees at the icddr,b and registered at clinicaltrials.gov (NCT02780570) ¹⁶. All
42
43 152 patients provided written informed consent to participate in this study.
44
45 153

46
47 154 Patient and Public Involvement

48
49 155 Patients and or public were not involved either in the development of the research question, study
50
51 156 design and outcome measure or recruitment to and conduct of the study.
52
53
54
55
56
57
58
59
60

157 Inclusion and exclusion criteria for patients with GBS

158 Patients aged ≥ 18 -years-old fulfilling the diagnostic criteria for GBS of the National Institute of
159 Neurological and Communicative Disorders and Stroke (NINDS)¹⁷ were enrolled, provided they
160 were unable to walk unaided for more than 10 meters (GBS disability score ≥ 3), presented
161 within 2 weeks of the onset of weakness, and were unable to afford standard treatment with IVIg
162 or PE. Patients with concomitant severe or terminal illnesses, evidence of healthcare-associated
163 infection (HAI) on admission (except for aspiration pneumonia), a previous history of severe
164 allergic reactions to properly matched blood products, and pregnant women were excluded from
165 the study.

167 Control cohort

168 To compare the safety of SVPE in patients with GBS in the context of the background risk of
169 central line-associated blood stream infection (CLABSI) at our institution, we prospectively
170 assessed the incidence of CLABSI in a hospital control group of 24 adult patients without GBS
171 receiving neurocritical care. Hospital controls were eligible based on the following
172 characteristics: ≥ 18 -years-old, a neurological diagnosis other than GBS, and a CVC placed for $>$
173 2 and ≤ 8 calendar days after admission to the same ICU or HDU unit as the SVPE-treated
174 patients. Patients with a HAI (except aspiration pneumonia) and pregnant women were excluded
175 from the control group.

177 Primary and secondary outcome measures

178 The primary outcome measures of safety were the number of patients with GBS treated with
179 SVPE who developed either severe sepsis or septic shock due to CLABSI¹⁸ and the occurrence
180 of venous thrombosis in the limb where the CVC was placed. The primary outcome measure of
181 feasibility was the ability to remove at least 8 L of plasma over 8 days.

182 The secondary outcome measures of the safety of SVPE were the relative risk of CLABSI due to
183 SVPE (compared to CLABSI in the hospital control group without GBS), hemodynamic
184 instability during the SVPE procedure, and development of anaemia (Hb < 8 gm/dL) or any
185 catheter-related haemorrhage requiring a blood transfusion.
186 The secondary outcome measure of feasibility of SVPE was the rate of CVC occlusion during the
187 SVPE procedure. In addition, neurological outcome was assessed using the GBS disability score
188 ¹⁹, MRC sum score ²⁰, Overall Neuropathy Limitation Scale (ONLS) ²¹ and Rasch-built Overall
189 Disability Scale (R-ODS) ²² at 1st, 2nd, 3rd, and 6th months from the start of SVPE.

191 Procedure safety and documentation

192 Strict aseptic procedures were followed to prevent CLABSI ²³⁻²⁵. SVPE was documented in terms
193 of the duration and amount of plasma removed in each session, and the type and volume of
194 replacement fluid and fresh frozen plasma (FFP) used. Throughout the procedure, the
195 haemodynamic, haematological, biochemical, coagulation and infection profiles of the SVPE-
196 treated patients were monitored according to the protocol ¹⁶. Screening for hepatitis B and C
197 viruses, human immunodeficiency virus (HIV) and syphilis were performed as patient baseline
198 assessments, and also on donor FFP before administration. CLABSI, primary and secondary
199 bloodstream infections ¹⁸, catheter-associated urinary tract infection (CAUTI) ²⁶, ventilator-
200 associated pneumonia (VAP) ²⁷ and other HAI ^{28, 29} were documented in the SVPE-treated
201 patients with GBS and the hospital control group.

203 Sample size

204 This safety and feasibility study enrolled 20 patients with GBS for SVPE. We could not
205 perform a formal power calculation for this safety and feasibility study. The sample size
206 was based on previous pilot studies conducted in GBS ^{30, 31}. The baseline rate of CLABSI

was measured in the hospital control group of 24 patients without GBS admitted to the same study facility who required a CVC for at least 8 days during the study period.

Stopping rules for the trial based on safety and feasibility

Decision to stop the SVPE trial was designated using a Bayesian approach³²⁻³⁴.

Accordingly, a predictive success rate of 75% was predefined for the SVPE procedure. If more than 5 of 20 patients experienced an SAE, or if it appeared impossible to remove at least 8 L of plasma over 8 days in at least 15 of 20 patients, the procedure was considered unsafe or unfeasible.

Statistical analysis

The rate of HAIs (CLABSI, VAP and CAUTI) per 1000 device days were calculated by dividing the number of each HAI during the study period by the number of device days and multiplying the result by 1000. The infection safety profile for SVPE was assessed by calculating the standardized infection ratio to define the risk of HAIs in patients with GBS treated with SVPE. The standardised infection ratio (SIR) was calculated by dividing the number of observed HAI by the number of HAI predicted (i.e., the infection rate in the control group). The predicted HAI rate was calculated using the rates of HAI in the hospital control group of patients without GBS during the study period. Percentage values were compared using the Chi-square test or Fisher's exact test (two-tailed) and median values, the Mann-Whitney U-test using SPSS 22 software (IBM SPSS Statistics for Windows Version 22.0., IBM Corp., Armonk, NY, USA). Analyses were performed on an intention-to treat basis. All *P*-values reported are two-sided; $p < 0.05$ was considered significant.

231 **Results**

232 *Patients and hospital controls*

233 The demographic and clinical characteristics of the 20 patients with GBS are given in Table 1.

234 The median age of the patients with GBS was 33 years (range; 18-55); median body weight was

235 60 kg (IQR, 55-65 kg; range, 50-72 kg) and 13 (65%) patients were male (Fig. 1). On admission

236 and before the start of SVPE, all 20 patients with GBS were unable to walk independently (GBS

237 disability score, 4). One patient required mechanical ventilation from the second day after the

238 onset of weakness; SVPE was started on the fourth day of mechanical ventilation (patient 9, Fig.

239 1). Two of the 19 patients who did not require mechanical ventilation at the start of the study

240 required mechanical ventilation on the second day after initiation of SVPE (patients 11 and 19,

241 11 and 2 days after the onset of weakness, respectively; Fig. 1). The median MRC sum score for

242 the limb muscles in all 20 patients was 20 (IQR: 0-29; range: 0-36; Fig. 1). Symptoms of a

243 preceding infection in the 4 weeks before the onset of weakness were present in 18 (90%)

244 patients with GBS, of whom 10 (50%) had diarrhoea. Median duration from admission to start of

245 SVPE was two days (IQR, 2-3 days; range, 0-7 days). Median duration to nadir from the onset of

246 weakness was five days (range, 1-13 days). Electrodiagnostic nerve conduction studies indicated

247 15 (75%) patients had an axonal subtype and 5 (25%) patients had a demyelinating subtype of

248 GBS. Median duration from onset of weakness to NCS examination was 10 days (range, 4-16

249 days). All patients had albuminocytologic dissociation; median CSF protein was 166 mg/dL

250 (range 117-253 mg/dL). Median duration from onset of weakness to CSF examination was 11

251 days (range, 4-17 days).

252

253 Median age of the 24 hospital control patients without GBS was 44 years (IQR, 25-57; range; 18-

254 74); 10 (42%) were male. Age and gender distribution were not significantly different compared

255 to the 20 patients with GBS ($p = 0.2155$, $p = 0.1434$, respectively). The diagnoses for these 24

patients were: brain tumour ($n = 5$), transverse myelitis ($n = 5$), head trauma after road traffic accident ($n = 3$), viral meningoencephalitis ($n = 2$), myasthenia gravis ($n = 2$), compressive cervical myelopathy ($n = 2$), cerebrovascular accident ($n = 2$), motor neuron disease ($n = 1$), electrolyte imbalance ($n = 1$) and status epilepticus ($n = 1$).

Primary endpoints

One patient with GBS treated with SVPE developed severe sepsis, possibly due to SVPE-related CLABSI (SVPE window-period blood culture revealed methicillin-resistant *Staphylococcus aureus*). This patient required intravenous fluid, noradrenalin infusion and intravenous antibiotics, but eventually improved (patient 11, Fig. 1). This patient also had signs and symptoms suggestive of aspiration pneumonia and VAP; *Streptococcus spp.* was isolated from pulmonary aspirates. Further laboratory results revealed dys-electrolytemia, anaemia and hypoalbuminemia. No patients experienced deep vein thrombosis due to the CVC for SVPE. Fifteen (75%) of the 20 patients met the primary endpoint of feasibility, defined as the ability to remove at least 8 L of plasma in eight days. The median volume of plasma removed was 8.5 L (IQR, 7.9-8.8 L; range, 6.3-9.6 L; Fig. 1). The median plasma exchange rate was 140 mL/kg bodyweight (IQR, 125-155 mL/kg; range, 110-175 mL/kg) over 8 days and 16 (80%) patients had a plasma exchange rate > 120 mL/kg (Table 2).

Secondary endpoints

Infections among SVPE-treated patients with GBS and hospital controls

Among the 20 patients with GBS treated with SVPE, six (30%) had fever during SVPE (Fig. 1, Supplementary Figure 1), including 2 (10%) patients with leucocytosis who were diagnosed with HAI (VAP and CAUTI in one patient; VAP in one patient). In three out of four (20%) patients with fever without leucocytosis, fever subsided within two to three days without antimicrobial

therapy (Fig. 1). The remaining patient with pyrexia without leucocytosis had microbiological evidence of both CLABSI and VAP (patient 11, Fig. 1). In all other 14 patients with GBS, no fever was documented during the course of SVPE until the tenth day of SVPE (second day after removal of the CVC for SVPE). Five of these 14 patients had leucocytosis, but no site-specific HAI could be detected. However, one of the nine patients without fever but leucocytosis fulfilled the criteria for CAUTI (patient 12, Fig. 1). All three patients who required mechanical ventilation subsequently developed VAP; two of the 13 patients who required a urinary catheter developed a CAUTI (patient 11, Fig. 1). No patients died during the 6 months follow-up.

All 24-hospital control patients without GBS required mechanical ventilation and an indwelling urinary catheter. Of these patients, 22 (92%) patients had fever, of whom 15 (63%) had leucocytosis; a diagnosis of a specific HAI could be made 14 of these 15 patients (CLABSI in two, CAUTI in one, VAP in 11) and four (17%) fulfilled the criteria for severe sepsis (Supplementary Figure 1). Seven (29%) of the 24 hospital control patients had fever without leucocytosis. In two of these seven patients, a specific HAI was diagnosed (CAUTI and VAP in one, and VAP in one). In two hospital control patients, no fever was documented until day 10 after first placement of the CVC, but leucocytosis was present and no site-specific HAI could be detected (Supplementary Figure 1).

The rates of CLABSI, CAUTI and VAP per 1000 device days in the SVPE-treated patients with GBS were 6.25, 19.2 and 40 compared to 10.4, 10.4 and 67.7 for the hospital control patients without GBS, respectively. The relative risks of CLABSI, CAUTI and VAP associated with SVPE were 0.6, 1.2 and 1.8, respectively, compared to hospital control patients. The rates of CLABSI, CAUTI and VAP were comparable between SVPE-treated patients with GBS and hospital control patients ($p > 0.05$). Antimicrobial agents were used more frequently in the

hospital control patients ($p < 0.0001$; Fig. 2). The standardised infection ratios for CLABSI, CAUTI and VAP for SVPE-treated patients with GBS were 0.6, 1.8 and 1.9, respectively.

Other secondary endpoints

Ten (50%) of the 20 patients treated with SVPE experienced transient hypotension during SVPE, which was corrected by infusion of 200-300 mL crystalloid saline (Fig. 1). Minor bleeding through the CVC insertion site (excluding at the time of insertion) was observed in 10/20 patients (50%; Fig. 1); these bleeds required a pressure pack. Reduction of the anticoagulant dose along with a pressure pack was required in 3/20 patients, who all had a prolonged prothrombin time (PT). Three patients had single episode of haemorrhage through the urinary catheter: one was diagnosed with a CAUTI with normal coagulation profile, one had a prolonged PT, the other had sterile haematuria with normal PT. Overall, PT and activated partial thromboplastin time (aPTT) were prolonged in 4/20 patients and only PT was prolonged in 2/20 patients. Clotting time and bleeding time were not prolonged in any patient. One patient developed anaemia (haemoglobin, 8 gm/L) at the end of SVPE; this patient also had severe sepsis and required one unit of blood transfusion (patient 11, Fig. 1). CVC blockages were not observed in any SVPE-treated patients with GBS. One patient with increased clotting tendency who required an increased dose of low molecular weight heparin had shortened clotting time (CT) ($< 50\%$ of upper limit of normal), though PT was normal (patient 10, Fig. 1).

The neurological outcomes of the SVPE-treated patients with GBS at six months in terms of neurological scores are given in Table 3. Median time to recover the ability to walk unaided was 4 weeks (Fig. 3). Fourteen (70%) of the 20 patients had an improvement in GBS disability score of one or more grades at four weeks after the onset of SVPE. At one month, 12 patients (60%) were able to walk unaided, two patients (10%) were able to walk aided and six (30%) patients

331 were bedbound, of whom three still required mechanical ventilation. At three months, 14 (70%)
332 patients were able to walk unaided, one (5%) could walk with aid and five (25%) patients were
333 bedbound. At six months, 14 (70%) patients were able to walk unaided, three (5%) could walk
334 with aid and three (15%) remained bedbound (Table 3).

335
336 *Other relevant clinical and laboratory findings*

337 Allergic/transfusion reaction to FFP was observed in four patients with GBS treated with SVPE
338 (Fig. 1). These transfusion reactions presented as an itchy erythematous skin rash (three patients),
339 fever (two patients), hypotension (one patient) following transfusion of FFP; all of these reactions
340 were managed with oral antihistamine (and intravenous saline in one patient) without further
341 complications.

342
343 The other documented haematological and biochemical abnormalities were hypo-albuminemia (n
344 = 4), thrombocytopenia ($n = 6$), hyponatraemia ($n = 1$), hypokalaemia ($n = 3$), hypomagnesaemia
345 ($n = 1$), hypocalcaemia ($n = 3$); (Table 2).

346

347

Discussion

Principal findings

This study suggests SVPE may represent a safe and feasible alternative to conventional plasma exchange for patients with severe GBS in limited-resource settings. Of the 20 patients in this study, one (5%) experienced a SAE (severe sepsis due to probable CLABSI). The rate of SAE was not significantly higher than the hospital control group without GBS with a CVC, and no patients had a CVC-related thromboembolic event in patients with SVPE. We were able to remove the prespecified target volume (8 L) of plasma as the target primary endpoint of feasibility in 15/20 (75%) patients with GBS. Median plasma exchange volume and rate during SVPE were 8.4 L and 140 mL/kg, respectively. Minor adverse effects included transient hypotension during SVPE in 50% (10/20), minor haemorrhage from CVC insertion site in 50% (10/20), transfusion reaction to fresh frozen plasma in 20% (4/20), and hypo-albuminemia, anaemia and electrolyte imbalance in 20% (4/20) of patients. An improvement of at least one grade on the GBS disability score was observed for 14/20 (70%) patients at four weeks after the initiation of SVPE. No patients died.

Comparison with baseline hospital control patients and standard PE

With respect to HAIs, no significant differences were observed in the frequency of CLABSI, severe sepsis, VAP or CAUTI between the SVPE-treated patients with GBS and 24 hospital control patients without GBS treated using a CVC in the same ICU or HDU (Fig. 2). However, antimicrobial agents were used more frequently, usually prophylactically, in the hospital control patients compared to the patients with GBS treated with SVPE ($p < 0.0001$; Fig. 2). The probability of detecting microorganisms in clinical infections may have been reduced due to overzealous use of antibiotics in the hospital control patients. Early trials of PE in patients with GBS showed 34% of patients develop severe infections^{7, 35}. Subsequently, another large trial

documented septicaemia in 19% of patients⁵. However, the rates of CLABSI were not reported.

The volume exchanged during SVPE is within the range recommended in the protocol for standard PE [120-200 mL/kg (standard PE) vs. 140 mL/kg for SVPE]⁷. Exchange of 6 L of plasma in adult patients is clinically beneficial, but less effective than exchange of 12 L; exchanging 18 L provides no added benefit⁵. This suggests that the correlation between clinical benefit and the volume of plasma removed is not linear and exchanging more than 6 L of plasma is likely to have a beneficial effect. We were able to remove >120 mL/kg plasma in 80% of patients, which should provide a therapeutic effect³⁶. Notably, the body weight of our patients may be lower than that of patients in western countries. In addition, SVPE was complete within 8 days, shorter than the usual time required for a full session of PE (10 to 12 days).

Important observations in terms of secondary endpoints were transient hypotension, transfusion reaction to FFP and minor bleeding through the CVC insertion site. Hypotension is a common complication during traditional PE that affects nearly half of patients⁵. Spells of hypotension during SVPE were more frequent during the three to four days after initiation of SVPE, and could be easily corrected by rapid infusion of 300-400 mL saline (Fig. 1). The hypotension could possibly be explained by hypovolemia due to drawing blood or as a result of the compromised autonomic nervous system in patients with GBS. As SVPE proceeded, hypotensive spells were encountered less frequently despite drawing the same volume of blood, which may in part be explained by adaptation of the vasomotor system or recovery from autonomic dysfunction. Minor bleeding through the CVC insertion site occurred in 50% of patients and could be controlled by applying a simple pressure pack over the CVC insertion site in most cases; mild prolonged PT was noted in 30% (3/10) patients. However, spontaneous bleeding usually occurs if the PT is more than 2.5 times prolonged and PC is < 0.50 lac/ μ L³⁷. Movement of the limb where the CVC was placed may have caused traction on the CVC and contributed to local bleeding in the other

seven patients. Haematuria is not uncommon in patients with a UTI, as may have occurred in one SVPE treated patient; traumatic traction of the urinary catheter may cause haematuria in two other catheterized SVPE-treated patient taking oral aspirin, who had haematuria and sterile urine. We also monitored the major organ function and biochemical status of the patients treated with SVPE. No patients experienced hepatic or renal impairment. One patient developed anaemia and hypoalbuminemia; this patient had severe sepsis, a common cause of anaemia and hypoalbuminemia in critically ill patients admitted to an ICU (patient 11, Fig. 1). Electrolyte imbalances were detected in 15% of the SVPE-treated patients with GBS, and were mild, subclinical and easily corrected.

The median reported durations to recovery of independent walking in patients with GBS in large-scale RCTs after PE are 53, 52 and 70 days^{4, 5, 7}; compared to 30 days in our patients treated with SVPE. Moreover, 60% of the patients with GBS treated with SVPE were able to walk independently at four weeks, whereas 20% of patients with GBS acquired independent walking ability at four weeks after traditional PE³⁵. However, these differences may possibly may be due to the small sample size and variations in demographic and neurophysiological characteristics between cohorts. Finally, SVPE was completed in all 20 patients and no patients died.

Limitations of SVPE

SVPE is a time-consuming and labour-intensive procedure, which is a limitation. We used multiple thin-lumen tubing systems interconnected with a multichannel connector device, which may increase the chance of blood coagulating within the tubing system. Coagulation may require manipulation or replacement of the tubing to ensure free flow of blood and saline. Such handling could increase the chance of microbial contamination. A single continuous wide-lumen tubing system (SVPE kit) could resolve this problem. Most importantly, personnel conducting the SVPE

423 procedure should maintain proper aseptic technique, which can sometimes be challenging in
424 developing countries. Furthermore, other adaptations such as provision of a larger blood bag or
425 increasing the number of days for SVPE could be considered to increase the plasma exchange
426 rate.

427
428 *Clinical implications and future research*

429 Despite the limitations, our study showed SVPE is a safe and feasible treatment for GBS in a
430 resource-limited setting where IVIg or PE are either unavailable or unaffordable. Specifically, the
431 poorest 20% of the world's population (1.8 billion people) who typically earn less than 10 US\$
432 per day and who are not covered by a national health insurance system may benefit. Considering
433 the incidence of GBS is 2/100,000 in developing countries, approximately 40,000 patients could
434 potentially benefit from SVPE every year, worldwide. In the future, a multicentre RCT is
435 required to assess the clinical efficacy of SVPE for patients with GBS. If proven effective, SVPE
436 could be an affordable and easily available alternative plasma exchange technique in low-income
437 countries for patients with GBS and other disorders, who at present cannot afford standard PE
438 due to its high cost and unavailability.

439

Declarations

Acknowledgements: This research activity was funded by GBS/CIDP Foundation International, USA and Fondation Mérieux, Lyon, France. The icddr,b acknowledges with gratitude the contributions of the Government of Bangladesh, Global Affairs Canada (GAC), Swedish International Development Cooperation Agency (Sida), and Department for International Development, UK (DFID). Md Ekhlas Mia and Smrity Akhter assisted this study in a full-time capacity. We are grateful to all of the neurologists from the NINS who referred their patients to us and K. S. Fahim for his support in preparation of the diagrams in this article.

Authors' contributions: BI, PVD, BJ, QDM, ZI, and HPE conceived the study design and sample size of the study. MV, MVJ, SR, and HPE contributed to the infection safety guidelines in the study design. BI and QDM conducted the study and BI collected and analysed the data and drafted the manuscript. All authors have critically revised the manuscript and have read and approved the final manuscript.

Funding: This study was funded by two competitive research grants:

1. The GBS/CIDP Foundation International GBS grant (major contribution)
2. The Fondation Mérieux: Small Grants Program 2014 (partial contribution)

Role of the funding source: The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

1
2
3 463 Competing interests: No investigators have any competing financial, professional or personal
4
5 464 interests that may have influenced the findings described in this manuscript to disclose.
6
7 465
8
9 466 Ethics approval and consent to participate: The Institutional Review Board (IRB) of the icddr,b,
10
11 467 comprised of an Ethical Review Committee (ERC) and Research Review Committee (RRC),
12
13 468 reviewed and approved this study protocol on 09/12/2015 (reference number: PR-15086, version
14
15 469 no 3).
16
17
18 470
19
20 471 Data sharing: The dataset is available from the lead author on request.
21
22 472
23
24 473 Transparency: The corresponding author affirms that the manuscript is an honest, accurate and
25
26 474 transparent account of the study being reported; that no important aspects of the study have been
27
28 475 omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have
29
30 476 been explained.
31
32
33 477

References

1. Willison HJ, Jacobs BC, and van Doorn PA. Guillain-Barre syndrome. *Lancet* 2016;388(10045):717-27
2. Van Koningsveld R, Van Doorn PA, Schmitz PI et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. *Neurology* 2000;54(3):620-5
3. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. *Medicine* 1969;48:173-215
4. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. *Ann Neurol* 1987;22(6):753-61
5. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. *Ann Neurol* 1997;41(3):298-306
6. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Plasma exchange in Guillain-Barre syndrome: one-year follow-up. *Ann Neurol* 1992;32(1):94-7
7. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. *Neurology* 1985; 35(8):1096-104
8. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. *Lancet* 1984;1(8382):877-9

1
2
3 501 9. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma
4 502 exchange in acute inflammatory polyradiculoneuropathy. *Lancet*
5 503 1984;2(8415):1296-9
6
7
8
9 504 10. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for
10 505 Guillain-Barre syndrome. *Cochrane Database Syst Rev* 2014:Cd002063
11
12
13 506 11. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter:
14 507 immunotherapy for Guillain-Barre syndrome: report of the Quality
15 508 Standards Subcommittee of the American Academy of Neurology.
16 509 *Neurology* 2003; 61(6):736-40
17
18
19
20 510 12. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous
21 511 immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch
22 512 Guillain-Barre Study Group. *N Engl J Med* 1992; 326(17):1123-9
23
24
25
26
27
28 513 13. Islam MB, Islam Z, Farzana KS, et al. Guillain-Barre syndrome in
29 514 Bangladesh: validation of Brighton criteria. *J Peripher Nerv Syst* 2016;
30 515 21(4):345-351
31
32
33
34
35 516 14. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre
36 517 syndrome associated with *Campylobacter* infection in Bangladesh.
37 518 *Neurology* 2010; 74(7):581-7
38
39
40
41 519 15. Ishaque T, Islam MB, Ara G, et al. High mortality from Guillain-Barre
42 520 syndrome in Bangladesh. *J Peripher Nerv Syst* 2017;22(2):121-126
43
44
45
46 521 16. Islam MB, Islam Z, Rahman S, et al. Small volume plasma exchange for
47 522 Guillain-Barre syndrome in resource poor settings: a safety and feasibility
48 523 study. *Pilot Feasibility Stud* 2017;3:40
49
50
51
52 524 17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for
53 525 Guillain-Barre syndrome. *Ann Neurol* 1990;27 Suppl:S21-4
54
55
56
57
58
59
60

- 1
2
3 526 18. Centers for Disease Control and Prevention. Bloodstream Infection Event
4
5 527 (Central Line-Associated Bloodstream Infection and Non-central Line
6
7 528 Associated Bloodstream Infection) 2018;
8
9 529 [https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf]
10
11 530 Accessed 26 Feb 2018
12
13 531 19. Hughes RA, Newsom-Davis JM, Perkin GD et al. Controlled trial
14
15 532 prednisolone in acute polyneuropathy. *Lancet* 1978;2(8093):750-3
16
17 533 20. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in
18
19 534 the assessment of muscle strength and functional abilities in Guillain-Barre
20
21 535 syndrome. *Muscle Nerve* 1991;14(11):1103-9
22
23 536 21. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the
24
25 537 Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry*
26
27 538 2006;77(8):973-6
28
29 539 22. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall
30
31 540 Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
32
33 541 *Neurology* 2011;76(4):337-45
34
35 542 23. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in
36
37 543 catheter related bloodstream infections in Michigan intensive care units:
38
39 544 observational study. *Bmj* 2010;340:c309
40
41 545 24. Flodgren G, Conterno LO, Mayhew A et al. Interventions to improve
42
43 546 professional adherence to guidelines for prevention of device-related
44
45 547 infections. *Cochrane Database Syst Rev* 2013;3:Cd006559
46
47 548 25. O'Grady NP, Alexander M, Burns LA, et al. Summary of
48
49 549 recommendations: Guidelines for the Prevention of Intravascular Catheter-
50
51 550 related Infections. *Clin Infect Dis* 2011;52(9):1087-99.
52
53
54
55
56
57
58
59
60

551 26. Centers for Disease Control & Prevention. Urinary Tract Infection
552 (Catheter-Associated Urinary Tract Infection
553 [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and
554 Other Urinary System Infection [USI]) Events. 2018;
555 [<https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf>]
556 Accessed 26 Feb 2018.

557 27. Centers for Disease Control & Prevention. Pneumonia (Ventilator-
558 associated [VAP] and non-ventilator-associated
559 Pneumonia [PNEU]) Event. 2018;
560 [<https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf>] Accessed
561 26 Feb 2018.

562 28. Centers for Disease Control & Prevention. Identifying Healthcare-
563 associated Infections (HAI) for NHSN Surveillance. 2018;
564 [https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsncurrent.pdf] Accessed 26 Feb 2018.

566 29. Centers for Disease Control & Prevention. CDC/NHSN Surveillance
567 Definitions for Specific Types of Infections. 2018;
568 [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf]
569 Accessed 26 Feb 2018.

570 30. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre
571 syndrome with high-dose immune globulins combined with
572 methylprednisolone: a pilot study. *Ann Neurol* 1994;35(6):749-52.

573 31. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of
574 Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. *J*
575 *Neurol Neurosurg Psychiatry* 2007;78(9):1012-3.

- 1
2
3 576 32. Stigler SM. The True Title of Bayes's Essay. *Statistical Science*
4
5 577 2013;28(3):283-288.
6
7 578 33. Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of
8
9 579 Bayesian clinical trials monitoring. *Stat Med* 1994;13(13-14):1371-
10
11 580 83;discussion 1385-9.
12
13 581 34. Resnic FS, Zou KH, Do DV et al. Exploration of a bayesian updating
14
15 582 methodology to monitor the safety of interventional cardiovascular
16
17 583 procedures. *Med Decis Making* 2004; 24(4):399-407.
18
19
20 584 35. Chevret S, Hughes Richard AC, Annane D. Plasma exchange for Guillain-
21
22 585 BarrÈ syndrome. *Cochrane Database of Systematic Reviews*
23
24 586 2017;DOI:10.1002/14651858.CD001798.pub3.
25
26 587 36. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS,
27
28 588 Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of
29
30 589 prognostic factors and the effect of plasmapheresis. *Ann Neurol*
31
32 590 1988;23(4):347-53.
33
34
35 591 37. Izak M, Bussel JB. Management of thrombocytopenia. *F1000Prime Rep*
36
37 592 2014;6:45.
38
39
40 593
41
42 594

Table 1: Demographic and clinical characteristics of the 20 patients with GBS included in this small volume plasma exchange (SVPE) study at entry

Characteristic	Value
Demography	
Sex [males: females (ratio)]	13:7 (1.85)
Age (years) ¶	33 (18 - 55)
Body weight (kg) ¶	60 (50 - 72)
Antecedent events ‡ (total)	18 (90%)
Diarrhoea	10 (50%)
Respiratory infection	5 (25%)
Fever	3 (15%)
Days from antecedent events to weakness ¶	7 (3 - 30)
Days between onset of weakness to admission ¶	7 (2-12)
Neurological deficits at entry	
Weakness in arms and legs	20 (100%)
Cranial nerve deficits	12 (60%)
Decreased deep tendon reflexes	20 (100%)
Sensory involvement	5 (25%)
GBS disability score §	4
	19 (95%)
	5
	1 (5 %)
Severity of weakness (MRC sum-score) ¶	20 (0-29)
Autonomic dysfunction	11 (55%)

¶ Median (range); † increased protein level (> 45 mg/dL) in combination with CSF cell count < 50/µL; CSF = cerebrospinal fluid; NCS = nerve conduction study; ‡ symptoms of an infection in the four weeks preceding the onset of weakness; § GBS disability score (0 - 6) = 0: healthy state; 1: minor symptoms and capable of running; 2: able to walk 10 meters or more without assistance but unable to run; 3: able to walk 10 meters across an open space with help; 4: bedridden or chair-bound; 5: requiring assisted ventilation for at least part of the day; 6: dead.

Table 2: Treatment characteristics and complications associated with SVPE in the 20 patients with GBS

Characteristic/complication	Value
Treatment characteristics	
Number of sessions of SVPE per patient [¶]	30 (24 - 42)
Volume of plasma removed per patient [¶]	8.4 (6.3 – 9.6)
Plasma exchange rate (mL/kg) [¶]	140 (110-175)
Time between hospital admission and SVPE (days) [¶]	8 (5-10)
Time between onset of weakness and start of SVPE (days) [¶]	8 (5-10)
Need to stop SVPE due to poor hemodynamic tolerance	0/20 (0%)
Need for blood transfusion for anaemia	1/20 (5%)
Reduction of anticoagulant drug dose for bleeding	3/20 (15%)
Temporary withdrawal of antiplatelet drug for bleeding	4/20 (20%)
Increased anticoagulant drug dose to continue SVPE	1/20 (5%)
CVC blockade/replacement	0/20 (0%)
Complications during SVPE	
<i>Infection</i>	
Leukocytosis	7/20 (35%)
CLABSI [§]	6.25
VAP [§]	136.4
CAUTI [§]	40
Severe sepsis	1/20 (5%)
Antimicrobial agents used	6/20 (30%)
<i>Bleeding and coagulation</i>	
Bleeding from CVC insertion site	10/20 (50%)
Bleeding from mucosal area	3/20 (15%)
Prolonged BT (BT > 10 min)	0/20 (0%)
Prolonged CT (CT > 15 min)	0/20 (0%)
Prolonged PT (PT > 14 sec) [¶]	6/20 (30%) [15-19 sec]

Prolonged aPTT (aPTT > 40 sec) ¶	3/20 (15%) [51-240 sec]
<i>Other complications</i>	
Saline responsive hypotension	10/20 (50%)
Anaemia (Hb < 8 gm/L)	2/20 (10%)
Thrombocytopenia (PC < 1.5 lac/µL) ¶	6/20 (30%) [0.79-1.3 lac/µL]
Jaundice (serum bilirubin > 1.2 mg/dL)	0/20 (0%)
Renal impairment (serum creatinin > 1.2 mg/dL)	0/20 (0%)
Hyponatraemia (serum Na ⁺ < 135 mEq/L)	1/20 (5%) [126 mEq/L]
Hypokalaemia (serum K ⁺ < 3.5 mEq/L) ¶	3/20 (15%) [2.6-3.2 mEq/L]
Hypoalbuminemia (serum albumin > 35 gm/L) ¶	4/20 (20%) [26-32 gm/L]
Hypocalcaemia (serum Ca ⁺ < 2.2 mmol/L) ¶	3/20 (15%) [1.89-1.98 mmol/L]
Hypomagnesaemia (serum Mg ⁺ < 75 mEq/L) ¶	1/20 (5%) [73 mEq/L]
Hypersensitivity/transfusion reaction to FFP	4/20 (20%)

606

607 ¶ Median (range); § rate per 1000 device days; CLABSI: central line-associated bloodstream
608 infection; VAP: ventilator-associated pneumonia; CAUTI: catheter-associated urinary tract
609 infection; CVC: central venous catheter; BT: bleeding time, CT: clotting time; PT: prothrombin
610 time; APTT: activated partial thromboplastin time; FFP: fresh frozen plasma.

611

Table 3: Neurological outcomes of the 20 patients with GBS after SVPE

Clinical outcome	1 month	2 months	3 months	6 months
Cranial nerve involvement	7/20 (35%)	6/20 (30%)	4/20 (20%)	2/20 (10%)
Autonomic involvement	3/20 (15%)	3/20 (15%)	0/20 (0%)	0/20 (0%)
Sensory dysfunction	1/20 (5%)	1/20 (5%)	1/20 (5%)	1/20 (5%)
GBS disability score [¶]	0 = 0	0 = 1	0 = 1	0 = 2
	1 = 3	1 = 6	1 = 7	1 = 7
	2 = 9	2 = 6	2 = 6	2 = 5
	3 = 2	3 = 1	3 = 1	3 = 3
	4 = 3	4 = 5	4 = 5	4 = 3
	5 = 3	5 = 1	5 = 0	5 = 0
MRC sum score [†] *	47 (0-60)	49 (0-60)	53 (6-60)	58 (22-60)
ONLS [‡] *	4 (1-12)	3 (0-12)	3 (0-12)	2 (0-10)
R-ODS [§] *	26 (0-41)	33 (0-45)	37 (0-45)	38 (0-46)

* Median (range); ¶ GBS disability score (0 - 6) = 0: healthy state, 1: minor symptoms and capable of running, 2: able to walk 10 meters or more without assistance but unable to run, 3: able to walk 10 meters across an open space with help, 4: bedridden or chair-bound, 5: requiring assisted ventilation for at least part of the day, 6: dead; † MRC sum score: Medical Research Council sum score; ‡ ONLS: Overall Neuropathy Limitation Scale²¹; § R-ODS: Rash-built Overall Disability Score²²

Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS.

SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, ^A measured in litres, ●: spell of hypotension (systolic BP < 90 mm Hg), ◊ : CVC insertion site bleeding, ▲: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.

Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (*n* = 20): twenty patients with GBS aged ≥ 18-years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (*n*=20): twenty-four patients aged ≥ 18-years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * *p* < 0.0001.

Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.




Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS. SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, A measured in litres, black dot: spell of hypotension (systolic BP < 90 mm Hg), empty drop: CVC insertion site bleeding, black triangle: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.




Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (n = 20): twenty patients with GBS aged ≥ 18-years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (n=20): twenty-four patients aged ≥ 18-years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * p < 0.0001.





Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.

Supplementary Figure: Hospital-acquired infections in the 20 patients with GBS treated with SVPE and the 24-hospital control patients without GBS.



SVPE: small volume plasma exchange, CLABSI: central line-associated blood stream infection, CAUTI: catheter-associated urinary tract infection, VAP: ventilator-associated pneumonia.



Consent form

For a patient's consent to publication of images and/or information about them in BMJ publications.

Name of patient:	<u>ASHRAF ALI</u>
Relationship to patient (if patient not signing this form):	<u>Not applicable</u>
Description of the photo, image, text or other material (Material) about the patient. A copy of the Material should be attached to this form:	<u>Video documentation of the small volume plasma exchange (SVPE) procedure</u>
Provisional title of article in which Material will be included:	Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a safety and feasibility study

CONSENT

I ASHRAF ALI (35 years / Male) [PRINT FULL NAME] give my consent for the Material about me/the patient to appear in a BMJ publication.

I confirm that I: (please tick boxes to confirm)

- ☒ **have seen the video clip about me**
- ☒ **have read the article to be submitted to BMJ**
- ☒ **am legally entitled to give this consent.**

I understand the following:

- (1) The Material will be published without my/the patient's name attached, however I understand that complete anonymity cannot be guaranteed. It is possible that somebody somewhere - for example, somebody who looked after me/the patient or a relative - may recognise me/the patient.
- (2) The Material may show or include details of my/the patient's medical condition or injury and any prognosis, treatment or surgery that I have/the patient has, had or may have in the future.
- (3) The article may be published in a journal which is distributed worldwide. BMJ's publications go mainly to doctors and other healthcare professionals but are also seen by many others including academics, students and journalists.
- (4) The article, including the Material, may be the subject of a press release, and may be linked to from social media and/or used in other promotional activities. Once published, the article will be placed on a BMJ website and may also be available on other websites.
- (5) The text of the article will be edited for style, grammar and consistency before publication.

Patient consent form 031117



- (6) I/the patient will not receive any financial benefit from publication of the article.
- (7) The article may also be used in full or in part in other publications and products published by BMJ and/or by other publishers. This includes publication in English and in translation, in print, in digital formats, and in any other formats that may be used by BMJ or other publishers now and in the future. The article may appear in local editions of journals or other publications, published in the UK and overseas.
- (8) I can revoke my consent at any time before publication, but once the article has been committed to publication ("gone to press") it will not be possible to revoke the consent.
- (9) This consent form will be retained securely and in confidence by BMJ in accordance with the law, for no longer than necessary.

Please tick boxes to confirm the following:

- ☒ I consent to BMJ storing my contact details (including outside of the EEA) for the sole purpose of contacting me, if necessary, in the future.
- ☐ Where this consent relates to an article in *BMJ Case Reports*, I have/the patient has had the opportunity to comment on the article and I am satisfied that the comments, if any, have been reflected in the article.

Signed: ASHRAF ALI

Print name: ASHRAF ALI

Address:
House: 4; Road: 2/1; Rupnagar R/A; Mirpur-1;
Dhaka;
Bangladesh

Email address: ashrafali3972@gmail.com

Telephone no: +880 17 1201 0384

If signing on behalf of the patient, please give the reason why the patient can't consent for themselves (e.g. patient is deceased, under 18 or has cognitive or intellectual impairment). **Not applicable**

Date: 16. 02. 2018

- ☐ If you are signing for a family or other group, please tick the box to confirm that all relevant members of the family or group have been informed. **Not applicable**

If the patient is a child aged 7 years or older, they must also confirm their consent: **Not applicable**

Signed: _____ Print name: _____

Date of birth: _____ Date: _____

Details of person who has explained and administered the form to the patient or their representative
(e.g. the corresponding author or other person who has the authority to obtain consent).

Signed:_____



Print name: Dr Md Badrul Islam

Position:_____

Research Trainee and PhD Fellow

Institution:_____

**International Centre for Diarrhoeal
Disease Research, Bangladesh (icddr,b)**

Address:_____

**Laboratory Sciences and Services Division
(LSSD)**

**The International Centre for Diarrhoeal
Disease Research, Bangladesh (icddr,b)
68, Shaheed Tajuddin Ahmed Sarani,
Mohakhali, Dhaka-1212, Bangladesh**

Email address: badrul.islam@icddr.org
bislamdmch@gmail.com

Telephone no: +880 17 289 0172

Date: 16. 02. 2018

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

2017 CONSORT checklist of information to include when reporting a randomized trial assessing nonpharmacologic treatments (NPTs)*.
Modifications of the extension appear in italics and blue.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Title and abstract					
	1a	Identification as a randomized trial in the title	NA (Non-randomized)		
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4, 5	Refer to CONSORT extension for abstracts for NPT trials	3, 4, 5
Introduction					
Background and objectives	2a	Scientific background and explanation of rationale	6		
	2b	Specific objectives or hypotheses	6, 7		
Methods					
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7	When applicable, how care providers were allocated to each trial group	NA
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	No changes to methods after trial commencement		
Participants	4a	Eligibility criteria for participants	7, 8	When applicable, eligibility criteria for centers and for care providers	NA
	4b	Settings and locations where the data were collected	7		
Interventions†	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8	Precise details of both the experimental treatment and comparator	7, 8
	5a			Description of the different components of the interventions and, when applicable, description of the procedure for tailoring the interventions to individual participants.	9
	5b			Details of whether and how the interventions were standardized.	8, 9

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	5c.			Details of whether and how adherence of care providers to the protocol was assessed or enhanced	8, 9
	5d			Details of whether and how adherence of participants to interventions was assessed or enhanced	NA
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8, 9		
	6b	Any changes to trial outcomes after the trial commenced, with reasons	No changes to trial outcomes after the trial commenced		
Sample size	7a	How sample size was determined	9	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	7b	When applicable, explanation of any interim analyses and stopping guidelines	10		
Randomization:					
- Sequence generation	8a	Method used to generate the random allocation sequence	NA (Non-randomized)		
	8b	Type of randomization; details of any restriction (such as blocking and block size)	NA (Non-randomized)		
- Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	NA (Non-randomized)		
- Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA (Non-randomized)		
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Blinding was not possible	If done, who was blinded after assignment to interventions (e.g., participants, care providers, those administering co-interventions, those assessing outcomes) and how	Blinding was not possible

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40-7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	11b	If relevant, description of the similarity of interventions	7, 8		
	11c			If blinding was not possible, description of any attempts to limit bias	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA		
Results					
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	11	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center	Single center study
	13b	For each group, losses and exclusions after randomization, together with reasons	No losses and exclusions after inclusion		
	13c			For each group, the delay between randomization and the initiation of the intervention	11
	new			Details of the experimental treatment and comparator as they were implemented	11, 12, 13, 14
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7		
	14b	Why the trial ended or was stopped	NA (Trial completed)		
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.	NA
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	11		

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12, 13, 14		
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA		
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15		
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	12, 13, 14, 15		
Discussion					
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	18, 19	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group	NA
Generalizability	21	Generalizability (external validity, applicability) of the trial findings	16, 17, 18	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial	16, 17, 18
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	16, 17, 18		
Other information					
Registration	23	Registration number and name of trial registry	4		
Protocol	24	Where the full trial protocol can be accessed, if available	Manuscript reference no: 16		
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	20		

*Additions or modifications to the 2010 CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials

†The items 5, 5a, 5b, 5c, 5d are consistent with the Template for Intervention Description and Replication (TIDieR) checklist

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Table: Required documents of the safety and feasibility study of the small volume plasma exchange (SVPE) for Guillain-Barré syndrome patients for the World Health Organization Trial Registration Data Set

	Item/Label	Description
1	Primary Registry and Trial Identifying Number	Clinicaltrials.gov NCT02780570
2	Date of Registration in Primary Registry	May 23, 2016
3	Secondary Identifying Numbers	International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Protocol Number: PR-15086, Version no. 3, Date: 09/12/2015
4	Source(s) of Monetary or Material Support	GBS/CIDP Foundation International Fondation Mérieux: (Small Grants Program 2015)
5	Primary Sponsor	GBS/CIDP Foundation International
6	Secondary Sponsor(s)	Fondation Mérieux: (Small Grants Program 2014)
7	Contact for public queries	MD. BADRUL ISLAM Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam

		Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
8	Contact for scientific queries	MD. BADRUL ISLAM Principal Investigator (PI) Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
9	Public title	Small volume plasma exchange for Guillain-Barré syndrome
10	Scientific title	Small volume plasma exchange for Guillain-Barré syndrome in low-income countries: a safety and feasibility study
11	Countries of Recruitment	Bangladesh
12	Health condition(s) or problem(s) studied	Guillain-Barré syndrome (GBS)
13	Interventions	<u>Small Volume Plasma Exchange (SVPE)</u> A loading dose of low-molecular weight heparin (1.5 mg/kg) will be given subcutaneously at least two hours

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

before initiation of SVPE; the same dose will be administered once daily or divided into two equal doses daily for eight days or until SVPE is completed. Whole blood (7 mL/kg body weight) will be drawn from the central venous catheter into the blood transfusion bag in each session. The blood bag will be hung beside the patient for 2.5 h on a saline stand and left uninterrupted to allow plasma and blood cells to separate. The blood cells will be infused back into the patient and plasma will be discarded and replaced with fresh frozen plasma and colloid solution alternately (in equal volumes) via the closed-circuit SVPE kit illustrated in. In case of excessive clotting (bleeding time reduction of > 50% of baseline for that patient), aspirin (600 mg) will be administered orally at least two hours before the next SVPE session and continued thereafter at 150 mg orally/day until SVPE is completed. One blood bag will be used each day, with a total of six sessions/day. A total of 48 sessions will be performed over eight days, removing approximately 8000 mL plasma in total.

Central venous catheterized patients without GBS

To compare the safety of SVPE in patients with GBS in the context of the background risk of central line-associated blood stream infection (CLABSI) at the study intensive care (ICU) and high-dependency care (HDU) units, the incidence of CLABSI will be assessed in a control group of adult patients with a diagnosis other than GBS admitted to the same ICU and HDU units in the same period of time the patients with GBS will be enrolled for SVPE. We will assess the rate of CLABSI in

		patients aged ≥ 18 -years-old requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units.
14	Key Inclusion and Exclusion Criteria	<p><u><i>Inclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old fulfilling the diagnostic criteria for GBS of the National Institute of Neurological and Communicative Disorders and Stroke (NINDS) 2. Unable to walk unaided for more than 10 meters (GBS disability score ≥ 3) 3. Presented within 2 weeks of the onset of weakness 4. Unable to afford standard treatment with IVIg or PE. <p><u><i>Exclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients with severe or terminal concomitant illness 2. Evidence of healthcare-associated infection on admission (except for aspiration pneumonia) 3. Previous history of severe allergic reaction to properly matched blood products and pregnant women will be excluded from the study. <p><u><i>Inclusion criteria for patients without GBS</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old 2. Requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period of time the patients with GBS enrolled for SVPE. <p><u><i>Exclusion criteria for patients without GBS</i></u></p>

		<ol style="list-style-type: none">1. Patients with healthcare-associated infection present on admission (except aspiration pneumonia)2. Pregnant women
15	Study type	<p><u>Type of the study:</u> Interventional</p> <p><u>Method of allocation:</u> Non-randomized</p> <p><u>Masking:</u> Non-masked</p> <p><u>Assignment:</u> Parallel arm</p> <ul style="list-style-type: none">• SVPE in patients with GBS• Rate of CLABSI in patients without GBS <p><u>Purpose:</u> Safety and feasibility of SVPE</p>
16	Date of first enrolment	February 20, 2016
17	Target sample size	SVPE in patients with GBS = 20 Rate of CLABSI in patients without GBS = ≥ 20
18	Recruitment status	Completed: <ul style="list-style-type: none">• Twenty cases of GBS have been successfully treated with SVPE and 24 control cases without GBS have been recruited.
19	Primary Outcome(s)	<p><u>Primary outcome of safety:</u></p> <ol style="list-style-type: none">1. Number of patients with GBS treated with SVPE developing severe sepsis or septic shock due to central line associated blood stream infection (CLABSI) as per standard guideline (Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection); CDC Device-associated Module, BSI. January 2017)2. Occurrence of venous thrombosis in the limb

		<p>where the CVC is placed. Venous thrombosis will be assessed according to Wells criteria (Philip S. Wells et al. <i>Evaluation of d -Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis</i>; <i>N Engl J Med</i> 2003;349:1227-35)</p> <p><u>Primary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Ability to remove at least eight litres of plasma by SVPE over eight days.
20	Secondary Outcome(s)	<p><u>Secondary outcome of safety:</u></p> <ol style="list-style-type: none"> 2. Relative risk of CLABSI due to SVPE compared to CLABSI in control patients without GBS treated using a CVC 3. Hemodynamic instability during the SVPE procedure (variations in systolic blood pressure greater than 30 mmHg or sudden bradycardia involving a reduction in heart rate by more than 20 beats per min within 30 min of starting SVPE or an increase in heart rate above 120 beats per min) 4. Development of anaemia (Hb <7 gm/dL) or serious haemorrhage requiring blood transfusion. <p><u>Secondary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Rate of CVC occlusion during the SVPE procedure 2. The healthcare personnel's acceptability and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		<p>satisfaction with the SVPE procedure and any unanticipated events compromising the SVPE procedure as assessed using a standard questionnaire.</p> <p>3. Neurological outcome will be assessed in terms of improvement in GBS disability score and MRC sum score at discharge and up to 4 weeks after entry.</p>
--	--	--

BMJ Open

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022862.R1
Article Type:	Research
Date Submitted by the Author:	02-May-2018
Complete List of Authors:	Islam, Md Badrul; International Centre for Diarrhoeal Disease Research Bangladesh, LSSD Islam, Zhahirul; The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) , Laboratory Sciences and Services Division (LSSD) Rahman, Shafiqur; Uttara Adhunik Medical College, Anaesthesia and Intensive Care Endtz, Hubert; Erasmus University Medical Center, Department of Medical Microbiology and Infectious Diseases; Fondation Merieux Vos, Margreet; Erasmus MC Medical Center Rotterdam, Department of Medical Microbiology and Infectious diseases van der Jagt, Mathieu; Erasmus MC, Department of Intensive Care Van Doorn, Peter; Erasmus University Medical Center, Department of Neurology Jacobs, BC; Erasmus University Medical Center, Departments of Neurology and Immunology Mohammad, Quazi; National Institute of Neuroscience
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Medical management
Keywords:	Guillain-Barré syndrome, Small volume plasma exchange, Safety, Feasibility
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.	
SUPPLEMENTARY VIDEO.mp4	

SCHOLARONE™
Manuscripts

1 Title:

2 Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings:
3 a phase II safety and feasibility study

4 Authors

5 1. Badrul Islam

6 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
7 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
8 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)

9 E-mail: badrul.islam@icddr.org
10 bislamdmch@gmail.com

11 2. Zhahirul Islam

12 Laboratory Sciences and Services Division (LSSD)
13 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

14 E-mail: zislam@icddr.org

15 3. Shafiqur Rahman

16 Department of Intensive Care Medicine, Uttara Adhunik Medical College & Hospital.

17 E-mail: drshafiqk23@yahoo.com

18 4. Hubert P. Endtz

19 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
20 Center, Rotterdam, The Netherlands, and Fondation Mérieux, Lyon, France.

21 Email: hubert.endtz@fondation-merieux.org

22 5. Margreet C. Vos

23 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
24 Center, Rotterdam, The Netherlands.

25 Email: m.vos@erasmusmc.nl

26 6. Mathieu van der Jagt

27 Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The
28 Netherlands.

29 Email: m.vanderjagt@erasmusmc.nl

30 7. Pieter A. van Doorn

31 Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.

32 E-mail: p.a.vandoorn@erasmusmc.nl

33 8. Bart C. Jacobs

34 Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam,
35 The Netherlands.

36 E-mail: b.jacobs@erasmusmc.nl

37 9. Quazi D. Mohammad

38 National Institute of Neuroscience (NINS), Dhaka, Bangladesh.

39 E-mail: quazideenmohammad@gmail.com

41 Corresponding author

42 Badrul Islam

43 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
44 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
45 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

46 E-mail: bislamdmch@gmail.com

48 Word count: 4904 (Excluding abstract, reference, table and figures)

49

ABSTRACT

OBJECTIVE

To assess the safety and feasibility of small volume plasma exchange (SVPE) as an alternative to standard plasma exchange (PE) or intravenous immunoglobulin (IVIg) for Guillain-Barré syndrome (GBS) patients.

DESIGN

Non-randomized, single arm, interventional trial.

SETTING

National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.

PARTICIPANTS

Twenty adult (>18 years) patients with GBS presented within 2 weeks of onset of weakness who were unable to walk unaided for more than 10 meters.

INTERVENTIONS

SVPE involves blood cell sedimentation in a blood bag and removal of supernatant plasma after blood cells are re-transfused. This procedure was repeated three to six times a day, for eight consecutive days.

OUTCOME MEASURES

Serious adverse events (SAE) were defined as severe sepsis and deep venous thrombosis related to the central vein catheter (CVC) used during SVPE. SVPE was considered safe if less than 5/20 patients experienced a SAE, and feasible if 8 L plasma could be removed within 8 days in at least 15/20 patients.

RESULTS

Median patient age 33 years (IQR 23-46; range 18-55); 13 (65%) were male. Median MRC sum score was 20 (IQR 0-29; range 0-36); three (15%) patients required mechanical ventilation. One patient developed SAE (severe sepsis, possibly related to CVC). Minor adverse effects were

transient hypotension in 10 (50%) patients; CVC-associated bleeding in 10 (50%); transfusion reaction to fresh frozen plasma in 4 (20%); and hypo-albuminemia, anaemia or electrolyte imbalance in 4 (20%). Removal of 8 L plasma was possible in 15 (75%) patients. GBS disability score improved by at least one grade in 14 (70%) patients four weeks after SVPE started. No patients died.

CONCLUSION

SVPE seems a safe and feasible alternative treatment to standard PE or IVIg for GBS; further studies of clinical efficacy in low-resource developing countries are warranted.

TRIAL REGISTRATION

Clinicaltrials.gov NCT02780570 on May 23, 2016

94 **Strength and limitations of the study:**

95

- 96 1. The strength of this study underlies the novel and simple technique of SVPE, which is
- 97 much less expensive than conventional immunotherapies (plasma exchange and
- 98 intravenous immunoglobulin)
- 99 2. SVPE is corroborated as safe and feasible for the first time in a prospective and
- 100 standardized cohort of patients with Guillain-Barré syndrome (GBS).
- 101 3. The intrinsic limitations of this study are its non-randomized, single arm nature, which is
- 102 conducted in a single center with a limited sample size of GBS patients.
- 103 4. Clinical efficacy of SVPE on patients with GBS was a secondary end-point assessment
- 104 and therefore deserves a randomized controlled trial in future to assess the clinical
- 105 efficacy of SVPE for the patients with GBS.

106

107 Introduction

108 Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a
109 yearly incidence of 1.2 to 2.3 cases per 100,000 per year.¹ GBS is characterized by rapidly
110 progressive limb weakness and, in a proportion of cases, respiratory failure (25%) or severe
111 autonomic dysfunction (10%). Plasma exchange (PE) was the first treatment proven to be
112 effective for GBS, if given within 4 weeks of the onset of weakness.²⁻¹⁰ Conventionally for GBS
113 patients, three to six plasma exchange sessions are done in alternate days targeting removal of
114 nearly 12 litres of patient plasma (approximately 3 litres of plasma at each session) within a span
115 of 9 to 14 days.¹¹ This give rise to the plasma exchange rate of 120 - 200 ml/kg (40-
116 50ml/kg/day). Later studies showed treatment with intravenous immunoglobulin (IVIg) (0.4 g/kg
117 per day for 5 days) has a similar efficacy as PE in patients with GBS who are unable to walk, if
118 started within 2 weeks of the onset of weakness.^{12 13}

119
120 Unfortunately, most patients in low-income countries cannot afford expensive treatment with
121 either PE or IVIg.¹⁴ In Bangladesh, a full course of IVIg for a 60 kg adult costs approximately
122 12,000-16,000 US\$ and treatment with conventional PE for 5 days costs approximately 4,500-
123 5,000 US\$. The mean income in Bangladesh was 4 US\$ per day in 2016 (World Bank and
124 Bangladesh Bureau of Statistics 2016); IVIg and PE cost the equivalent of 3,000 and 1,250 mean
125 income days, respectively. At present, the majority (92%) of patients with GBS in Bangladesh
126 receive supportive care only.¹⁴ In addition, mobile PE equipment is not available in Bangladesh;
127 therefore, patients admitted to the intensive care unit (ICU) cannot receive PE. We previously
128 reported the mortality rates for GBS in Bangladesh range from 12 to 14% and observed 29% of
129 patients with GBS in Bangladesh are unable to walk at 6 months after onset; these poor outcomes
130 are undoubtedly due to the low rates of specific treatment with PE or IVIg.^{15 16}

131

Small volume plasma exchange (SVPE) may represent a cheap, effective alternative treatment for GBS. SVPE is based on the same principle as conventional PE (selective removal of plasma) but uses a novel, simple technique with much lower costs (approximately 500 US\$). The current non-randomized trial was designed to investigate the safety and feasibility of SVPE in 20 patients with GBS admitted to the National Institute of Neurosciences Hospital in Dhaka, Bangladesh.

Methods/Design

Study design

For this non-randomized, single arm, interventional safety and feasibility trial, 20 adult patients with GBS were enrolled between March 2016 and December 2016 for SVPE at the National Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh. A detailed study protocol was published previously and includes definitions of all variables used in this study.¹⁷

Four to six daily sessions of whole blood sedimentation and removal of supernatant plasma after re-transfusion of the sedimented blood cells was planned for the 20 patients with GBS, with a target of removing an overall volume of at least 8 litres (L) of plasma over a total of 8 days.¹⁷ (See supplementary video for SVPE procedure)

Patients with GBS were monitored according to a standard protocol throughout the course of SVPE until the second day after withdrawal of the central venous catheter (CVC) in order to assess predefined measures of safety and feasibility and followed up for six months to assess neurological outcome. The protocol was reviewed and approved by the institutional research and ethics review committees at the icddr,b and registered at clinicaltrials.gov (NCT02780570).¹⁷ All patients provided written informed consent to participate in this study.

157 *Patient and Public Involvement*

158 Patients and or public were not involved either in the development of the research question, study
159 design and outcome measure or recruitment to and conduct of the study.

160

161 *Inclusion and exclusion criteria for patients with GBS*

162 Patients aged ≥ 18 -years-old fulfilling the diagnostic criteria for GBS of the National Institute of
163 Neurological and Communicative Disorders and Stroke (NINDS)¹⁸ were enrolled, provided they
164 were unable to walk unaided for more than 10 meters (GBS disability score ≥ 3), presented
165 within 2 weeks of the onset of weakness, and were unable to afford standard treatment with IVIg
166 or PE. Patients with concomitant severe or terminal illnesses, evidence of healthcare-associated
167 infection (HAI) on admission (except for aspiration pneumonia), a previous history of severe
168 allergic reactions to properly matched blood products, and pregnant women were excluded from
169 the study.

170

171 *Control cohort*

172 To compare the safety of SVPE in patients with GBS in the context of the background risk of
173 central line-associated blood stream infection (CLABSI) at our institution, we prospectively
174 assessed the incidence of CLABSI in a hospital control group of 24 adult patients without GBS
175 receiving neurocritical care. Hospital controls were eligible based on the following
176 characteristics: ≥ 18 -years-old, a neurological diagnosis other than GBS, and a CVC placed for $>$
177 2 and ≤ 8 calendar days after admission to the same ICU or HDU unit as the SVPE-treated
178 patients. Patients with a HAI (except aspiration pneumonia) and pregnant women were excluded
179 from the control group.

180

181

182 *Primary and secondary outcome measures*

183 The primary outcome measures of safety were the number of patients with GBS treated with
184 SVPE who developed either severe sepsis or septic shock due to CLABSI¹⁹ and the occurrence of
185 venous thrombosis in the limb where the CVC was placed. The primary outcome measure of
186 feasibility was the ability to remove at least 8 L of plasma over 8 days.

187 The secondary outcome measures of the safety of SVPE were the relative risk of CLABSI due to
188 SVPE (compared to CLABSI in the hospital control group without GBS), hemodynamic
189 instability during the SVPE procedure, and development of anaemia (Hb < 8 gm/dL) or any
190 catheter-related haemorrhage requiring a blood transfusion.

191 The secondary outcome measure of feasibility of SVPE was the rate of CVC occlusion during the
192 SVPE procedure. In addition, neurological outcome was assessed using the GBS disability
193 score²⁰, MRC sum score²¹, Overall Neuropathy Limitation Scale (ONLS)²² and Rasch-built
194 Overall Disability Scale (R-ODS)²³ at 1st, 2nd, 3rd, and 6th months from the start of SVPE.

196 *Procedure safety and documentation*

197 Strict aseptic procedures were followed to prevent CLABSI.²⁴⁻²⁶ SVPE was documented in terms
198 of the duration and amount of plasma removed in each session, and the type and volume of
199 replacement fluid and fresh frozen plasma (FFP) used. Throughout the procedure, the
200 haemodynamic, haematological, biochemical, coagulation and infection profiles of the SVPE-
201 treated patients were monitored according to the protocol.¹⁷ Screening for hepatitis B and C
202 viruses, human immunodeficiency virus (HIV) and syphilis were performed as patient baseline
203 assessments, and also on donor FFP before administration. CLABSI, primary and secondary
204 bloodstream infections¹⁹, catheter-associated urinary tract infection (CAUTI)²⁷, ventilator-
205 associated pneumonia (VAP)²⁸ and other HAI^{29 30} were documented in the SVPE-treated patients
206 with GBS and the hospital control group.

207 *Sample size*

208 This safety and feasibility study enrolled 20 patients with GBS for SVPE. We could not
209 perform a formal power calculation for this safety and feasibility study. The sample size
210 was based on previous pilot studies conducted in GBS.^{31 32} The baseline rate of CLABSI
211 was measured in the hospital control group of 24 patients without GBS admitted to the
212 same study facility who required a CVC for at least 8 days during the study period.

214 *Stopping rules for the trial based on safety and feasibility*

215 Decision to stop the SVPE trial was designated using a Bayesian approach.³³⁻³⁵
216 Accordingly, a predictive success rate of 75% was predefined for the SVPE procedure. If
217 more than 5 of 20 patients experienced an SAE, or if it appeared impossible to remove at
218 least 8 L of plasma over 8 days in at least 15 of 20 patients, the procedure was considered
219 unsafe or unfeasible.

221 *Statistical analysis*

222 The rate of HAIs (CLABSI, VAP and CAUTI) per 1000 device days were calculated by
223 dividing the number of each HAI during the study period by the number of device days and
224 multiplying the result by 1000. The infection safety profile for SVPE was assessed by
225 calculating the standardized infection ratio to define the risk of HAIs in patients with GBS
226 treated with SVPE. The standardised infection ratio (SIR) was calculated by dividing the
227 number of observed HAI by the number of HAI predicted (i.e., the infection rate in the control
228 group). The predicted HAI rate was calculated using the rates of HAI in the hospital control
229 group of patients without GBS during the study period. Percentage values were compared using
230 the Chi-square test or Fisher's exact test (two-tailed) and median values, the Mann-Whitney U-
231 test using SPSS 22 software (IBM SPSS Statistics for Windows Version 22.0., IBM Corp.,

Armonk, NY, USA). Analyses were performed on an intention-to treat basis. All *P*-values reported are two-sided; *p* < 0.05 was considered significant.

Results

Patients and hospital controls

The demographic and clinical characteristics of the 20 patients with GBS are given in Table 1. The median age of the patients with GBS was 33 years (range; 18-55); median body weight was 60 kg (IQR, 55-65 kg; range, 50-72 kg) and 13 (65%) patients were male (Fig. 1). On admission and before the start of SVPE, all 20 patients with GBS were unable to walk independently (GBS disability score, 4). One patient required mechanical ventilation from the second day after the onset of weakness; SVPE was started on the fourth day of mechanical ventilation (patient 9, Fig. 1). Two of the 19 patients who did not require mechanical ventilation at the start of the study required mechanical ventilation on the second day after initiation of SVPE (patients 11 and 19, 11 and 2 days after the onset of weakness, respectively; Fig. 1). The median MRC sum score for the limb muscles in all 20 patients was 20 (IQR: 0-29; range: 0-36; Fig. 1). Symptoms of a preceding infection in the 4 weeks before the onset of weakness were present in 18 (90%) patients with GBS, of whom 10 (50%) had diarrhoea. Median duration from admission to start of SVPE was two days (IQR, 2-3 days; range, 0-7 days). Median duration to nadir from the onset of weakness was five days (range, 1-13 days). Electrodiagnostic nerve conduction studies indicated 15 (75%) patients had an axonal subtype and 5 (25%) patients had a demyelinating subtype of GBS. Median duration from onset of weakness to NCS examination was 10 days (range, 4-16 days). All patients had albuminocytologic dissociation; median CSF protein was 166 mg/dL (range 117-253 mg/dL). Median duration from onset of weakness to CSF examination was 11 days (range, 4-17 days).

Median age of the 24 hospital control patients without GBS was 44 years (IQR, 25-57; range, 18-74); 10 (42%) were male. Age and gender distribution were not significantly different compared to the 20 patients with GBS ($p = 0.2155$, $p = 0.1434$, respectively). The diagnoses for these 24 patients were: brain tumour ($n = 5$), transverse myelitis ($n = 5$), head trauma after road traffic accident ($n = 3$), viral meningoencephalitis ($n = 2$), myasthenia gravis ($n = 2$), compressive cervical myelopathy ($n = 2$), cerebrovascular accident ($n = 2$), motor neuron disease ($n = 1$), electrolyte imbalance ($n = 1$) and status epilepticus ($n = 1$).

Primary endpoints

One patient with GBS treated with SVPE developed severe sepsis, possibly due to SVPE-related CLABSI (SVPE window-period blood culture revealed methicillin-resistant *Staphylococcus aureus*). This patient required intravenous fluid, noradrenalin infusion and intravenous antibiotics, but eventually improved (patient 11, Fig. 1). This patient also had signs and symptoms suggestive of aspiration pneumonia and VAP; *Streptococcus spp.* was isolated from pulmonary aspirates. Further laboratory results revealed dys-electrolytemia, anaemia and hypoalbuminemia. No patients experienced deep vein thrombosis due to the CVC for SVPE. Fifteen (75%) of the 20 patients met the primary endpoint of feasibility, defined as the ability to remove at least 8 L of plasma in eight days. The median volume of plasma removed was 8.5 L (IQR, 7.9-8.8 L; range, 6.3-9.6 L; Fig. 1). The median plasma exchange rate was 140 mL/kg bodyweight (IQR, 125-155 mL/kg; range, 110-175 mL/kg) over 8 days and 16 (80%) patients had a plasma exchange rate > 120 mL/kg (Table 2).

282 *Secondary endpoints*

283 *Infections among SVPE-treated patients with GBS and hospital controls*

284 Among the 20 patients with GBS treated with SVPE, six (30%) had fever during SVPE (Fig. 1,
285 Supplementary Figure 1), including 2 (10%) patients with leucocytosis who were diagnosed with
286 HAI (VAP and CAUTI in one patient; VAP in one patient). In three out of four (20%) patients
287 with fever without leucocytosis, fever subsided within two to three days without antimicrobial
288 therapy (Fig. 1). The remaining patient with pyrexia without leucocytosis had microbiological
289 evidence of both CLABSI and VAP (patient 11, Fig. 1). In all other 14 patients with GBS, no
290 fever was documented during the course of SVPE until the tenth day of SVPE (second day after
291 removal of the CVC for SVPE). Five of these 14 patients had leucocytosis, but no site-specific
292 HAI could be detected. However, one of the nine patients without fever but leucocytosis fulfilled
293 the criteria for CAUTI (patient 12, Fig. 1). All three patients who required mechanical ventilation
294 subsequently developed VAP; two of the 13 patients who required a urinary catheter developed a
295 CAUTI (patient 11, Fig. 1). No patients died during the 6 months follow-up.

296
297 All 24-hospital control patients without GBS required mechanical ventilation and an indwelling
298 urinary catheter. Of these patients, 22 (92%) patients had fever, of whom 15 (63%) had
299 leucocytosis; a diagnosis of a specific HAI could be made 14 of these 15 patients (CLABSI in
300 two, CAUTI in one, VAP in 11) and four (17%) fulfilled the criteria for severe sepsis
301 (Supplementary Figure 1). Seven (29%) of the 24 hospital control patients had fever without
302 leucocytosis. In two of these seven patients, a specific HAI was diagnosed (CAUTI and VAP in
303 one, and VAP in one). In two hospital control patients, no fever was documented until day 10
304 after first placement of the CVC, but leucocytosis was present and no site-specific HAI could be
305 detected (Supplementary Figure 1).

306

The rates of CLABSI, CAUTI and VAP per 1000 device days in the SVPE-treated patients with GBS were 6.25, 19.2 and 40 compared to 10.4, 10.4 and 67.7 for the hospital control patients without GBS, respectively. The relative risks of CLABSI, CAUTI and VAP associated with SVPE were 0.6, 1.2 and 1.8, respectively, compared to hospital control patients. The rates of CLABSI, CAUTI and VAP were comparable between SVPE-treated patients with GBS and hospital control patients ($p > 0.05$). Antimicrobial agents were used more frequently in the hospital control patients ($p < 0.0001$; Fig. 2). The standardised infection ratios for CLABSI, CAUTI and VAP for SVPE-treated patients with GBS were 0.6, 1.8 and 1.9, respectively.

Other secondary endpoints

Ten (50%) of the 20 patients treated with SVPE experienced transient hypotension during SVPE, which was corrected by infusion of 200-300 mL crystalloid saline (Fig. 1). Minor bleeding through the CVC insertion site (excluding at the time of insertion) was observed in 10/20 patients (50%; Fig. 1); these bleeds required a pressure pack. Reduction of the anticoagulant dose along with a pressure pack was required in 3/20 patients, who all had a prolonged prothrombin time (PT). Three patients had single episode of haemorrhage through the urinary catheter: one was diagnosed with a CAUTI with normal coagulation profile, one had a prolonged PT, the other had sterile haematuria with normal PT. Overall, PT and activated partial thromboplastin time (aPTT) were prolonged in 4/20 patients and only PT was prolonged in 2/20 patients. Clotting time and bleeding time were not prolonged in any patient. One patient developed anaemia (haemoglobin, 8 gm/L) at the end of SVPE; this patient also had severe sepsis and required one unit of blood transfusion (patient 11, Fig. 1). CVC blockages were not observed in any SVPE-treated patients with GBS. One patient with increased clotting tendency who required an increased dose of low molecular weight heparin had shortened clotting time (CT) ($< 50\%$ of upper limit of normal), though PT was normal (patient 10, Fig. 1).

332 The neurological outcomes of the SVPE-treated patients with GBS at six months in terms of
333 neurological scores are given in Table 3. Median time to recover the ability to walk unaided was
334 4 weeks (Fig. 3). Fourteen (70%) of the 20 patients had an improvement in GBS disability score
335 of one or more grades at four weeks after the onset of SVPE. At one month, 12 patients (60%)
336 were able to walk unaided, two patients (10%) were able to walk aided and six (30%) patients
337 were bedbound, of whom three still required mechanical ventilation. At three months, 14 (70%)
338 patients were able to walk unaided, one (5%) could walk with aid and five (25%) patients were
339 bedbound. At six months, 14 (70%) patients were able to walk unaided, three (5%) could walk
340 with aid and three (15%) remained bedbound (Table 3).

342 *Other relevant clinical and laboratory findings*

343 Allergic/transfusion reaction to FFP was observed in four patients with GBS treated with SVPE
344 (Fig. 1). These transfusion reactions presented as an itchy erythematous skin rash (three patients),
345 fever (two patients), hypotension (one patient) following transfusion of FFP; all of these reactions
346 were managed with oral antihistamine (and intravenous saline in one patient) without further
347 complications.

349 The other documented haematological and biochemical abnormalities were hypo-albuminemia (n
350 = 4), thrombocytopenia (n = 6), hyponatraemia (n = 1), hypokalaemia (n = 3), hypomagnesaemia
351 (n = 1), hypocalcaemia (n = 3); (Table 2).

353 *Immunoglobulin dosage admitted by FFP*

354 During SVPE the median volume of FFP received per GBS patient as replacement fluid was
355 6000 ml (range, 5000 ml to 6000 ml). Considering the normal plasma IgG level of 11.20 mg/ml

(range, 6.9 mg – 17.6 mg)³⁶, SVPE treated GBS patients received IgG dose of median 0.9 g/kg (range 0.6 g/kg – 1.3 g/kg).

Discussion

Principal findings

This study suggests SVPE may represent a safe and feasible alternative to conventional plasma exchange for patients with severe GBS in limited-resource settings. Of the 20 patients in this study, one (5%) experienced a SAE (severe sepsis due to probable CLABSI). The rate of SAE was not significantly higher than the hospital control group without GBS with a CVC, and no patients had a CVC-related thromboembolic event in patients with SVPE. We were able to remove the prespecified target volume (8 L) of plasma as the target primary endpoint of feasibility in 15/20 (75%) patients with GBS. Median plasma exchange volume and rate during SVPE were 8.4 L and 140 mL/kg, respectively. Minor adverse effects included transient hypotension during SVPE in 50% (10/20), minor haemorrhage from CVC insertion site in 50% (10/20), transfusion reaction to fresh frozen plasma in 20% (4/20), and hypo-albuminemia, anaemia and electrolyte imbalance in 20% (4/20) of patients. An improvement of at least one grade on the GBS disability score was observed for 14/20 (70%) patients at four weeks after the initiation of SVPE. No patients died.

Comparison with baseline hospital control patients and standard/modified PE

With respect to HAIs, no significant differences were observed in the frequency of CLABSI, severe sepsis, VAP or CAUTI between the SVPE-treated patients with GBS and 24 hospital control patients without GBS treated using a CVC in the same ICU or HDU (Fig. 2). However, antimicrobial agents were used more frequently, usually prophylactically, in the hospital control patients compared to the patients with GBS treated with SVPE ($p < 0.0001$; Fig. 2). The

probability of detecting microorganisms in clinical infections may have been reduced due to overzealous use of antibiotics in the hospital control patients. Early trials of PE in patients with GBS showed 34% of patients develop severe infections.^{7 11} Subsequently, another large trial documented septicaemia in 19% of patients.⁵ However, the rates of CLABSI were not reported. The volume exchanged during SVPE is within the range recommended as per one large RCT on PE [120-200 mL/kg (standard PE)⁷ vs. 140 mL/kg for SVPE]. In GBS exchange of 6 L of plasma in adult patients is clinically beneficial in mild to moderate cases and less effective than exchange of 12 L in severe cases, however exchanging 18 L provides no added benefit over 12 L in severe cases of GBS.⁵ This suggests that the correlation between clinical benefit and the volume of plasma removed is not linear and exchanging more than 6 L of plasma is likely to have a beneficial effect. During the piloting of the SVPE procedure we assessed that removal of 1 L of patient plasma could be feasible in a day. Therefore we defined our target plasma volume of 8 L to be removed in 8 days. We were able to remove >120 mL/kg plasma in 80% of patients, which should provide a therapeutic effect.³⁷ Notably, the body weight of our patients may be lower than that of patients in western countries. In addition, SVPE was complete within 8 days, shorter than the usual time required for a full session of PE (10 to 14 days).

Replacement fluid used in SVPE was FFP. We have several justifications in favour of using FFP instead of human albumin or other available colloidal solutions available in Bangladesh. First FFP is safe in terms of microbiological safety since stringent screening for viral and bacterial contamination was performed before infusion. Second, in contrast to human albumin and colloid solutions, FFP contains normal human IgG that could contribute beneficial immunotherapeutic effect in GBS and previously used as replacement fluid in large PE trials.^{4 5} SVPE treated GBS patients received approximately half the amount of IgG from the FFP used as replacement fluid compared to the total IVIg doses traditionally used in GBS (2gm/kg). Third, FFP contains all

human plasma proteins that helps preservation of plasma colloid osmotic pressure and prevents formation of oedema and hypotension. Lastly FFP is much cheaper than commercial human albumin.

In each day three units of FFP were transfused as replacement fluid after the last session of SVPE and in the initial two to three sessions, normal saline was used as replacement fluid. This was done to achieve the maximum immunotherapeutic effect of FFP as SVPE was not resumed before the next day and the IgG in FFP remained in the circulation overnight for a longer period of time (10 to 12 hours). However due to long half life of IgG this effect may have reduced due to repeated plasma removal between the transfusion of FFP throughout the course of SVPE.

In GBS, treatment with modified methods of PE done previously, were device based and done on limited number of GBS patients. In one study on 25 GBS patients from India, daily removal of small volume of plasma (10-15 ml plasma/kg body weight) for duration of median 3 days using traditional PE machine was shown to be clinically beneficial.³⁸ In another study from the same country, 12 GBS patients were treated with PE over 10 days using different PE-machine kit (REF627 kit from Haemonetics Corporation Limited on MCS+ machine) where authors claimed clinical improvement, however the main focus was on cost effectiveness and the total plasma volume exchanged per patient was not mentioned.³⁹ Nevertheless these methods are based on specific devices those are not in common practice, nor the trained personnel for these are available in the developing countries.

Important observations in terms of secondary endpoints were transient hypotension, transfusion reaction to FFP and minor bleeding through the CVC insertion site. Hypotension is a common complication during traditional PE that affects nearly half of patients.⁵ Spells of hypotension

during SVPE were more frequent during the three to four days after initiation of SVPE, and could be easily corrected by rapid infusion of 300-400 mL saline (Fig. 1). The hypotension could possibly be explained by hypovolemia due to drawing blood or as a result of the compromised autonomic nervous system in patients with GBS. As SVPE proceeded, hypotensive spells were encountered less frequently despite drawing the same volume of blood, which may in part be explained by adaptation of the vasomotor system or recovery from autonomic dysfunction. Minor bleeding through the CVC insertion site occurred in 50% of patients and could be controlled by applying a simple pressure pack over the CVC insertion site in most cases; mild prolonged PT was noted in 30% (3/10) patients. However, spontaneous bleeding usually occurs if the PT is more than 2.5 times prolonged and PC is $< 0.50 \text{ lac}/\mu\text{L}$.⁴⁰ Movement of the limb where the CVC was placed may have caused traction on the CVC and contributed to local bleeding in the other seven patients. Haematuria is not uncommon in patients with a UTI, as may have occurred in one SVPE treated patient; traumatic traction of the urinary catheter may cause haematuria in two other catheterized SVPE-treated patient taking oral aspirin, who had haematuria and sterile urine. We also monitored the major organ function and biochemical status of the patients treated with SVPE. No patients experienced hepatic or renal impairment. One patient developed anaemia and hypoalbuminemia; this patient had severe sepsis, a common cause of anaemia and hypoalbuminemia in critically ill patients admitted to an ICU (patient 11, Fig. 1). Electrolyte imbalances were detected in 15% of the SVPE-treated patients with GBS, and were mild, subclinical and easily corrected.

The median reported durations to recovery of independent walking in patients with GBS in large-scale RCTs after PE are 53, 52 and 70 days^{4 5 7}; compared to 30 days in our patients treated with SVPE. Moreover, 60% of the patients with GBS treated with SVPE were able to walk independently at four weeks, whereas 20% of patients with GBS acquired independent walking

ability at four weeks after traditional PE. However, these differences may possibly be due to the small sample size and variations in demographic and neurophysiological characteristics between cohorts. Finally, SVPE was completed in all 20 patients and no patients died.

Limitations of SVPE

SVPE is a time-consuming and labour-intensive procedure, which is a limitation. We used multiple thin-lumen tubing systems interconnected with a multichannel connector device, which may increase the chance of blood coagulating within the tubing system. Coagulation may require manipulation or replacement of the tubing to ensure free flow of blood and saline. Such handling could increase the chance of microbial contamination. A single continuous wide-lumen tubing system (SVPE kit) could resolve this problem. Most importantly, personnel conducting the SVPE procedure should maintain proper aseptic technique, which can sometimes be challenging in developing countries. Furthermore, other adaptations such as provision of a larger blood bag or increasing the number of days for SVPE could be considered to increase the plasma exchange rate.

Clinical implications and future research

Despite the limitations, our study showed SVPE is a safe and feasible treatment for GBS in a resource-limited setting where IVIg or PE are either unavailable or unaffordable. Specifically, the poorest 20% of the world's population (1.8 billion people) who typically earn less than 10 US\$ per day and who are not covered by a national health insurance system may benefit. Considering the incidence of GBS is 2/100,000 in developing countries, approximately 40,000 patients could potentially benefit from SVPE every year, worldwide. In the future, a multicentre RCT is required to assess the clinical efficacy of SVPE for patients with GBS. If proven effective, SVPE could be an affordable and easily available alternative plasma exchange technique in low-income

481 countries for patients with GBS and other disorders, who at present cannot afford standard PE
482 due to its high cost and unavailability.

484 **Declarations**

485 *Acknowledgements:* This research activity was funded by GBS/CIDP Foundation International,
486 USA and Fondation Mérieux, Lyon, France. The icddr,b acknowledges with gratitude the
487 contributions of the Government of Bangladesh, Global Affairs Canada (GAC), Swedish
488 International Development Cooperation Agency (Sida), and Department for International
489 Development, UK (DFID). Md Ekhlash Mia and Smrity Akhter assisted this study in a full-time
490 capacity. We are grateful to all of the neurologists from the NINS who referred their patients to
491 us and K. S. Fahim for his support in preparation of the diagrams in this article.

493 *Authors' contributions:* BI, PVD, BJ, QDM, ZI, and HPE conceived the study design and sample
494 size of the study. MV, MVJ, SR, and HPE contributed to the infection safety guidelines in the
495 study design. BI and QDM conducted the study and BI collected and analysed the data and
496 drafted the manuscript. All authors have critically revised the manuscript and have read and
497 approved the final manuscript.

499 *Funding:* This study was funded by two competitive research grants:
500 1. The GBS/CIDP Foundation International GBS grant (major contribution)
501 2. The Fondation Mérieux: Small Grants Program 2014 (partial contribution)

502

503 *Role of the funding source:* The funders had no role in study design, data collection, data
504 analysis, data interpretation, or writing of the report.

505

506

507 *Competing interests:* No investigators have any competing financial, professional or personal
508 interests that may have influenced the findings described in this manuscript to disclose.

509

510 *Ethics approval and consent to participate:* The Institutional Review Board (IRB) of the icddr,b,
511 comprised of an Ethical Review Committee (ERC) and Research Review Committee (RRC),
512 reviewed and approved this study protocol on 09/12/2015 (reference number: PR-15086, version
513 no 3).

514

515 *Patient consent:* Obtained.

516

517 *Data sharing:* The dataset is available from the lead author on request.

518

519 *Transparency:* The corresponding author affirms that the manuscript is an honest, accurate and
520 transparent account of the study being reported; that no important aspects of the study have been
521 omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have
522 been explained.

523

524 **References**

525 1. Willison HJ, Jacobs BC, and van Doorn PA. Guillain-Barre syndrome.
526 *Lancet* 2016;388(10045):717-27.

527 2. Van Koningsveld R, Van Doorn PA, Schmitz PI et al. Mild forms of
528 Guillain-Barre syndrome in an epidemiologic survey in The Netherlands.
529 *Neurology* 2000;54(3):620-5.

530 3. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in
531 idiopathic polyneuritis. Its role in pathogenesis. *Medicine* 1969;48:173-
532 215.

533 4. French Cooperative Group on Plasma Exchange in Guillain-Barre
534 syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome:
535 role of replacement fluids. *Ann Neurol* 1987;22(6):753-61.

536 5. The French Cooperative Group on Plasma Exchange in Guillain-Barre
537 Syndrome. Appropriate number of plasma exchanges in Guillain-Barre
538 syndrome. *Ann Neurol* 1997;41(3):298-306.

539 6. French Cooperative Group on Plasma Exchange in Guillain-Barre
540 Syndrome. Plasma exchange in Guillain-Barre syndrome: one-year follow-
541 up. *Ann Neurol* 1992;32(1):94-7.

542 7. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute
543 Guillain-Barre syndrome. *Neurology* 1985; 35(8):1096-104.

544 8. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of
545 plasma exchange in acute inflammatory polyradiculoneuropathy. *Lancet*
546 1984;1(8382):877-9.

- 547 9. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma
 548 exchange in acute inflammatory polyradiculoneuropathy. *Lancet*
 549 1984;2(8415):1296-9.
- 550 10. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for
 551 Guillain-Barre syndrome. *Cochrane Database Syst Rev* 2014:Cd002063.
 552 [http://cochranelibrary-
 553 wiley.com/doi/10.1002/14651858.CD002063.pub6/epdf] Accessed 23
 554 April 2018.
- 555 11. Chevret S, Hughes Richard AC, Annane D. Plasma exchange for Guillain-
 556 Barré syndrome. *Cochrane Database Syst Rev* 2017; (2).
 557 [http://cochranelibrary-
 558 wiley.com/doi/10.1002/14651858.CD001798.pub3/epdf] Accessed 23 April
 559 2018.
- 560 12. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter:
 561 immunotherapy for Guillain-Barre syndrome: report of the Quality
 562 Standards Subcommittee of the American Academy of Neurology.
 563 *Neurology* 2003; 61(6):736-40.
- 564 13. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous
 565 immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch
 566 Guillain-Barre Study Group. *N Engl J Med* 1992; 326(17):1123-9.
- 567 14. Islam MB, Islam Z, Farzana KS, et al. Guillain-Barre syndrome in
 568 Bangladesh: validation of Brighton criteria. *J Peripher Nerv Syst* 2016;
 569 21(4):345-351.

1
2
3 570 15. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre
4
5 571 syndrome associated with Campylobacter infection in Bangladesh.
6
7 572 *Neurology* 2010; 74(7):581-7.
8
9 573 16. Ishaque T, Islam MB, Ara G, et al. High mortality from Guillain-Barre
10
11 574 syndrome in Bangladesh. *J Peripher Nerv Syst* 2017;22(2):121-126.
12
13 575 17. Islam MB, Islam Z, Rahman S, et al. Small volume plasma exchange for
14
15 576 Guillain-Barre syndrome in resource poor settings: a safety and feasibility
16
17 577 study. *Pilot Feasibility Stud* 2017;3:40.
18
19 578 18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for
20
21 579 Guillain-Barre syndrome. *Ann Neurol* 1990;27 Suppl:S21-4.
22
23 580 19. Centers for Disease Control and Prevention. Bloodstream Infection Event
24
25 581 (Central Line-Associated Bloodstream Infection and Non-central Line
26
27 582 Associated Bloodstream Infection) 2018;
28
29 583 [https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf]
30
31 584 Accessed 23 April 2018.
32
33 585 20. Hughes RA, Newsom-Davis JM, Perkin GD et al. Controlled trial
34
35 586 prednisolone in acute polyneuropathy. *Lancet* 1978;2(8093):750-3.
36
37 587 21. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in
38
39 588 the assessment of muscle strength and functional abilities in Guillain-Barre
40
41 589 syndrome. *Muscle Nerve* 1991;14(11):1103-9.
42
43 590 22. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the
44
45 591 Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry*
46
47 592 2006;77(8):973-6.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 593 23. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall
594 Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
595 *Neurology* 2011;76(4):337-45.
- 596 24. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in
597 catheter related bloodstream infections in Michigan intensive care units:
598 observational study. *Bmj* 2010;340:c309.
- 599 25. Flodgren G, Conterno LO, Mayhew A et al. Interventions to improve
600 professional adherence to guidelines for prevention of device-related
601 infections. *Cochrane Database Syst Rev* 2013;3:CD006559.
602 [http://cochranelibrary-
603 wiley.com/doi/10.1002/14651858.CD006559.pub2/epdf] Accessed 23
604 April 2018.
- 605 26. O'Grady NP, Alexander M, Burns LA, et al. Summary of
606 recommendations: Guidelines for the Prevention of Intravascular Catheter-
607 related Infections. *Clin Infect Dis* 2011;52(9):1087-99.
- 608 27. Centers for Disease Control & Prevention. Urinary Tract Infection
609 (Catheter-Associated Urinary Tract Infection
610 [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and
611 Other Urinary System Infection [USI]) Events. 2018;
612 [https://www.cdc.gov/nhsn/pdfs/psemanual/7psccauticurrent.pdf] Accessed
613 23 April 2018.
- 614 28. Centers for Disease Control & Prevention. Pneumonia (Ventilator-
615 associated [VAP] and non-ventilator-associated Pneumonia [PNEU])
616 Event. 2018;

617 [https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvcapcurrent.pdf] Accessed
618 23 April 2018.

619 29. Centers for Disease Control & Prevention. Identifying Healthcare-
620 associated Infections (HAI) for NHSN Surveillance. 2018;
621 [https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsnc
622 urrent.pdf] Accessed 23 April 2018.

623 30. Centers for Disease Control & Prevention. CDC/NHSN Surveillance
624 Definitions for Specific Types of Infections. 2018;
625 [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf]
626 Accessed 23 April 2018.

627 31. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre
628 syndrome with high-dose immune globulins combined with
629 methylprednisolone: a pilot study. *Ann Neurol* 1994;35(6):749-52.

630 32. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of
631 Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. *J*
632 *Neurol Neurosurg Psychiatry* 2007;78(9):1012-3.

633 33. Stigler SM. The True Title of Bayes's Essay. *Statistical Science*
634 2013;28(3):283-288.

635 34. Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of
636 Bayesian clinical trials monitoring. *Stat Med* 1994;13(13-14):1371-
637 83;discussion 1385-9.

638 35. Resnic FS, Zou KH, Do DV et al. Exploration of a bayesian updating
639 methodology to monitor the safety of interventional cardiovascular
640 procedures. *Med Decis Making* 2004; 24(4):399-407.

- 1
2
3 641 36. Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of
4
5 642 immunoglobulins (IgG, IgA, IgM) in a general adult population and their
6
7 643 relationship with alcohol consumption, smoking and common metabolic
8
9 644 abnormalities. *Clin Exp Immunol* 2008;151(1):42-50. doi: 10.1111/j.1365-
10 645 2249.2007.03545.x
11
12
13 646 37. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS,
14
15 647 Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of
16
17 648 prognostic factors and the effect of plasmapheresis. *Ann Neurol*
18
19 649 1988;23(4):347-53.
20
21
22 650 38. Tharakan J, Jayaprakash PA, Iyer VP. Small volume plasma exchange in
23
24 651 Guillain-Barre syndrome: experience in 25 patients. *J Assoc Physicians*
25
26 652 *India* 1990;38(8):550-3.
27
28
29 653 39. Iyer RR, Shah PH, Roy SS, et al. Reducing the economic burden in
30
31 654 management of Guillain-Barre syndrome using modified plasmapheresis.
32
33 655 *Asian journal of transfusion science* 2016;10(2):118-21. doi:
34
35 656 10.4103/0973-6247.187940.
36
37 657 40. Izak M, Bussel JB. Management of thrombocytopenia. *F1000prime*
38
39 658 *reports* 2014;6:45. doi: 10.12703/p6-45.
40
41
42 659
43
44 660
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Demographic and clinical characteristics of the 20 patients with GBS included in this small volume plasma exchange (SVPE) study at entry

Characteristic	Value
Demography	
Sex [males: females (ratio)]	13:7 (1.85)
Age (years) ¶	33 (18 - 55)
Body weight (kg) ¶	60 (50 - 72)
Antecedent events ‡ (total)	18 (90%)
Diarrhoea	10 (50%)
Respiratory infection	5 (25%)
Fever	3 (15%)
Days from antecedent events to weakness ¶	7 (3 - 30)
Days between onset of weakness to admission ¶	7 (2-12)
Neurological deficits at entry	
Weakness in arms and legs	20 (100%)
Cranial nerve deficits	12 (60%)
Decreased deep tendon reflexes	20 (100%)
Sensory involvement	5 (25%)
GBS disability score §	4 19 (95%)
	5 1 (5 %)
Severity of weakness (MRC sum-score) ¶	20 (0-29)
Autonomic dysfunction	11 (55%)

¶ Median (range); † increased protein level (> 45 mg/dL) in combination with CSF cell count < 50/µL; CSF = cerebrospinal fluid; NCS = nerve conduction study; ‡ symptoms of an infection in the four weeks preceding the onset of weakness; § GBS disability score (0 - 6) = 0: healthy state; 1: minor symptoms and capable of running; 2: able to walk 10 meters or more without assistance but unable to run; 3: able to walk 10 meters across an open space with help; 4: bedridden or chair-bound; 5: requiring assisted ventilation for at least part of the day; 6: dead.

Table 2: Treatment characteristics and complications associated with SVPE in the 20 patients with GBS

Characteristic/complication	Value
Treatment characteristics	
Number of sessions of SVPE per patient [¶]	30 (24 - 42)
Volume of plasma removed per patient [¶]	8.4 (6.3 – 9.6)
Plasma exchange rate (mL/kg) [¶]	140 (110-175)
Time between hospital admission and SVPE (days) [¶]	8 (5-10)
Time between onset of weakness and start of SVPE (days) [¶]	8 (5-10)
Need to stop SVPE due to poor hemodynamic tolerance	0/20 (0%)
Need for blood transfusion for anaemia	1/20 (5%)
Reduction of anticoagulant drug dose for bleeding	3/20 (15%)
Temporary withdrawal of antiplatelet drug for bleeding	4/20 (20%)
Increased anticoagulant drug dose to continue SVPE	1/20 (5%)
CVC blockade/replacement	0/20 (0%)
Complications during SVPE	
<i>Infection</i>	
Leukocytosis	7/20 (35%)
CLABSI [§]	6.25
VAP [§]	136.4
CAUTI [§]	40
Severe sepsis	1/20 (5%)
Antimicrobial agents used	6/20 (30%)
<i>Bleeding and coagulation</i>	
Bleeding from CVC insertion site	10/20 (50%)
Bleeding from mucosal area	3/20 (15%)
Prolonged BT (BT > 10 min)	0/20 (0%)
Prolonged CT (CT > 15 min)	0/20 (0%)
Prolonged PT (PT > 14 sec) [¶]	6/20 (30%) [15-19 sec]

Prolonged aPTT (aPTT > 40 sec) ¶	3/20 (15%) [51-240 sec]
<i>Other complications</i>	
Saline responsive hypotension	10/20 (50%)
Anaemia (Hb < 8 gm/L)	2/20 (10%)
Thrombocytopenia (PC < 1.5 lac/µL) ¶	6/20 (30%) [0.79-1.3 lac/µL]
Jaundice (serum bilirubin > 1.2 mg/dL)	0/20 (0%)
Renal impairment (serum creatinin > 1.2 mg/dL)	0/20 (0%)
Hyponatraemia (serum Na ⁺ < 135 mEq/L)	1/20 (5%) [126 mEq/L]
Hypokalaemia (serum K ⁺ < 3.5 mEq/L) ¶	3/20 (15%) [2.6-3.2 mEq/L]
Hypoalbuminemia (serum albumin > 35 gm/L) ¶	4/20 (20%) [26-32 gm/L]
Hypocalcaemia (serum Ca ⁺ < 2.2 mmol/L) ¶	3/20 (15%) [1.89-1.98 mmol/L]
Hypomagnesaemia (serum Mg ⁺ < 75 mEq/L) ¶	1/20 (5%) [73 mEq/L]
Hypersensitivity/transfusion reaction to FFP	4/20 (20%)

672

673 ¶ Median (range); § rate per 1000 device days; CLABSI: central line-associated bloodstream
674 infection; VAP: ventilator-associated pneumonia; CAUTI: catheter-associated urinary tract
675 infection; CVC: central venous catheter; BT: bleeding time, CT: clotting time; PT: prothrombin
676 time; APTT: activated partial thromboplastin time; FFP: fresh frozen plasma.

677

Table 3: Neurological outcomes of the 20 patients with GBS after SVPE

Clinical outcome	1 month	2 months	3 months	6 months
Cranial nerve involvement	7/20 (35%)	6/20 (30%)	4/20 (20%)	2/20 (10%)
Autonomic involvement	3/20 (15%)	3/20 (15%)	0/20 (0%)	0/20 (0%)
Sensory dysfunction	1/20 (5%)	1/20 (5%)	1/20 (5%)	1/20 (5%)
GBS disability score [¶]	0 = 0	0 = 1	0 = 1	0 = 2
	1 = 3	1 = 6	1 = 7	1 = 7
	2 = 9	2 = 6	2 = 6	2 = 5
	3 = 2	3 = 1	3 = 1	3 = 3
	4 = 3	4 = 5	4 = 5	4 = 3
	5 = 3	5 = 1	5 = 0	5 = 0
MRC sum score [†] *	47 (0-60)	49 (0-60)	53 (6-60)	58 (22-60)
ONLS [‡] *	4 (1-12)	3 (0-12)	3 (0-12)	2 (0-10)
R-ODS [§] *	26 (0-41)	33 (0-45)	37 (0-45)	38 (0-46)

* Median (range); ¶ GBS disability score (0 - 6) = 0: healthy state, 1: minor symptoms and capable of running, 2: able to walk 10 meters or more without assistance but unable to run, 3: able to walk 10 meters across an open space with help, 4: bedridden or chair-bound, 5: requiring assisted ventilation for at least part of the day, 6: dead; † MRC sum score: Medical Research Council sum score; ‡ ONLS: Overall Neuropathy Limitation Scale²²; § R-ODS: Rash-built Overall Disability Score²³

Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS.

SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, ^A measured in litres, ●: spell of hypotension (systolic BP < 90 mm Hg), ○: CVC insertion site bleeding, ▲: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.

Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (*n* = 20): twenty patients with GBS aged ≥ 18-years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (*n*=20): twenty-four patients aged ≥ 18-years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * *p* < 0.0001.

Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.




Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS. SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, A measured in litres, black dot: spell of hypotension (systolic BP < 90 mm Hg), empty drop: CVC insertion site bleeding, black triangle: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.




Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (n = 20): twenty patients with GBS aged ≥ 18-years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (n=20): twenty-four patients aged ≥ 18-years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * p < 0.0001.





Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.

Supplementary Figure: Hospital-acquired infections in the 20 patients with GBS treated with SVPE and the 24-hospital control patients without GBS.



SVPE: small volume plasma exchange, CLABSI: central line-associated blood stream infection, CAUTI: catheter-associated urinary tract infection, VAP: ventilator-associated pneumonia.

2017 CONSORT checklist of information to include when reporting a randomized trial assessing nonpharmacologic treatments (NPTs)*.
Modifications of the extension appear in italics and blue.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Title and abstract					
	1a	Identification as a randomized trial in the title	NA (Non-randomized)		
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4, 5	Refer to CONSORT extension for abstracts for NPT trials	3, 4, 5
Introduction					
Background and objectives	2a	Scientific background and explanation of rationale	6		
	2b	Specific objectives or hypotheses	6, 7		
Methods					
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7	When applicable, how care providers were allocated to each trial group	NA
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	No changes to methods after trial commencement		
Participants	4a	Eligibility criteria for participants	7, 8	When applicable, eligibility criteria for centers and for care providers	NA
	4b	Settings and locations where the data were collected	7		
Interventions†	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8	Precise details of both the experimental treatment and comparator	7, 8
	5a			Description of the different components of the interventions and, when applicable, description of the procedure for tailoring the interventions to individual participants.	9
	5b			Details of whether and how the interventions were standardized.	8, 9

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	5c.			Details of whether and how adherence of care providers to the protocol was assessed or enhanced	8, 9
	5d			Details of whether and how adherence of participants to interventions was assessed or enhanced	NA
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9		
	6b	Any changes to trial outcomes after the trial commenced, with reasons	No changes to trial outcomes after the trial commenced		
Sample size	7a	How sample size was determined	9	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	7b	When applicable, explanation of any interim analyses and stopping guidelines	10		
Randomization:					
- Sequence generation	8a	Method used to generate the random allocation sequence	NA (Non-randomized)		
	8b	Type of randomization; details of any restriction (such as blocking and block size)	NA (Non-randomized)		
- Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	NA (Non-randomized)		
- Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA (Non-randomized)		
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Blinding was not possible	If done, who was blinded after assignment to interventions (e.g., participants, care providers, those administering co-interventions, those assessing outcomes) and how	Blinding was not possible

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	11b	If relevant, description of the similarity of interventions	7, 8		
	11c			If blinding was not possible, description of any attempts to limit bias	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA		
Results					
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	11	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center	Single center study
	13b	For each group, losses and exclusions after randomization, together with reasons	No losses and exclusions after inclusion		
	13c			For each group, the delay between randomization and the initiation of the intervention	11
	new			Details of the experimental treatment and comparator as they were implemented	11-16
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7		
	14b	Why the trial ended or was stopped	NA (Trial completed)		
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.	NA
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	11-12		

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12-16		
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA		
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15		
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	12-15		
Discussion					
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group	NA
Generalizability	21	Generalizability (external validity, applicability) of the trial findings	16-20	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial	16-20
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	16-20		
Other information					
Registration	23	Registration number and name of trial registry	4		
Protocol	24	Where the full trial protocol can be accessed, if available	Manuscript reference no: 17		
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	21		

*Additions or modifications to the 2010 CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials
†The items 5, 5a, 5b, 5c, 5d are consistent with the Template for Intervention Description and Replication (TIDieR) checklist

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Table: Required documents of the safety and feasibility study of the small volume plasma exchange (SVPE) for Guillain-Barré syndrome patients for the World Health Organization Trial Registration Data Set

	Item/Label	Description
1	Primary Registry and Trial Identifying Number	Clinicaltrials.gov NCT02780570
2	Date of Registration in Primary Registry	May 23, 2016
3	Secondary Identifying Numbers	International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Protocol Number: PR-15086, Version no. 3, Date: 09/12/2015
4	Source(s) of Monetary or Material Support	GBS/CIDP Foundation International Fondation Mérieux: (Small Grants Program 2015)
5	Primary Sponsor	GBS/CIDP Foundation International
6	Secondary Sponsor(s)	Fondation Mérieux: (Small Grants Program 2014)
7	Contact for public queries	MD. BADRUL ISLAM Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam

		Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
8	Contact for scientific queries	MD. BADRUL ISLAM Principal Investigator (PI) Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
9	Public title	Small volume plasma exchange for Guillain-Barré syndrome
10	Scientific title	Small volume plasma exchange for Guillain-Barré syndrome in low-income countries: a safety and feasibility study
11	Countries of Recruitment	Bangladesh
12	Health condition(s) or problem(s) studied	Guillain-Barré syndrome (GBS)
13	Interventions	<u>Small Volume Plasma Exchange (SVPE)</u> A loading dose of low-molecular weight heparin (1.5 mg/kg) will be given subcutaneously at least two hours

before initiation of SVPE; the same dose will be administered once daily or divided into two equal doses daily for eight days or until SVPE is completed. Whole blood (7 mL/kg body weight) will be drawn from the central venous catheter into the blood transfusion bag in each session. The blood bag will be hung beside the patient for 2.5 h on a saline stand and left uninterrupted to allow plasma and blood cells to separate. The blood cells will be infused back into the patient and plasma will be discarded and replaced with fresh frozen plasma and colloid solution alternately (in equal volumes) via the closed-circuit SVPE kit illustrated in. In case of excessive clotting (bleeding time reduction of > 50% of baseline for that patient), aspirin (600 mg) will be administered orally at least two hours before the next SVPE session and continued thereafter at 150 mg orally/day until SVPE is completed. One blood bag will be used each day, with a total of six sessions/day. A total of 48 sessions will be performed over eight days, removing approximately 8000 mL plasma in total.

Central venous catheterized patients without GBS

To compare the safety of SVPE in patients with GBS in the context of the background risk of central line-associated blood stream infection (CLABSI) at the study intensive care (ICU) and high-dependency care (HDU) units, the incidence of CLABSI will be assessed in a control group of adult patients with a diagnosis other than GBS admitted to the same ICU and HDU units in the same period of time the patients with GBS will be enrolled for SVPE. We will assess the rate of CLABSI in

		patients aged ≥ 18 -years-old requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units.
14	Key Inclusion and Exclusion Criteria	<p><u><i>Inclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none">1. Patients aged ≥ 18-years-old fulfilling the diagnostic criteria for GBS of the National Institute of Neurological and Communicative Disorders and Stroke (NINDS)2. Unable to walk unaided for more than 10 meters (GBS disability score ≥ 3)3. Presented within 2 weeks of the onset of weakness4. Unable to afford standard treatment with IVIg or PE. <p><u><i>Exclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none">1. Patients with severe or terminal concomitant illness2. Evidence of healthcare-associated infection on admission (except for aspiration pneumonia)3. Previous history of severe allergic reaction to properly matched blood products and pregnant women will be excluded from the study. <p><u><i>Inclusion criteria for patients without GBS</i></u></p> <ol style="list-style-type: none">1. Patients aged ≥ 18-years-old2. Requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period of time the patients with GBS enrolled for SVPE. <p><u><i>Exclusion criteria for patients without GBS</i></u></p>

		<ol style="list-style-type: none"> 1. Patients with healthcare-associated infection present on admission (except aspiration pneumonia) 2. Pregnant women
15	Study type	<p><u>Type of the study:</u> Interventional</p> <p><u>Method of allocation:</u> Non-randomized</p> <p><u>Masking:</u> Non-masked</p> <p><u>Assignment:</u> Parallel arm</p> <ul style="list-style-type: none"> • SVPE in patients with GBS • Rate of CLABSI in patients without GBS <p><u>Purpose:</u> Safety and feasibility of SVPE</p>
16	Date of first enrolment	February 20, 2016
17	Target sample size	<p>SVPE in patients with GBS = 20</p> <p>Rate of CLABSI in patients without GBS = ≥ 20</p>
18	Recruitment status	<p>Completed:</p> <ul style="list-style-type: none"> • Twenty cases of GBS have been successfully treated with SVPE and 24 control cases without GBS have been recruited.
19	Primary Outcome(s)	<p><u>Primary outcome of safety:</u></p> <ol style="list-style-type: none"> 1. Number of patients with GBS treated with SVPE developing severe sepsis or septic shock due to central line associated blood stream infection (CLABSI) as per standard guideline (Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection); CDC Device-associated Module, BSI. January 2017) 2. Occurrence of venous thrombosis in the limb

		<p>where the CVC is placed. Venous thrombosis will be assessed according to Wells criteria (Philip S. Wells et al. Evaluation of d -Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis; N Engl J Med 2003;349:1227-35)</p> <p><u>Primary outcome of feasibility:</u></p> <ol style="list-style-type: none">1. Ability to remove at least eight litres of plasma by SVPE over eight days.
20	Secondary Outcome(s)	<p><u>Secondary outcome of safety:</u></p> <ol style="list-style-type: none">2. Relative risk of CLABSI due to SVPE compared to CLABSI in control patients without GBS treated using a CVC3. Hemodynamic instability during the SVPE procedure (variations in systolic blood pressure greater than 30 mmHg or sudden bradycardia involving a reduction in heart rate by more than 20 beats per min within 30 min of starting SVPE or an increase in heart rate above 120 beats per min)4. Development of anaemia (Hb <7 gm/dL) or serious haemorrhage requiring blood transfusion. <p><u>Secondary outcome of feasibility:</u></p> <ol style="list-style-type: none">1. Rate of CVC occlusion during the SVPE procedure2. The healthcare personnel's acceptability and

satisfaction with the SVPE procedure and any unanticipated events compromising the SVPE procedure as assessed using a standard questionnaire.

3. Neurological outcome will be assessed in terms of improvement in GBS disability score and MRC sum score at discharge and up to 4 weeks after entry.

BMJ Open

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022862.R2
Article Type:	Research
Date Submitted by the Author:	25-May-2018
Complete List of Authors:	Islam, Md Badrul; International Centre for Diarrhoeal Disease Research Bangladesh, LSSD Islam, Zhahirul; The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) , Laboratory Sciences and Services Division (LSSD) Rahman, Shafiqur; Uttara Adhunik Medical College, Anaesthesia and Intensive Care Endtz, Hubert; Erasmus University Medical Center, Department of Medical Microbiology and Infectious Diseases; Fondation Merieux Vos, Margreet; Erasmus MC Medical Center Rotterdam, Department of Medical Microbiology and Infectious diseases van der Jagt, Mathieu; Erasmus MC, Department of Intensive Care Van Doorn, Peter; Erasmus University Medical Center, Department of Neurology Jacobs, BC; Erasmus University Medical Center, Departments of Neurology and Immunology Mohammad, Quazi; National Institute of Neuroscience
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Medical management
Keywords:	Guillain-Barré syndrome, Small volume plasma exchange, Safety, Feasibility
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.	
SUPPLEMENTARY VIDEO.mp4	

SCHOLARONE™
Manuscripts

1 Title:

2 Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings:
3 a phase II safety and feasibility study

4 Authors

5 1. Badrul Islam

6 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
7 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
8 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)

9 E-mail: badrul.islam@icddr.org
10 bislamdmch@gmail.com

11 2. Zhahirul Islam

12 Laboratory Sciences and Services Division (LSSD)
13 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

14 E-mail: zislam@icddr.org

15 3. Shafiqur Rahman

16 Department of Intensive Care Medicine, Uttara Adhunik Medical College & Hospital.

17 E-mail: drshafiqk23@yahoo.com

18 4. Hubert P. Endtz

19 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
20 Center, Rotterdam, The Netherlands, and Fondation Mérieux, Lyon, France.

21 Email: hubert.endtz@fondation-merieux.org

22 5. Margreet C. Vos

23 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
24 Center, Rotterdam, The Netherlands.

25 Email: m.vos@erasmusmc.nl

26 6. Mathieu van der Jagt

27 Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The
28 Netherlands.

29 Email: m.vanderjagt@erasmusmc.nl

30 7. Pieter A. van Doorn

31 Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.

32 E-mail: p.a.vandoorn@erasmusmc.nl

33 8. Bart C. Jacobs

34 Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam,
35 The Netherlands.

36 E-mail: b.jacobs@erasmusmc.nl

37 9. Quazi D. Mohammad

38 National Institute of Neuroscience (NINS), Dhaka, Bangladesh.

39 E-mail: quazideenmohammad@gmail.com

41 Corresponding author

42 Badrul Islam

43 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
44 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
45 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

46 E-mail: bislamdmch@gmail.com

48 Word count: 4904 (Excluding abstract, reference, table and figures)

49

ABSTRACT

OBJECTIVE

To assess the safety and feasibility of small volume plasma exchange (SVPE) as an alternative to standard plasma exchange (PE) or intravenous immunoglobulin (IVIg) for Guillain-Barré syndrome (GBS) patients.

DESIGN

Non-randomized, single arm, interventional trial.

SETTING

National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.

PARTICIPANTS

Twenty adult (>18 years) patients with GBS presented within 2 weeks of onset of weakness who were unable to walk unaided for more than 10 meters.

INTERVENTIONS

SVPE involves blood cell sedimentation in a blood bag and removal of supernatant plasma after blood cells are re-transfused. This procedure was repeated three to six times a day, for eight consecutive days.

OUTCOME MEASURES

Serious adverse events (SAE) were defined as severe sepsis and deep venous thrombosis related to the central vein catheter (CVC) used during SVPE. SVPE was considered safe if less than 5/20 patients experienced a SAE, and feasible if 8 L plasma could be removed within 8 days in at least 15/20 patients.

RESULTS

Median patient age 33 years (IQR 23-46; range 18-55); 13 (65%) were male. Median MRC sum score was 20 (IQR 0-29; range 0-36); three (15%) patients required mechanical ventilation. One patient developed SAE (severe sepsis, possibly related to CVC). Minor adverse effects were

transient hypotension in 10 (50%) patients; CVC-associated bleeding in 10 (50%); transfusion reaction to fresh frozen plasma in 4 (20%); and hypo-albuminemia, anaemia or electrolyte imbalance in 4 (20%). Removal of 8 L plasma was possible in 15 (75%) patients. GBS disability score improved by at least one grade in 14 (70%) patients four weeks after SVPE started. No patients died.

CONCLUSION

SVPE seems a safe and feasible alternative treatment to standard PE or IVIg for GBS; further studies of clinical efficacy in low-resource developing countries are warranted.

TRIAL REGISTRATION

Clinicaltrials.gov NCT02780570 on May 23, 2016

94 **Strength and limitations of the study:**

95

- 96 1. The strength of this study underlies the novel and simple technique of SVPE, which is
- 97 much less expensive than conventional immunotherapies (plasma exchange and
- 98 intravenous immunoglobulin)
- 99 2. SVPE is corroborated as safe and feasible for the first time in a prospective and
- 100 standardized cohort of patients with Guillain-Barré syndrome (GBS).
- 101 3. The intrinsic limitations of this study are its non-randomized, single arm nature, which is
- 102 conducted in a single center with a limited sample size of GBS patients.
- 103 4. Clinical efficacy of SVPE on patients with GBS was a secondary end-point assessment
- 104 and therefore deserves a randomized controlled trial in future to assess the clinical
- 105 efficacy of SVPE for the patients with GBS.

106

107 Introduction

108 Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a
109 yearly incidence of 1.2 to 2.3 cases per 100,000 per year.¹ GBS is characterized by rapidly
110 progressive limb weakness and, in a proportion of cases, respiratory failure (25%) or severe
111 autonomic dysfunction (10%). Plasma exchange (PE) was the first treatment proven to be
112 effective for GBS, if given within 4 weeks of the onset of weakness.²⁻¹¹ Conventionally for GBS
113 patients, three to five plasma exchange sessions are done in alternate days within a span of 7 to
114 14 days targeting a plasma exchange rate of 120 - 200 ml/kg (40-50ml/kg/day).⁷ Later studies
115 showed treatment with intravenous immunoglobulin (IVIg) (0.4 g/kg per day for 5 days) has a
116 similar efficacy as PE in patients with GBS who are unable to walk, if started within 2 weeks of
117 the onset of weakness.^{12 13}

118
119 Unfortunately, most patients in low-income countries cannot afford expensive treatment with
120 either PE or IVIg.¹⁴ In Bangladesh, a full course of IVIg for a 60 kg adult costs approximately
121 12,000-16,000 US\$ and treatment with conventional PE for 5 days costs approximately 4,500-
122 5,000 US\$. The mean income in Bangladesh was 4 US\$ per day in 2016 (World Bank and
123 Bangladesh Bureau of Statistics 2016); IVIg and PE cost the equivalent of 3,000 and 1,250 mean
124 income days, respectively. At present, the majority (92%) of patients with GBS in Bangladesh
125 receive supportive care only.¹⁴ In addition, mobile PE equipment is not available in Bangladesh;
126 therefore, patients admitted to the intensive care unit (ICU) cannot receive PE. We previously
127 reported the mortality rates for GBS in Bangladesh range from 12 to 14% and observed 29% of
128 patients with GBS in Bangladesh are unable to walk at 6 months after onset; these poor outcomes
129 are undoubtedly due to the low rates of specific treatment with PE or IVIg.^{15 16}

130

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

131 Small volume plasma exchange (SVPE) may represent a cheap, effective alternative treatment for

132 GBS. SVPE is based on the same principle as conventional PE (selective removal of plasma) but

133 uses a novel, simple technique with much lower costs (approximately 500 US\$). The current non-

134 randomized trial was designed to investigate the safety and feasibility of SVPE in 20 patients

135 with GBS admitted to the National Institute of Neurosciences Hospital in Dhaka, Bangladesh.

136

137 **Methods/Design**

138 *Study design*

139 For this non-randomized, single arm, interventional safety and feasibility trial, 20 adult patients

140 with GBS were enrolled between March 2016 and December 2016 for SVPE at the National

141 Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh. A detailed study protocol

142 was published previously and includes definitions of all variables used in this study.¹⁷

143

144 Four to six daily sessions of whole blood sedimentation and removal of supernatant plasma after

145 re-transfusion of the sedimented blood cells was planned for the 20 patients with GBS, with a

146 target of removing an overall volume of at least 8 litres (L) of plasma over a total of 8 days.¹⁷

147 (See supplementary video for SVPE procedure)

148

149 Patients with GBS were monitored according to a standard protocol throughout the course of

150 SVPE until the second day after withdrawal of the central venous catheter (CVC) in order to

151 assess predefined measures of safety and feasibility and followed up for six months to assess

152 neurological outcome. The protocol was reviewed and approved by the institutional research and

153 ethics review committees at the icddr,b and registered at clinicaltrials.gov (NCT02780570).¹⁷ All

154 patients provided written informed consent to participate in this study.

155

156 *Patient and Public Involvement*

157 Patients and or public were not involved either in the development of the research question, study
158 design and outcome measure or recruitment to and conduct of the study.

159

160 *Inclusion and exclusion criteria for patients with GBS*

161 Patients aged ≥ 18 -years-old fulfilling the diagnostic criteria for GBS of the National Institute of
162 Neurological and Communicative Disorders and Stroke (NINDS)¹⁸ were enrolled, provided they
163 were unable to walk unaided for more than 10 meters (GBS disability score ≥ 3), presented
164 within 2 weeks of the onset of weakness, and were unable to afford standard treatment with IVIg
165 or PE. Patients with concomitant severe or terminal illnesses, evidence of healthcare-associated
166 infection (HAI) on admission (except for aspiration pneumonia), a previous history of severe
167 allergic reactions to properly matched blood products, and pregnant women were excluded from
168 the study.

169

170 *Control cohort*

171 To compare the safety of SVPE in patients with GBS in the context of the background risk of
172 central line-associated blood stream infection (CLABSI) at our institution, we prospectively
173 assessed the incidence of CLABSI in a hospital control group of 24 adult patients without GBS
174 receiving neurocritical care. Hospital controls were eligible based on the following
175 characteristics: ≥ 18 -years-old, a neurological diagnosis other than GBS, and a CVC placed for $>$
176 2 and ≤ 8 calendar days after admission to the same ICU or HDU unit as the SVPE-treated
177 patients. Patients with a HAI (except aspiration pneumonia) and pregnant women were excluded
178 from the control group.

179

180

181 *Primary and secondary outcome measures*

182 The primary outcome measures of safety were the number of patients with GBS treated with
183 SVPE who developed either severe sepsis or septic shock due to CLABSI¹⁹ and the occurrence of
184 venous thrombosis in the limb where the CVC was placed. The primary outcome measure of
185 feasibility was the ability to remove at least 8 L of plasma over 8 days.

186 The secondary outcome measures of the safety of SVPE were the relative risk of CLABSI due to
187 SVPE (compared to CLABSI in the hospital control group without GBS), hemodynamic
188 instability during the SVPE procedure, and development of anaemia (Hb < 8 gm/dL) or any
189 catheter-related haemorrhage requiring a blood transfusion.

190 The secondary outcome measure of feasibility of SVPE was the rate of CVC occlusion during the
191 SVPE procedure. In addition, neurological outcome was assessed using the GBS disability
192 score²⁰, MRC sum score²¹, Overall Neuropathy Limitation Scale (ONLS)²² and Rasch-built
193 Overall Disability Scale (R-ODS)²³ at 1st, 2nd, 3rd, and 6th months from the start of SVPE.

195 *Procedure safety documentation and cost of SVPE*

196 Strict aseptic procedures were followed to prevent CLABSI.²⁴⁻²⁶ SVPE was documented in terms
197 of the duration and amount of plasma removed in each session, and the type and volume of
198 replacement fluid and fresh frozen plasma (FFP) used. Throughout the procedure, the
199 haemodynamic, haematological, biochemical, coagulation and infection profiles of the SVPE-
200 treated patients were monitored according to the protocol.¹⁷ Screening for hepatitis B and C
201 viruses, human immunodeficiency virus (HIV) and syphilis were performed as patient baseline
202 assessments, and also on donor FFP before administration. CLABSI, primary and secondary
203 bloodstream infections¹⁹, catheter-associated urinary tract infection (CAUTI)²⁷, ventilator-
204 associated pneumonia (VAP)²⁸ and other HAI^{29 30} were documented in the SVPE-treated patients
205 with GBS and the hospital control group. Expenditure for the full course of SVPE will be

approximately 500 US\$ [fresh frozen plasma (24 bags) = 240 US\$, blood bag and saline sets: 40 US\$, low molecular weight heparin: 110 US\$, routine investigation: 50 US\$, saline: 10 US\$, CV catheter: 40 US\$ = total 490 US\$].

Sample size

This safety and feasibility study enrolled 20 patients with GBS for SVPE. We could not perform a formal power calculation for this safety and feasibility study. The sample size was based on previous pilot studies conducted in GBS.^{31 32} The baseline rate of CLABSI was measured in the hospital control group of 24 patients without GBS admitted to the same study facility who required a CVC for at least 8 days during the study period.

Stopping rules for the trial based on safety and feasibility

Decision to stop the SVPE trial was designated using a Bayesian approach.³³⁻³⁵ Accordingly, a predictive success rate of 75% was predefined for the SVPE procedure. If more than 5 of 20 patients experienced an SAE, or if it appeared impossible to remove at least 8 L of plasma over 8 days in at least 15 of 20 patients, the procedure was considered unsafe or unfeasible.

Statistical analysis

The rate of HAIs (CLABSI, VAP and CAUTI) per 1000 device days were calculated by dividing the number of each HAI during the study period by the number of device days and multiplying the result by 1000. The infection safety profile for SVPE was assessed by calculating the standardized infection ratio to define the risk of HAIs in patients with GBS treated with SVPE. The standardised infection ratio (SIR) was calculated by dividing the number of observed HAI by the number of HAI predicted (i.e., the infection rate in the control

group). The predicted HAI rate was calculated using the rates of HAI in the hospital control group of patients without GBS during the study period. Percentage values were compared using the Chi-square test or Fisher's exact test (two-tailed) and median values, the Mann-Whitney U-test using SPSS 22 software (IBM SPSS Statistics for Windows Version 22.0., IBM Corp., Armonk, NY, USA). Analyses were performed on an intention-to treat basis. All *P*-values reported are two-sided; *p* < 0.05 was considered significant.

Results

Patients and hospital controls

The demographic and clinical characteristics of the 20 patients with GBS are given in Table 1. The median age of the patients with GBS was 33 years (range; 18-55); median body weight was 60 kg (IQR, 55-65 kg; range, 50-72 kg) and 13 (65%) patients were male (Fig. 1). On admission and before the start of SVPE, all 20 patients with GBS were unable to walk independently (GBS disability score, 4). One patient required mechanical ventilation from the second day after the onset of weakness; SVPE was started on the fourth day of mechanical ventilation (patient 9, Fig. 1). Two of the 19 patients who did not require mechanical ventilation at the start of the study required mechanical ventilation on the second day after initiation of SVPE (patients 11 and 19, 11 and 2 days after the onset of weakness, respectively; Fig. 1). The median MRC sum score for the limb muscles in all 20 patients was 20 (IQR: 0-29; range: 0-36; Fig. 1). Symptoms of a preceding infection in the 4 weeks before the onset of weakness were present in 18 (90%) patients with GBS, of whom 10 (50%) had diarrhoea. Median duration from admission to start of SVPE was two days (IQR, 2-3 days; range, 0-7 days). Median duration to nadir from the onset of weakness was five days (range, 1-13 days). Electrodiagnostic nerve conduction studies indicated 15 (75%) patients had an axonal subtype and 5 (25%) patients had a demyelinating subtype of GBS. Median duration from onset of weakness to NCS examination was 10 days (range, 4-16

days). All patients had albuminocytologic dissociation; median CSF protein was 166 mg/dL (range 117-253 mg/dL). Median duration from onset of weakness to CSF examination was 11 days (range, 4-17 days).

Median age of the 24 hospital control patients without GBS was 44 years (IQR, 25-57; range, 18-74); 10 (42%) were male. Age and gender distribution were not significantly different compared to the 20 patients with GBS ($p = 0.2155$, $p = 0.1434$, respectively). The diagnoses for these 24 patients were: brain tumour ($n = 5$), transverse myelitis ($n = 5$), head trauma after road traffic accident ($n = 3$), viral meningoencephalitis ($n = 2$), myasthenia gravis ($n = 2$), compressive cervical myelopathy ($n = 2$), cerebrovascular accident ($n = 2$), motor neuron disease ($n = 1$), electrolyte imbalance ($n = 1$) and status epilepticus ($n = 1$).

Primary endpoints

One patient with GBS treated with SVPE developed severe sepsis, possibly due to SVPE-related CLABSI (SVPE window-period blood culture revealed methicillin-resistant *Staphylococcus aureus*). This patient required intravenous fluid, noradrenalin infusion and intravenous antibiotics, but eventually improved (patient 11, Fig. 1). This patient also had signs and symptoms suggestive of aspiration pneumonia and VAP; *Streptococcus spp.* was isolated from pulmonary aspirates. Further laboratory results revealed dys-electrolytemia, anaemia and hypoalbuminemia. No patients experienced deep vein thrombosis due to the CVC for SVPE. Fifteen (75%) of the 20 patients met the primary endpoint of feasibility, defined as the ability to remove at least 8 L of plasma in eight days. The median volume of plasma removed was 8.5 L (IQR, 7.9-8.8 L; range, 6.3-9.6 L; Fig. 1). The median plasma exchange rate was 140 mL/kg bodyweight (IQR, 125-155 mL/kg; range, 110-175 mL/kg) over 8 days and 16 (80%) patients had a plasma exchange rate > 120 mL/kg (Table 2).

281 *Secondary endpoints*

282 *Infections among SVPE-treated patients with GBS and hospital controls*

283 Among the 20 patients with GBS treated with SVPE, six (30%) had fever during SVPE (Fig. 1,
284 Supplementary Figure 1), including 2 (10%) patients with leucocytosis who were diagnosed with
285 HAI (VAP and CAUTI in one patient; VAP in one patient). In three out of four (20%) patients
286 with fever without leucocytosis, fever subsided within two to three days without antimicrobial
287 therapy (Fig. 1). The remaining patient with pyrexia without leucocytosis had microbiological
288 evidence of both CLABSI and VAP (patient 11, Fig. 1). In all other 14 patients with GBS, no
289 fever was documented during the course of SVPE until the tenth day of SVPE (second day after
290 removal of the CVC for SVPE). Five of these 14 patients had leucocytosis, but no site-specific
291 HAI could be detected. However, one of the nine patients without fever but leucocytosis fulfilled
292 the criteria for CAUTI (patient 12, Fig. 1). All three patients who required mechanical ventilation
293 subsequently developed VAP; two of the 13 patients who required a urinary catheter developed a
294 CAUTI (patient 11, Fig. 1). No patients died during the 6 months follow-up.

295

296 All 24-hospital control patients without GBS required mechanical ventilation and an indwelling
297 urinary catheter. Of these patients, 22 (92%) patients had fever, of whom 15 (63%) had
298 leucocytosis; a diagnosis of a specific HAI could be made 14 of these 15 patients (CLABSI in
299 two, CAUTI in one, VAP in 11) and four (17%) fulfilled the criteria for severe sepsis
300 (Supplementary Figure 1). Seven (29%) of the 24 hospital control patients had fever without
301 leucocytosis. In two of these seven patients, a specific HAI was diagnosed (CAUTI and VAP in
302 one, and VAP in one). In two hospital control patients, no fever was documented until day 10
303 after first placement of the CVC, but leucocytosis was present and no site-specific HAI could be
304 detected (Supplementary Figure 1).

305

The rates of CLABSI, CAUTI and VAP per 1000 device days in the SVPE-treated patients with GBS were 6.25, 19.2 and 40 compared to 10.4, 10.4 and 67.7 for the hospital control patients without GBS, respectively. The relative risks of CLABSI, CAUTI and VAP associated with SVPE were 0.6, 1.2 and 1.8, respectively, compared to hospital control patients. The rates of CLABSI, CAUTI and VAP were comparable between SVPE-treated patients with GBS and hospital control patients ($p > 0.05$). Antimicrobial agents were used more frequently in the hospital control patients ($p < 0.0001$; Fig. 2). The standardised infection ratios for CLABSI, CAUTI and VAP for SVPE-treated patients with GBS were 0.6, 1.8 and 1.9, respectively.

Other secondary endpoints

Ten (50%) of the 20 patients treated with SVPE experienced transient hypotension during SVPE, which was corrected by infusion of 200-300 mL crystalloid saline (Fig. 1). Minor bleeding through the CVC insertion site (excluding at the time of insertion) was observed in 10/20 patients (50%; Fig. 1); these bleeds required a pressure pack. Reduction of the anticoagulant dose along with a pressure pack was required in 3/20 patients, who all had a prolonged prothrombin time (PT). Three patients had single episode of haemorrhage through the urinary catheter: one was diagnosed with a CAUTI with normal coagulation profile, one had a prolonged PT, the other had sterile haematuria with normal PT. Overall, PT and activated partial thromboplastin time (aPTT) were prolonged in 4/20 patients and only PT was prolonged in 2/20 patients. Clotting time and bleeding time were not prolonged in any patient. One patient developed anaemia (haemoglobin, 8 gm/L) at the end of SVPE; this patient also had severe sepsis and required one unit of blood transfusion (patient 11, Fig. 1). CVC blockages were not observed in any SVPE-treated patients with GBS. One patient with increased clotting tendency who required an increased dose of low molecular weight heparin had shortened clotting time (CT) ($< 50\%$ of upper limit of normal), though PT was normal (patient 10, Fig. 1).

331 The neurological outcomes of the SVPE-treated patients with GBS at six months in terms of
332 neurological scores are given in Table 3. Median time to recover the ability to walk unaided was
333 4 weeks (Fig. 3). Fourteen (70%) of the 20 patients had an improvement in GBS disability score
334 of one or more grades at four weeks after the onset of SVPE. At one month, 12 patients (60%)
335 were able to walk unaided, two patients (10%) were able to walk aided and six (30%) patients
336 were bedbound, of whom three still required mechanical ventilation. At three months, 14 (70%)
337 patients were able to walk unaided, one (5%) could walk with aid and five (25%) patients were
338 bedbound. At six months, 14 (70%) patients were able to walk unaided, three (5%) could walk
339 with aid and three (15%) remained bedbound (Table 3).

340

341 *Other relevant clinical and laboratory findings*

342 Allergic/transfusion reaction to FFP was observed in four patients with GBS treated with SVPE
343 (Fig. 1). These transfusion reactions presented as an itchy erythematous skin rash (three patients),
344 fever (two patients), hypotension (one patient) following transfusion of FFP; all of these reactions
345 were managed with oral antihistamine (and intravenous saline in one patient) without further
346 complications.

347

348 The other documented haematological and biochemical abnormalities were hypo-albuminemia (n
349 = 4), thrombocytopenia ($n = 6$), hyponatraemia ($n = 1$), hypokalaemia ($n = 3$), hypomagnesaemia
350 ($n = 1$), hypocalcaemia ($n = 3$); (Table 2).

351

352 *Immunoglobulin dosage admitted by FFP*

353 During SVPE the median volume of FFP received per GBS patient as replacement fluid was
354 6000 ml (range, 5000 ml to 6000 ml). Considering the normal plasma IgG level of 11.20 mg/ml

(range, 6.9 mg – 17.6 mg)³⁶, SVPE treated GBS patients received IgG dose of median 0.9 g/kg (range 0.6 g/kg – 1.3 g/kg).

Discussion

Principal findings

This study suggests SVPE may represent a safe and feasible alternative to conventional plasma exchange for patients with severe GBS in limited-resource settings. Of the 20 patients in this study, one (5%) experienced a SAE (severe sepsis due to probable CLABSI). The rate of SAE was not significantly higher than the hospital control group without GBS with a CVC, and no patients had a CVC-related thromboembolic event in patients with SVPE. We were able to remove the prespecified target volume (8 L) of plasma as the target primary endpoint of feasibility in 15/20 (75%) patients with GBS. Median plasma exchange volume and rate during SVPE were 8.4 L and 140 mL/kg, respectively. Minor adverse effects included transient hypotension during SVPE in 50% (10/20), minor haemorrhage from CVC insertion site in 50% (10/20), transfusion reaction to fresh frozen plasma in 20% (4/20), and hypo-albuminemia, anaemia and electrolyte imbalance in 20% (4/20) of patients. An improvement of at least one grade on the GBS disability score was observed for 14/20 (70%) patients at four weeks after the initiation of SVPE. No patients died.

Comparison with baseline hospital control patients and standard/modified PE

With respect to HAIs, no significant differences were observed in the frequency of CLABSI, severe sepsis, VAP or CAUTI between the SVPE-treated patients with GBS and 24 hospital control patients without GBS treated using a CVC in the same ICU or HDU (Fig. 2). However, antimicrobial agents were used more frequently, usually prophylactically, in the hospital control patients compared to the patients with GBS treated with SVPE ($p < 0.0001$; Fig. 2). The

probability of detecting microorganisms in clinical infections may have been reduced due to overzealous use of antibiotics in the hospital control patients. Early trials of PE in patients with GBS showed 34% of patients develop severe infections.^{7 11} Subsequently, another large trial documented septicaemia in 19% of patients.⁵ However, the rates of CLABSI were not reported.

A previous RCT on GBS from the US showed a beneficial effect with PE rate of 40-50 ml/kg/session, for 3 to 5 sessions in 7 to 14 days, which comes to a total PE volume of 120-250 ml/kg.⁷ The first French RCT on adult GBS patients showed beneficial effect of 4 PE sessions [2 plasma volume (3.5 L) per PE session] over 8 days and in range, 6 – 12 L plasma was removed per patient.⁴ Subsequent French RCT with PE dose escalation showed, 2 PE sessions [1.5 plasma volume per PE session] is beneficial in mild to moderate GBS cases but less effective than 4 PE sessions in severe GBS cases and 6 PE sessions are as effective as 4 PE sessions in severe cases of GBS.⁵ In this RCT the exact total plasma volume exchanged per patient was not mentioned, but the authors indicated that the rate of plasma exchange was 40-ml/kg body weight per PE session. As to that a 60-70 kg person should have an exchange of 2.4 L-2.8 L per session and the therapeutic range of plasma volume to be exchanged would be 5.6 L to 11.2 L ml (2 to 4 PE sessions).

During the piloting of the SVPE procedure we assessed that removal of 1 L of patient plasma could be feasible in a day. Therefore we defined our target plasma volume of 8 L to be removed in 8 days. The median total PE volume and rate in SVPE was 8.4 L and 140 ml/kg, which is within the same range as in both the French and American RCT on PE for adult GBS patients. We were able to remove >120 mL/kg plasma in 80% of patients, which should provide a therapeutic effect.³⁷ Notably, the body weight of our patients may be lower than that of patients

in western countries. In addition, SVPE was complete within 8 days, shorter than the usual time required for a full session of PE (10 to 12 days).

Replacement fluid used in SVPE was FFP. We have several justifications in favour of using FFP instead of human albumin or other available colloidal solutions available in Bangladesh. First FFP is safe in terms of microbiological safety since stringent screening for viral and bacterial contamination was performed before infusion. Second, in contrast to human albumin and colloid solutions, FFP contains normal human IgG that could contribute beneficial immunotherapeutic effect in GBS and previously used as replacement fluid in large PE trials, quintessentially with the same volume (half the volume of replacement fluid) we used in SVPE.⁴⁵ SVPE treated GBS patients received approximately half the amount of IgG from the FFP used as replacement fluid compared to the total IVIg doses traditionally used in GBS (2gm/kg). Third, FFP contains all human plasma proteins that helps preservation of plasma colloid osmotic pressure and prevents formation of oedema and hypotension. Lastly FFP is much cheaper than commercial human albumin.

In each day three units of FFP were transfused as replacement fluid after the last session of SVPE and in the initial two to three sessions, normal saline was used as replacement fluid. This was done to achieve the maximum immunotherapeutic effect of FFP as SVPE was not resumed before the next day and the IgG in FFP remained in the circulation overnight for a longer period of time (10 to 12 hours). However due to long half life of IgG, substantial amount of IgG present in FFP were probably washed away due to repeated plasma removal both during SVPE and standard PE.

In GBS, treatment with modified methods of PE done previously, were device based and done on limited number of GBS patients. In one study on 25 GBS patients from India, daily removal of small volume of plasma (10-15 ml plasma/kg body weight) for duration of median 3 days using

traditional PE machine was shown to be clinically beneficial.³⁸ In another study from the same country, 12 GBS patients were treated with PE over 10 days using different PE-machine kit (REF627 kit from Haemonetics Corporation Limited on MCS+ machine) where authors claimed clinical improvement, however the main focus was on cost effectiveness and the total plasma volume exchanged per patient was not mentioned.³⁹ Nevertheless these methods are based on specific devices those are not in common practice, nor the trained personnel for these are available in the developing countries.

Important observations in terms of secondary endpoints were transient hypotension, transfusion reaction to FFP and minor bleeding through the CVC insertion site. Hypotension is a common complication during traditional PE that affects nearly half of patients.⁵ Spells of hypotension during SVPE were more frequent during the three to four days after initiation of SVPE, and could be easily corrected by rapid infusion of 300-400 mL saline (Fig. 1). The hypotension could possibly be explained by hypovolemia due to drawing blood or as a result of the compromised autonomic nervous system in patients with GBS. As SVPE proceeded, hypotensive spells were encountered less frequently despite drawing the same volume of blood, which may in part be explained by adaptation of the vasomotor system or recovery from autonomic dysfunction. Minor bleeding through the CVC insertion site occurred in 50% of patients and could be controlled by applying a simple pressure pack over the CVC insertion site in most cases; mild prolonged PT was noted in 30% (3/10) patients. However, spontaneous bleeding usually occurs if the PT is more than 2.5 times prolonged and PC is $< 0.50 \text{ lac}/\mu\text{L}$.⁴⁰ Movement of the limb where the CVC was placed may have caused traction on the CVC and contributed to local bleeding in the other seven patients. Haematuria is not uncommon in patients with a UTI, as may have occurred in one SVPE treated patient; traumatic traction of the urinary catheter may cause haematuria in two other catheterized SVPE-treated patient taking oral aspirin, who had haematuria and sterile urine.

We also monitored the major organ function and biochemical status of the patients treated with SVPE. No patients experienced hepatic or renal impairment. One patient developed anaemia and hypoalbuminemia; this patient had severe sepsis, a common cause of anaemia and hypoalbuminemia in critically ill patients admitted to an ICU (patient 11, Fig. 1). Electrolyte imbalances were detected in 15% of the SVPE-treated patients with GBS, and were mild, subclinical and easily corrected.

460

The median reported durations to recovery of independent walking in patients with GBS in large-scale RCTs after PE are 53, 52 and 70 days^{4 5 7}; compared to 30 days in our patients treated with SVPE. Moreover, 60% of the patients with GBS treated with SVPE were able to walk independently at four weeks, whereas 20% of patients with GBS acquired independent walking ability at four weeks after traditional PE. However, these differences may possibly be due to the small sample size and variations in demographic and neurophysiological characteristics between cohorts. Finally, SVPE was completed in all 20 patients and no patients died.

468

469 *Limitations of SVPE*

SVPE is a time-consuming and labour-intensive procedure, which is a limitation. We used multiple thin-lumen tubing systems interconnected with a multichannel connector device, which may increase the chance of blood coagulating within the tubing system. Coagulation may require manipulation or replacement of the tubing to ensure free flow of blood and saline. Such handling could increase the chance of microbial contamination. A single continuous wide-lumen tubing system (SVPE kit) could resolve this problem. Most importantly, personnel conducting the SVPE procedure should maintain proper aseptic technique, which can sometimes be challenging in developing countries. Furthermore, other adaptations such as provision of a larger blood bag or

478 increasing the number of days for SVPE could be considered to increase the plasma exchange
479 rate.
480
481 *Clinical implications and future research*
482 Despite the limitations, our study showed SVPE is a safe and feasible treatment for GBS in a
483 resource-limited setting where IVIg or PE are either unavailable or unaffordable. Specifically, the
484 poorest 20% of the world's population (1.8 billion people) who typically earn less than 10 US\$
485 per day and who are not covered by a national health insurance system may benefit. Considering
486 the incidence of GBS is 2/100,000 in developing countries, approximately 40,000 patients could
487 potentially benefit from SVPE every year, worldwide. In the future, a multicentre RCT is
488 required to assess the clinical efficacy of SVPE for patients with GBS. If proven effective, SVPE
489 could be an affordable and easily available alternative plasma exchange technique in low-income
490 countries for patients with GBS and other disorders, who at present cannot afford standard PE
491 due to its high cost and unavailability.

Declarations

Acknowledgements: This research activity was funded by GBS/CIDP Foundation International, USA and Fondation Mérieux, Lyon, France. The icddr,b acknowledges with gratitude the contributions of the Government of Bangladesh, Global Affairs Canada (GAC), Swedish International Development Cooperation Agency (Sida), and Department for International Development, UK (DFID). Md Ekhlash Mia and Smrity Akhter assisted this study in a full-time capacity. We are grateful to all of the neurologists from the NINS who referred their patients to us and K. S. Fahim for his support in preparation of the diagrams in this article.

Authors' contributions: BI, PVD, BJ, QDM, ZI, and HPE conceived the study design and sample size of the study. MV, MVJ, SR, and HPE contributed to the infection safety guidelines in the study design. BI and QDM conducted the study and BI collected and analysed the data and drafted the manuscript. All authors have critically revised the manuscript and have read and approved the final manuscript.

Funding: This study was funded by two competitive research grants:

1. The GBS/CIDP Foundation International GBS grant (major contribution)
2. The Fondation Mérieux: Small Grants Program 2014 (partial contribution)

Role of the funding source: The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

523 *Competing interests:* No investigators have any competing financial, professional or personal
524 interests that may have influenced the findings described in this manuscript to disclose.
525
526 *Ethics approval and consent to participate:* The Institutional Review Board (IRB) of the icddr,b,
527 comprised of an Ethical Review Committee (ERC) and Research Review Committee (RRC),
528 reviewed and approved this study protocol on 09/12/2015 (reference number: PR-15086, version
529 no 3).
530
531 *Patient consent:* Obtained.
532
533 *Data sharing:* The dataset is available from the lead author on request.
534
535 *Transparency:* The corresponding author affirms that the manuscript is an honest, accurate and
536 transparent account of the study being reported; that no important aspects of the study have been
537 omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have
538 been explained.
539

References

1. Willison HJ, Jacobs BC, and van Doorn PA. Guillain-Barre syndrome. *Lancet* 2016;388(10045):717-27.
2. Van Koningsveld R, Van Doorn PA, Schmitz PI et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. *Neurology* 2000;54(3):620-5.
3. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. *Medicine* 1969;48:173-215.
4. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. *Ann Neurol* 1987;22(6):753-61.
5. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. *Ann Neurol* 1997;41(3):298-306.
6. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Plasma exchange in Guillain-Barre syndrome: one-year follow-up. *Ann Neurol* 1992;32(1):94-7.
7. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. *Neurology* 1985; 35(8):1096-104.
8. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. *Lancet* 1984;1(8382):877-9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

563 9. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma
564 exchange in acute inflammatory polyradiculoneuropathy. *Lancet*
565 1984;2(8415):1296-9.

566 10. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for
567 Guillain-Barre syndrome. *Cochrane Database Syst Rev* 2014:Cd002063.
568 [http://cochranelibrary-
569 wiley.com/doi/10.1002/14651858.CD002063.pub6/epdf] Accessed 23
570 April 2018.

571 11. Chevret S, Hughes Richard AC, Annane D. Plasma exchange for Guillain-
572 Barré syndrome. *Cochrane Database Syst Rev* 2017; (2).
573 [http://cochranelibrary-
574 wiley.com/doi/10.1002/14651858.CD001798.pub3/epdf] Accessed 23 April
575 2018.

576 12. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter:
577 immunotherapy for Guillain-Barre syndrome: report of the Quality
578 Standards Subcommittee of the American Academy of Neurology.
579 *Neurology* 2003; 61(6):736-40.

580 13. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous
581 immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch
582 Guillain-Barre Study Group. *N Engl J Med* 1992; 326(17):1123-9.

583 14. Islam MB, Islam Z, Farzana KS, et al. Guillain-Barre syndrome in
584 Bangladesh: validation of Brighton criteria. *J Peripher Nerv Syst* 2016;
585 21(4):345-351.

- 586 15. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre
587 syndrome associated with Campylobacter infection in Bangladesh.
588 *Neurology* 2010; 74(7):581-7.
- 589 16. Ishaque T, Islam MB, Ara G, et al. High mortality from Guillain-Barre
590 syndrome in Bangladesh. *J Peripher Nerv Syst* 2017;22(2):121-126.
- 591 17. Islam MB, Islam Z, Rahman S, et al. Small volume plasma exchange for
592 Guillain-Barre syndrome in resource poor settings: a safety and feasibility
593 study. *Pilot Feasibility Stud* 2017;3:40.
- 594 18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for
595 Guillain-Barre syndrome. *Ann Neurol* 1990;27 Suppl:S21-4.
- 596 19. Centers for Disease Control and Prevention. Bloodstream Infection Event
597 (Central Line-Associated Bloodstream Infection and Non-central Line
598 Associated Bloodstream Infection) 2018;
599 [https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf]
600 Accessed 23 May 2018.
- 601 20. Hughes RA, Newsom-Davis JM, Perkin GD et al. Controlled trial
602 prednisolone in acute polyneuropathy. *Lancet* 1978;2(8093):750-3.
- 603 21. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in
604 the assessment of muscle strength and functional abilities in Guillain-Barre
605 syndrome. *Muscle Nerve* 1991;14(11):1103-9.
- 606 22. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the
607 Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry*
608 2006;77(8):973-6.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

609 23. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall
610 Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
611 *Neurology* 2011;76(4):337-45.

612 24. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in
613 catheter related bloodstream infections in Michigan intensive care units:
614 observational study. *Bmj* 2010;340:c309.

615 25. Flodgren G, Conterno LO, Mayhew A et al. Interventions to improve
616 professional adherence to guidelines for prevention of device-related
617 infections. *Cochrane Database Syst Rev* 2013;3:Cd006559.
618 [http://cochranelibrary-
619 wiley.com/doi/10.1002/14651858.CD006559.pub2/epdf] Accessed 23
620 May 2018.

621 26. O'Grady NP, Alexander M, Burns LA, et al. Summary of
622 recommendations: Guidelines for the Prevention of Intravascular Catheter-
623 related Infections. *Clin Infect Dis* 2011;52(9):1087-99.

624 27. Centers for Disease Control & Prevention. Urinary Tract Infection
625 (Catheter-Associated Urinary Tract Infection
626 [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and
627 Other Urinary System Infection [USI]) Events. 2018;
628 [https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf] Accessed
629 23 May 2018.

630 28. Centers for Disease Control & Prevention. Pneumonia (Ventilator-
631 associated [VAP] and non-ventilator-associated Pneumonia [PNEU])
632 Event. 2018;

- 633 [https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvcapcurrent.pdf] Accessed
634 23 May 2018.
- 635 29. Centers for Disease Control & Prevention. Identifying Healthcare-
636 associated Infections (HAI) for NHSN Surveillance. 2018;
637 [https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsnc
638 urrent.pdf] Accessed 23 May 2018.
- 639 30. Centers for Disease Control & Prevention. CDC/NHSN Surveillance
640 Definitions for Specific Types of Infections. 2018;
641 [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf]
642 Accessed 23 May 2018.
- 643 31. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre
644 syndrome with high-dose immune globulins combined with
645 methylprednisolone: a pilot study. *Ann Neurol* 1994;35(6):749-52.
- 646 32. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of
647 Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. *J*
648 *Neurol Neurosurg Psychiatry* 2007;78(9):1012-3.
- 649 33. Stigler SM. The True Title of Bayes's Essay. *Statistical Science*
650 2013;28(3):283-288.
- 651 34. Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of
652 Bayesian clinical trials monitoring. *Stat Med* 1994;13(13-14):1371-
653 83;discussion 1385-9.
- 654 35. Resnic FS, Zou KH, Do DV et al. Exploration of a bayesian updating
655 methodology to monitor the safety of interventional cardiovascular
656 procedures. *Med Decis Making* 2004; 24(4):399-407.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

657 36. Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of
658 immunoglobulins (IgG, IgA, IgM) in a general adult population and their
659 relationship with alcohol consumption, smoking and common metabolic
660 abnormalities. *Clin Exp Immunol* 2008;151(1):42-50. doi: 10.1111/j.1365-
661 2249.2007.03545.x

662 37. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS,
663 Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of
664 prognostic factors and the effect of plasmapheresis. *Ann Neurol*
665 1988;23(4):347-53.

666 38. Tharakan J, Jayaprakash PA, Iyer VP. Small volume plasma exchange in
667 Guillain-Barre syndrome: experience in 25 patients. *J Assoc Physicians*
668 *India* 1990;38(8):550-3.

669 39. Iyer RR, Shah PH, Roy SS, et al. Reducing the economic burden in
670 management of Guillain-Barre syndrome using modified plasmapheresis.
671 *Asian journal of transfusion science* 2016;10(2):118-21. doi:
672 10.4103/0973-6247.187940.

673 40. Izak M, Bussel JB. Management of thrombocytopenia. *F1000prime*
674 *reports* 2014;6:45. doi: 10.12703/p6-45.

675
676
677

Table 1: Demographic and clinical characteristics of the 20 patients with GBS included in this small volume plasma exchange (SVPE) study at entry

Characteristic	Value
Demography	
Sex [males: females (ratio)]	13:7 (1.85)
Age (years) [¶]	33 (18 - 55)
Body weight (kg) [¶]	60 (50 - 72)
Antecedent events [‡] (total)	18 (90%)
Diarrhoea	10 (50%)
Respiratory infection	5 (25%)
Fever	3 (15%)
Days from antecedent events to weakness [¶]	7 (3 - 30)
Days between onset of weakness to admission [¶]	7 (2-12)
Neurological deficits at entry	
Weakness in arms and legs	20 (100%)
Cranial nerve deficits	12 (60%)
Decreased deep tendon reflexes	20 (100%)
Sensory involvement	5 (25%)
GBS disability score [§]	4 19 (95%)
	5 1 (5 %)
Severity of weakness (MRC sum-score) [¶]	20 (0-29)
Autonomic dysfunction	11 (55%)

¶ Median (range); † increased protein level (> 45 mg/dL) in combination with CSF cell count < 50/μL; CSF = cerebrospinal fluid; NCS = nerve conduction study; ‡ symptoms of an infection in the four weeks preceding the onset of weakness; § GBS disability score (0 - 6) = 0: healthy state; 1: minor symptoms and capable of running; 2: able to walk 10 meters or more without assistance but unable to run; 3: able to walk 10 meters across an open space with help; 4: bedridden or chair-bound; 5: requiring assisted ventilation for at least part of the day; 6: dead.

Table 2: Treatment characteristics and complications associated with SVPE in the 20 patients with GBS

Characteristic/complication	Value
Treatment characteristics	
Number of sessions of SVPE per patient ¶	30 (24 - 42)
Volume of plasma removed per patient ¶	8.4 (6.3 – 9.6)
Plasma exchange rate (mL/kg) ¶	140 (110-175)
Time between hospital admission and SVPE (days) ¶	8 (5-10)
Time between onset of weakness and start of SVPE (days) ¶	8 (5-10)
Need to stop SVPE due to poor hemodynamic tolerance	0/20 (0%)
Need for blood transfusion for anaemia	1/20 (5%)
Reduction of anticoagulant drug dose for bleeding	3/20 (15%)
Temporary withdrawal of antiplatelet drug for bleeding	4/20 (20%)
Increased anticoagulant drug dose to continue SVPE	1/20 (5%)
CVC blockade/replacement	0/20 (0%)
Complications during SVPE	
<i>Infection</i>	
Leukocytosis	7/20 (35%)
CLABSI §	6.25
VAP §	136.4
CAUTI §	40
Severe sepsis	1/20 (5%)
Antimicrobial agents used	6/20 (30%)
<i>Bleeding and coagulation</i>	
Bleeding from CVC insertion site	10/20 (50%)
Bleeding from mucosal area	3/20 (15%)
Prolonged BT (BT > 10 min)	0/20 (0%)
Prolonged CT (CT > 15 min)	0/20 (0%)
Prolonged PT (PT > 14 sec) ¶	6/20 (30%) [15-19 sec]

Prolonged aPTT (aPTT > 40 sec) ¶	3/20 (15%) [51-240 sec]
<i>Other complications</i>	
Saline responsive hypotension	10/20 (50%)
Anaemia (Hb < 8 gm/L)	2/20 (10%)
Thrombocytopenia (PC < 1.5 lac/μL) ¶	6/20 (30%) [0.79-1.3 lac/μL]
Jaundice (serum bilirubin > 1.2 mg/dL)	0/20 (0%)
Renal impairment (serum creatinin > 1.2 mg/dL)	0/20 (0%)
Hyponatraemia (serum Na ⁺ < 135 mEq/L)	1/20 (5%) [126 mEq/L]
Hypokalaemia (serum K ⁺ < 3.5 mEq/L) ¶	3/20 (15%) [2.6-3.2 mEq/L]
Hypoalbuminemia (serum albumin > 35 gm/L) ¶	4/20 (20%) [26-32 gm/L]
Hypocalcaemia (serum Ca ⁺ < 2.2 mmol/L) ¶	3/20 (15%) [1.89-1.98 mmol/L]
Hypomagnesaemia (serum Mg ⁺ < 75 mEq/L) ¶	1/20 (5%) [73 mEq/L]
Hypersensitivity/transfusion reaction to FFP	4/20 (20%)

689

¶ Median (range); § rate per 1000 device days; CLABSI: central line-associated bloodstream infection; VAP: ventilator-associated pneumonia; CAUTI: catheter-associated urinary tract infection; CVC: central venous catheter; BT: bleeding time, CT: clotting time; PT: prothrombin time; APTT: activated partial thromboplastin time; FFP: fresh frozen plasma.

694

Table 3: Neurological outcomes of the 20 patients with GBS after SVPE

Clinical outcome	1 month	2 months	3 months	6 months
Cranial nerve involvement	7/20 (35%)	6/20 (30%)	4/20 (20%)	2/20 (10%)
Autonomic involvement	3/20 (15%)	3/20 (15%)	0/20 (0%)	0/20 (0%)
Sensory dysfunction	1/20 (5%)	1/20 (5%)	1/20 (5%)	1/20 (5%)
GBS disability score [¶]	0 = 0	0 = 1	0 = 1	0 = 2
	1 = 3	1 = 6	1 = 7	1 = 7
	2 = 9	2 = 6	2 = 6	2 = 5
	3 = 2	3 = 1	3 = 1	3 = 3
	4 = 3	4 = 5	4 = 5	4 = 3
	5 = 3	5 = 1	5 = 0	5 = 0
MRC sum score [†] *	47 (0-60)	49 (0-60)	53 (6-60)	58 (22-60)
ONLS [‡] *	4 (1-12)	3 (0-12)	3 (0-12)	2 (0-10)
R-ODS [§] *	26 (0-41)	33 (0-45)	37 (0-45)	38 (0-46)

* Median (range); ¶ GBS disability score (0 - 6) = 0: healthy state, 1: minor symptoms and capable of running, 2: able to walk 10 meters or more without assistance but unable to run, 3: able to walk 10 meters across an open space with help, 4: bedridden or chair-bound, 5: requiring assisted ventilation for at least part of the day, 6: dead; † MRC sum score: Medical Research Council sum score; ‡ ONLS: Overall Neuropathy Limitation Scale²²; § R-ODS: Rash-built Overall Disability Score²³

Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS.

SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, ^A measured in litres, ●: spell of hypotension (systolic BP < 90 mm Hg), ○: CVC insertion site bleeding, ▲: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.

Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE ($n = 20$): twenty patients with GBS aged ≥ 18 -years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE ($n=20$): twenty-four patients aged ≥ 18 -years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * $p < 0.0001$.

Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.




Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS. SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, A measured in litres, black dot: spell of hypotension (systolic BP < 90 mm Hg), empty drop: CVC insertion site bleeding, black triangle: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.




Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (n = 20): twenty patients with GBS aged ≥ 18 -years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (n=20): twenty-four patients aged ≥ 18 -years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * $p < 0.0001$.





Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.

Supplementary Figure: Hospital-acquired infections in the 20 patients with GBS treated with SVPE and the 24-hospital control patients without GBS.



SVPE: small volume plasma exchange, CLABSI: central line-associated blood stream infection, CAUTI: catheter-associated urinary tract infection, VAP: ventilator-associated pneumonia.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

2017 CONSORT checklist of information to include when reporting a randomized trial assessing nonpharmacologic treatments (NPTs)*.
Modifications of the extension appear in italics and blue.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Title and abstract					
	1a	Identification as a randomized trial in the title	NA (Non-randomized)		
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4, 5	Refer to CONSORT extension for abstracts for NPT trials	3, 4, 5
Introduction					
Background and objectives	2a	Scientific background and explanation of rationale	6		
	2b	Specific objectives or hypotheses	6, 7		
Methods					
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7	When applicable, how care providers were allocated to each trial group	NA
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	No changes to methods after trial commencement		
Participants	4a	Eligibility criteria for participants	7, 8	When applicable, eligibility criteria for centers and for care providers	NA
	4b	Settings and locations where the data were collected	7		
Interventions†	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8	Precise details of both the experimental treatment and comparator	7, 8
	5a			Description of the different components of the interventions and, when applicable, description of the procedure for tailoring the interventions to individual participants.	9
	5b			Details of whether and how the interventions were standardized.	8, 9

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	5c.			Details of whether and how adherence of care providers to the protocol was assessed or enhanced	8, 9
	5d			Details of whether and how adherence of participants to interventions was assessed or enhanced	NA
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9		
	6b	Any changes to trial outcomes after the trial commenced, with reasons	No changes to trial outcomes after the trial commenced		
Sample size	7a	How sample size was determined	9	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	7b	When applicable, explanation of any interim analyses and stopping guidelines	10		
Randomization:					
- Sequence generation	8a	Method used to generate the random allocation sequence	NA (Non-randomized)		
	8b	Type of randomization; details of any restriction (such as blocking and block size)	NA (Non-randomized)		
- Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	NA (Non-randomized)		
- Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA (Non-randomized)		
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Blinding was not possible	If done, who was blinded after assignment to interventions (e.g., participants, care providers, those administering co-interventions, those assessing outcomes) and how	Blinding was not possible

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40-7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	11b	If relevant, description of the similarity of interventions	7, 8		
	11c			If blinding was not possible, description of any attempts to limit bias	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA		
Results					
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	11	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center	Single center study
	13b	For each group, losses and exclusions after randomization, together with reasons	No losses and exclusions after inclusion		
	13c			For each group, the delay between randomization and the initiation of the intervention	11
	new			Details of the experimental treatment and comparator as they were implemented	11-16
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7		
	14b	Why the trial ended or was stopped	NA (Trial completed)		
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.	NA
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	11-12		

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12-16		
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA		
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15		
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	12-15		
Discussion					
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20-21	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group	NA
Generalizability	21	Generalizability (external validity, applicability) of the trial findings	16-20	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial	16-20
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	16-20		
Other information					
Registration	23	Registration number and name of trial registry	4		
Protocol	24	Where the full trial protocol can be accessed, if available	Manuscript reference no: 17		
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	22		

*Additions or modifications to the 2010 CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials

†The items 5, 5a, 5b, 5c, 5d are consistent with the Template for Intervention Description and Replication (TIDieR) checklist

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40-7.

Table: Required documents of the safety and feasibility study of the small volume plasma exchange (SVPE) for Guillain-Barré syndrome patients for the World Health Organization Trial Registration Data Set

	Item/Label	Description
1	Primary Registry and Trial Identifying Number	Clinicaltrials.gov NCT02780570
2	Date of Registration in Primary Registry	May 23, 2016
3	Secondary Identifying Numbers	International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Protocol Number: PR-15086, Version no. 3, Date: 09/12/2015
4	Source(s) of Monetary or Material Support	GBS/CIDP Foundation International Fondation Mérieux: (Small Grants Program 2015)
5	Primary Sponsor	GBS/CIDP Foundation International
6	Secondary Sponsor(s)	Fondation Mérieux: (Small Grants Program 2014)
7	Contact for public queries	MD. BADRUL ISLAM Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam

		Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
8	Contact for scientific queries	MD. BADRUL ISLAM Principal Investigator (PI) Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
9	Public title	Small volume plasma exchange for Guillain-Barré syndrome
10	Scientific title	Small volume plasma exchange for Guillain-Barré syndrome in low-income countries: a safety and feasibility study
11	Countries of Recruitment	Bangladesh
12	Health condition(s) or problem(s) studied	Guillain-Barré syndrome (GBS)
13	Interventions	<u><i>Small Volume Plasma Exchange (SVPE)</i></u> A loading dose of low-molecular weight heparin (1.5 mg/kg) will be given subcutaneously at least two hours

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

before initiation of SVPE; the same dose will be administered once daily or divided into two equal doses daily for eight days or until SVPE is completed. Whole blood (7 mL/kg body weight) will be drawn from the central venous catheter into the blood transfusion bag in each session. The blood bag will be hung beside the patient for 2.5 h on a saline stand and left uninterrupted to allow plasma and blood cells to separate. The blood cells will be infused back into the patient and plasma will be discarded and replaced with fresh frozen plasma and colloid solution alternately (in equal volumes) via the closed-circuit SVPE kit illustrated in. In case of excessive clotting (bleeding time reduction of > 50% of baseline for that patient), aspirin (600 mg) will be administered orally at least two hours before the next SVPE session and continued thereafter at 150 mg orally/day until SVPE is completed. One blood bag will be used each day, with a total of six sessions/day. A total of 48 sessions will be performed over eight days, removing approximately 8000 mL plasma in total.

Central venous catheterized patients without GBS

To compare the safety of SVPE in patients with GBS in the context of the background risk of central line-associated blood stream infection (CLABSI) at the study intensive care (ICU) and high-dependency care (HDU) units, the incidence of CLABSI will be assessed in a control group of adult patients with a diagnosis other than GBS admitted to the same ICU and HDU units in the same period of time the patients with GBS will be enrolled for SVPE. We will assess the rate of CLABSI in

		patients aged ≥ 18 -years-old requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units.
14	Key Inclusion and Exclusion Criteria	<p><u><i>Inclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old fulfilling the diagnostic criteria for GBS of the National Institute of Neurological and Communicative Disorders and Stroke (NINDS) 2. Unable to walk unaided for more than 10 meters (GBS disability score ≥ 3) 3. Presented within 2 weeks of the onset of weakness 4. Unable to afford standard treatment with IVIg or PE. <p><u><i>Exclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients with severe or terminal concomitant illness 2. Evidence of healthcare-associated infection on admission (except for aspiration pneumonia) 3. Previous history of severe allergic reaction to properly matched blood products and pregnant women will be excluded from the study. <p><u><i>Inclusion criteria for patients without GBS</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old 2. Requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period of time the patients with GBS enrolled for SVPE. <p><u><i>Exclusion criteria for patients without GBS</i></u></p>

		<div>1. Patients with healthcare-associated infection present on admission (except aspiration pneumonia)</div> <div>2. Pregnant women</div>
15	Study type	<div><u>Type of the study</u>: Interventional</div> <div><u>Method of allocation</u>: Non-randomized</div> <div><u>Masking</u>: Non-masked</div> <div><u>Assignment</u>: Parallel arm</div> <div><ul style="list-style-type: none">SVPE in patients with GBSRate of CLABSI in patients without GBS</div> <div><u>Purpose</u>: Safety and feasibility of SVPE</div>
16	Date of first enrolment	February 20, 2016
17	Target sample size	<div>SVPE in patients with GBS = 20</div> <div>Rate of CLABSI in patients without GBS = ≥ 20</div>
18	Recruitment status	<div>Completed:</div> <div><ul style="list-style-type: none">Twenty cases of GBS have been successfully treated with SVPE and 24 control cases without GBS have been recruited.</div>
19	Primary Outcome(s)	<div><u>Primary outcome of safety</u>:</div> <div><div>1. Number of patients with GBS treated with SVPE developing severe sepsis or septic shock due to central line associated blood stream infection (CLABSI) as per standard guideline (Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection); CDC Device-associated Module, BSI. January 2017)</div><div>2. Occurrence of venous thrombosis in the limb</div></div>

		<p>where the CVC is placed. Venous thrombosis will be assessed according to Wells criteria (<i>Philip S. Wells et al. Evaluation of d -Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis; N Engl J Med 2003;349:1227-35</i>)</p> <p><u>Primary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Ability to remove at least eight litres of plasma by SVPE over eight days.
20	Secondary Outcome(s)	<p><u>Secondary outcome of safety:</u></p> <ol style="list-style-type: none"> 2. Relative risk of CLABSI due to SVPE compared to CLABSI in control patients without GBS treated using a CVC 3. Hemodynamic instability during the SVPE procedure (variations in systolic blood pressure greater than 30 mmHg or sudden bradycardia involving a reduction in heart rate by more than 20 beats per min within 30 min of starting SVPE or an increase in heart rate above 120 beats per min) 4. Development of anaemia (Hb <7 gm/dL) or serious haemorrhage requiring blood transfusion. <p><u>Secondary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Rate of CVC occlusion during the SVPE procedure 2. The healthcare personnel's acceptability and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		<p>satisfaction with the SVPE procedure and any unanticipated events compromising the SVPE procedure as assessed using a standard questionnaire.</p> <p>3. Neurological outcome will be assessed in terms of improvement in GBS disability score and MRC sum score at discharge and up to 4 weeks after entry.</p>
--	--	--

BMJ Open

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022862.R3
Article Type:	Research
Date Submitted by the Author:	08-Jun-2018
Complete List of Authors:	Islam, Md Badrul; International Centre for Diarrhoeal Disease Research Bangladesh, LSSD Islam, Zhahirul; The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) , Laboratory Sciences and Services Division (LSSD) Rahman, Shafiqur; Uttara Adhunik Medical College, Anaesthesia and Intensive Care Endtz, Hubert; Erasmus University Medical Center, Department of Medical Microbiology and Infectious Diseases; Fondation Merieux Vos, Margreet; Erasmus MC Medical Center Rotterdam, Department of Medical Microbiology and Infectious diseases van der Jagt, Mathieu; Erasmus MC, Department of Intensive Care Van Doorn, Peter; Erasmus University Medical Center, Department of Neurology Jacobs, BC; Erasmus University Medical Center, Departments of Neurology and Immunology Mohammad, Quazi; National Institute of Neuroscience
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Medical management
Keywords:	Guillain-Barré syndrome, Small volume plasma exchange, Safety, Feasibility
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.	
SUPPLEMENTARY VIDEO.mp4	

SCHOLARONE™
Manuscripts

1 Title:

2 Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings:
3 a phase II safety and feasibility study

4 Authors

5 1. Badrul Islam

6 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
7 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
8 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)

9 E-mail: badrul.islam@icddr.org
10 bislamdmch@gmail.com

11 2. Zhahirul Islam

12 Laboratory Sciences and Services Division (LSSD)
13 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

14 E-mail: zislam@icddr.org

15 3. Shafiqur Rahman

16 Department of Intensive Care Medicine, Uttara Adhunik Medical College & Hospital.

17 E-mail: drshafiqk23@yahoo.com

18 4. Hubert P. Endtz

19 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
20 Center, Rotterdam, The Netherlands, and Fondation Mérieux, Lyon, France.

21 Email: hubert.endtz@fondation-merieux.org

22 5. Margreet C. Vos

23 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
24 Center, Rotterdam, The Netherlands.

25 Email: m.vos@erasmusmc.nl

26 6. Mathieu van der Jagt

27 Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The
28 Netherlands.

29 Email: m.vanderjagt@erasmusmc.nl

30 7. Pieter A. van Doorn

31 Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.

32 E-mail: p.a.vandoorn@erasmusmc.nl

33 8. Bart C. Jacobs

34 Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam,
35 The Netherlands.

36 E-mail: b.jacobs@erasmusmc.nl

37 9. Quazi D. Mohammad

38 National Institute of Neuroscience (NINS), Dhaka, Bangladesh.

39 E-mail: quazideenmohammad@gmail.com

41 Corresponding author

42 Badrul Islam

43 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical
44 Center, Rotterdam, The Netherlands and Laboratory Sciences and Services Division (LSSD),
45 International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).

46 E-mail: bislamdmch@gmail.com

48 Word count: 5087 (Excluding abstract, reference, table and figures)

49

50 **ABSTRACT**

51 **OBJECTIVE**

52 To assess the safety and feasibility of small volume plasma exchange (SVPE) for Guillain-Barré
53 syndrome (GBS) patients.

54 **DESIGN**

55 Non-randomized, single arm, interventional trial.

56 **SETTING**

57 National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.

58 **PARTICIPANTS**

59 Twenty adult (>18 years) patients with GBS presented within 2 weeks of onset of weakness who
60 were unable to walk unaided for more than 10 meters.

61 **INTERVENTIONS**

62 SVPE involves blood cell sedimentation in a blood bag and removal of supernatant plasma after
63 blood cells are re-transfused. This procedure was repeated three to six times a day, for eight
64 consecutive days. Fresh frozen plasma (FFP) and normal saline were used as replacement fluid.

65 **OUTCOME MEASURES**

66 Serious adverse events (SAE) were defined as severe sepsis and deep venous thrombosis related
67 to the central vein catheter (CVC) used during SVPE. SVPE was considered safe if less than 5/20
68 patients experienced a SAE, and feasible if 8 L plasma could be removed within 8 days in at least
69 15/20 patients.

70 **RESULTS**

71 Median patient age 33 years (IQR 23-46; range 18-55); 13 (65%) were male. Median MRC sum
72 score was 20 (IQR 0-29; range 0-36); three (15%) patients required mechanical ventilation. One
73 patient developed SAE (severe sepsis, possibly related to CVC). The median plasma volume
74 exchanged was 140 mL/kg (range 110-175) and removal of 8 L plasma was possible in 15 (75%)

1
2
3 75 patients. Patients received a median 1g/kg IgG via FFP although a substantial proportion of IgG
4
5 76 was probably removed again by the SVPE sessions. GBS disability score improved by at least
6
7 77 one grade in 14 (70%) patients four weeks after SVPE started. No patients died.
8

9 78 CONCLUSION
10

11 79 SVPE seems a safe and feasible alternative treatment to standard PE or IVIg for GBS; further
12
13 80 studies of clinical efficacy in low-resource developing countries are warranted.
14
15

16 81

17
18 82 TRIAL REGISTRATION
19

20 83 Clinicaltrials.gov NCT02780570 on May 23, 2016
21
22 84
23 85
24 86
25 87
26 88
27 89
28 90
29 91
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strength and limitations of the study:

1. The strength of this study underlies the novel and simple technique of SVPE, which is much less expensive than conventional immunotherapies [plasma exchange (PE) and intravenous immunoglobulin (IVIg)]
2. SVPE is corroborated as safe and feasible for the first time in a prospective and standardized cohort of patients with Guillain-Barré syndrome (GBS).
3. The intrinsic limitations of this study are its non-randomized, single arm nature, which is conducted in a single center with a limited sample size of GBS patients. The volume exchanged was at the lower range compared to previous PE studies conducted in GBS.
4. Clinical efficacy of SVPE on patients with GBS was a secondary end-point assessment and therefore deserves a randomized controlled trial in future to assess the clinical efficacy of SVPE for the patients with GBS.

107 Introduction

108 Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a
109 yearly incidence of 1.2 to 2.3 cases per 100,000 per year.¹ GBS is characterized by rapidly
110 progressive limb weakness and, in a proportion of cases, respiratory failure (25%) or severe
111 autonomic dysfunction (10%). Plasma exchange (PE) was the first treatment proven to be
112 effective for GBS, if given within 4 weeks of the onset of weakness.²⁻¹¹ Conventionally for GBS
113 patients, three to five plasma exchange sessions are done in alternate days within a span of 7 to
114 14 days targeting a plasma exchange rate of 120 - 200 ml/kg (40-50ml/kg/day).⁷ Later studies
115 showed treatment with intravenous immunoglobulin (IVIg) (0.4 g/kg per day for 5 days) has a
116 similar efficacy as PE in patients with GBS who are unable to walk, if started within 2 weeks of
117 the onset of weakness.^{12 13}

118
119 Unfortunately, most patients in low-income countries cannot afford expensive treatment with
120 either PE or IVIg.¹⁴ In Bangladesh, a full course of IVIg for a 60 kg adult costs approximately
121 12,000-16,000 US\$ and treatment with conventional PE for 5 days costs approximately 4,500-
122 5,000 US\$. The mean income in Bangladesh was 4 US\$ per day in 2016 (World Bank and
123 Bangladesh Bureau of Statistics 2016); IVIg and PE cost the equivalent of 3,000 and 1,250 mean
124 income days, respectively. At present, the majority (92%) of patients with GBS in Bangladesh
125 receive supportive care only.¹⁴ In addition, mobile PE equipment is not available in Bangladesh;
126 therefore, patients admitted to the intensive care unit (ICU) cannot receive PE. We previously
127 reported the mortality rates for GBS in Bangladesh range from 12 to 14% and observed 29% of
128 patients with GBS in Bangladesh are unable to walk at 6 months after onset; these poor outcomes
129 are undoubtedly due to the low rates of specific treatment with PE or IVIg.^{15 16}

130

1
2
3 131 Small volume plasma exchange (SVPE) may represent a cheap, effective alternative treatment for
4
5 132 GBS. SVPE is based on the same principle as conventional PE (selective removal of plasma) but
6
7 133 uses a novel, simple technique with much lower costs (approximately 500 US\$). The current non-
8
9 134 randomized trial was designed to investigate the safety and feasibility of SVPE in 20 patients
10
11 135 with GBS admitted to the National Institute of Neurosciences Hospital in Dhaka, Bangladesh.
12
13
14 136

15
16 137 **Methods/Design**

17
18 138 *Study design*

19
20 139 For this non-randomized, single arm, interventional safety and feasibility trial, 20 adult patients
21
22 140 with GBS were enrolled between March 2016 and December 2016 for SVPE at the National
23
24 141 Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh. A detailed study protocol
25
26 142 was published previously and includes definitions of all variables used in this study.¹⁷
27
28
29 143

30
31 144 Four to six daily sessions of whole blood sedimentation and removal of supernatant plasma after
32
33 145 re-transfusion of the sedimented blood cells was planned for the 20 patients with GBS, with a
34
35 146 target of removing an overall volume of at least 8 litres (L) of plasma over a total of 8 days.¹⁷
36
37 147 (See supplementary video for SVPE procedure)
38
39 148

40
41
42 149 Patients with GBS were monitored according to a standard protocol throughout the course of
43
44 150 SVPE until the second day after withdrawal of the central venous catheter (CVC) in order to
45
46 151 assess predefined measures of safety and feasibility and followed up for six months to assess
47
48 152 neurological outcome. The protocol was reviewed and approved by the institutional research and
49
50 153 ethics review committees at the icddr,b and registered at clinicaltrials.gov (NCT02780570).¹⁷ All
51
52 154 patients provided written informed consent to participate in this study.
53
54
55 155

156 *Patient and Public Involvement*

157 Patients and or public were not involved either in the development of the research question, study
158 design and outcome measure or recruitment to and conduct of the study.

159

160 *Inclusion and exclusion criteria for patients with GBS*

161 Patients aged ≥ 18 -years-old fulfilling the diagnostic criteria for GBS of the National Institute of
162 Neurological and Communicative Disorders and Stroke (NINDS)¹⁸ were enrolled, provided they
163 were unable to walk unaided for more than 10 meters (GBS disability score ≥ 3), presented
164 within 2 weeks of the onset of weakness, and were unable to afford standard treatment with IVIg
165 or PE. Patients with concomitant severe or terminal illnesses, evidence of healthcare-associated
166 infection (HAI) on admission (except for aspiration pneumonia), a previous history of severe
167 allergic reactions to properly matched blood products, and pregnant women were excluded from
168 the study.

169

170 *Control cohort*

171 To compare the safety of SVPE in patients with GBS in the context of the background risk of
172 central line-associated blood stream infection (CLABSI) at our institution, we prospectively
173 assessed the incidence of CLABSI in a hospital control group of 24 adult patients without GBS
174 receiving neurocritical care. Hospital controls were eligible based on the following
175 characteristics: ≥ 18 -years-old, a neurological diagnosis other than GBS, and a CVC placed for $>$
176 2 and ≤ 8 calendar days after admission to the same ICU or HDU unit as the SVPE-treated
177 patients. Patients with a HAI (except aspiration pneumonia) and pregnant women were excluded
178 from the control group.

179

180

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

181 *Primary and secondary outcome measures*

182 The primary outcome measures of safety were the number of patients with GBS treated with

183 SVPE who developed either severe sepsis or septic shock due to CLABSI¹⁹ and the occurrence of

184 venous thrombosis in the limb where the CVC was placed. The primary outcome measure of

185 feasibility was the ability to remove at least 8 L of plasma over 8 days.

186 The secondary outcome measures of the safety of SVPE were the relative risk of CLABSI due to

187 SVPE (compared to CLABSI in the hospital control group without GBS), hemodynamic

188 instability during the SVPE procedure, and development of anaemia (Hb < 8 gm/dL) or any

189 catheter-related haemorrhage requiring a blood transfusion.

190 The secondary outcome measure of feasibility of SVPE was the rate of CVC occlusion during the

191 SVPE procedure. In addition, neurological outcome was assessed using the GBS disability

192 score²⁰, MRC sum score²¹, Overall Neuropathy Limitation Scale (ONLS)²² and Rasch-built

193 Overall Disability Scale (R-ODS)²³ at 1st, 2nd, 3rd, and 6th months from the start of SVPE.

194

195 *Procedure safety documentation and cost of SVPE*

196 Strict aseptic procedures were followed to prevent CLABSI.²⁴⁻²⁶ SVPE was documented in terms

197 of the duration and amount of plasma removed in each session, and the type and volume of

198 replacement fluid and fresh frozen plasma (FFP) used. Throughout the procedure, the

199 haemodynamic, haematological, biochemical, coagulation and infection profiles of the SVPE-

200 treated patients were monitored according to the protocol.¹⁷ Screening for hepatitis B and C

201 viruses, human immunodeficiency virus (HIV) and syphilis were performed as patient baseline

202 assessments, and also on donor FFP before administration. CLABSI, primary and secondary

203 bloodstream infections¹⁹, catheter-associated urinary tract infection (CAUTI)²⁷, ventilator-

204 associated pneumonia (VAP)²⁸ and other HAI^{29 30} were documented in the SVPE-treated patients

205 with GBS and the hospital control group. Expenditure for the full course of SVPE will be

approximately 500 US\$ [fresh frozen plasma (24 bags) = 240 US\$, blood bag and saline sets: 40 US\$, low molecular weight heparin: 110 US\$, routine investigation: 50 US\$, saline: 10 US\$, CV catheter: 40 US\$ = total 490 US\$].

Sample size

This safety and feasibility study enrolled 20 patients with GBS for SVPE. We could not perform a formal power calculation for this safety and feasibility study. The sample size was based on previous pilot studies conducted in GBS.^{31 32} The baseline rate of CLABSI was measured in the hospital control group of 24 patients without GBS admitted to the same study facility who required a CVC for at least 8 days during the study period.

Stopping rules for the trial based on safety and feasibility

Decision to stop the SVPE trial was designated using a Bayesian approach.³³⁻³⁵ Accordingly, a predictive success rate of 75% was predefined for the SVPE procedure. If more than 5 of 20 patients experienced an SAE, or if it appeared impossible to remove at least 8 L of plasma over 8 days in at least 15 of 20 patients, the procedure was considered unsafe or unfeasible.

Statistical analysis

The rate of HAIs (CLABSI, VAP and CAUTI) per 1000 device days were calculated by dividing the number of each HAI during the study period by the number of device days and multiplying the result by 1000. The infection safety profile for SVPE was assessed by calculating the standardized infection ratio to define the risk of HAIs in patients with GBS treated with SVPE. The standardised infection ratio (SIR) was calculated by dividing the number of observed HAI by the number of HAI predicted (i.e., the infection rate in the control

group). The predicted HAI rate was calculated using the rates of HAI in the hospital control group of patients without GBS during the study period. Percentage values were compared using the Chi-square test or Fisher's exact test (two-tailed) and median values, the Mann-Whitney U-test using SPSS 22 software (IBM SPSS Statistics for Windows Version 22.0., IBM Corp., Armonk, NY, USA). Analyses were performed on an intention-to treat basis. All *P*-values reported are two-sided; *p* < 0.05 was considered significant.

Results

Patients and hospital controls

The demographic and clinical characteristics of the 20 patients with GBS are given in Table 1. The median age of the patients with GBS was 33 years (range; 18-55); median body weight was 60 kg (IQR, 55-65 kg; range, 50-72 kg) and 13 (65%) patients were male (Fig. 1). On admission and before the start of SVPE, all 20 patients with GBS were unable to walk independently (GBS disability score, 4). One patient required mechanical ventilation from the second day after the onset of weakness; SVPE was started on the fourth day of mechanical ventilation (patient 9, Fig. 1). Two of the 19 patients who did not require mechanical ventilation at the start of the study required mechanical ventilation on the second day after initiation of SVPE (patients 11 and 19, 11 and 2 days after the onset of weakness, respectively; Fig. 1). The median MRC sum score for the limb muscles in all 20 patients was 20 (IQR: 0-29; range: 0-36; Fig. 1). Symptoms of a preceding infection in the 4 weeks before the onset of weakness were present in 18 (90%) patients with GBS, of whom 10 (50%) had diarrhoea. Median duration from admission to start of SVPE was two days (IQR, 2-3 days; range, 0-7 days). Median duration to nadir from the onset of weakness was five days (range, 1-13 days). Electrodiagnostic nerve conduction studies indicated 15 (75%) patients had an axonal subtype and 5 (25%) patients had a demyelinating subtype of GBS. Median duration from onset of weakness to NCS examination was 10 days (range, 4-16

days). All patients had albuminocytologic dissociation; median CSF protein was 166 mg/dL (range 117-253 mg/dL). Median duration from onset of weakness to CSF examination was 11 days (range, 4-17 days).

Median age of the 24 hospital control patients without GBS was 44 years (IQR, 25-57; range, 18-74); 10 (42%) were male. Age and gender distribution were not significantly different compared to the 20 patients with GBS ($p = 0.2155$, $p = 0.1434$, respectively). The diagnoses for these 24 patients were: brain tumour ($n = 5$), transverse myelitis ($n = 5$), head trauma after road traffic accident ($n = 3$), viral meningoencephalitis ($n = 2$), myasthenia gravis ($n = 2$), compressive cervical myelopathy ($n = 2$), cerebrovascular accident ($n = 2$), motor neuron disease ($n = 1$), electrolyte imbalance ($n = 1$) and status epilepticus ($n = 1$).

Primary endpoints

One patient with GBS treated with SVPE developed severe sepsis, possibly due to SVPE-related CLABSI (SVPE window-period blood culture revealed methicillin-resistant *Staphylococcus aureus*). This patient required intravenous fluid, noradrenalin infusion and intravenous antibiotics, but eventually improved (patient 11, Fig. 1). This patient also had signs and symptoms suggestive of aspiration pneumonia and VAP; *Streptococcus spp.* was isolated from pulmonary aspirates. Further laboratory results revealed dys-electrolytemia, anaemia and hypoalbuminemia. No patients experienced deep vein thrombosis due to the CVC for SVPE. Fifteen (75%) of the 20 patients met the primary endpoint of feasibility, defined as the ability to remove at least 8 L of plasma in eight days. The median volume of plasma removed was 8.5 L (IQR, 7.9-8.8 L; range, 6.3-9.6 L; Fig. 1). The median plasma exchange rate was 140 mL/kg bodyweight (IQR, 125-155 mL/kg; range, 110-175 mL/kg) over 8 days and 16 (80%) patients had a plasma exchange rate > 120 mL/kg (Table 2).

281 *Secondary endpoints*

282 *Infections among SVPE-treated patients with GBS and hospital controls*

283 Among the 20 patients with GBS treated with SVPE, six (30%) had fever during SVPE (Fig. 1,
284 Supplementary Figure 1), including 2 (10%) patients with leucocytosis who were diagnosed with
285 HAI (VAP and CAUTI in one patient; VAP in one patient). In three out of four (20%) patients
286 with fever without leucocytosis, fever subsided within two to three days without antimicrobial
287 therapy (Fig. 1). The remaining patient with pyrexia without leucocytosis had microbiological
288 evidence of both CLABSI and VAP (patient 11, Fig. 1). In all other 14 patients with GBS, no
289 fever was documented during the course of SVPE until the tenth day of SVPE (second day after
290 removal of the CVC for SVPE). Five of these 14 patients had leucocytosis, but no site-specific
291 HAI could be detected. However, one of the nine patients without fever but leucocytosis fulfilled
292 the criteria for CAUTI (patient 12, Fig. 1). All three patients who required mechanical ventilation
293 subsequently developed VAP; two of the 13 patients who required a urinary catheter developed a
294 CAUTI (patient 11, Fig. 1). No patients died during the 6 months follow-up.

295

296 All 24-hospital control patients without GBS required mechanical ventilation and an indwelling
297 urinary catheter. Of these patients, 22 (92%) patients had fever, of whom 15 (63%) had
298 leucocytosis; a diagnosis of a specific HAI could be made 14 of these 15 patients (CLABSI in
299 two, CAUTI in one, VAP in 11) and four (17%) fulfilled the criteria for severe sepsis
300 (Supplementary Figure 1). Seven (29%) of the 24 hospital control patients had fever without
301 leucocytosis. In two of these seven patients, a specific HAI was diagnosed (CAUTI and VAP in
302 one, and VAP in one). In two hospital control patients, no fever was documented until day 10
303 after first placement of the CVC, but leucocytosis was present and no site-specific HAI could be
304 detected (Supplementary Figure 1).

305

The rates of CLABSI, CAUTI and VAP per 1000 device days in the SVPE-treated patients with GBS were 6.25, 19.2 and 40 compared to 10.4, 10.4 and 67.7 for the hospital control patients without GBS, respectively. The relative risks of CLABSI, CAUTI and VAP associated with SVPE were 0.6, 1.2 and 1.8, respectively, compared to hospital control patients. The rates of CLABSI, CAUTI and VAP were comparable between SVPE-treated patients with GBS and hospital control patients ($p > 0.05$). Antimicrobial agents were used more frequently in the hospital control patients ($p < 0.0001$; Fig. 2). The standardised infection ratios for CLABSI, CAUTI and VAP for SVPE-treated patients with GBS were 0.6, 1.8 and 1.9, respectively.

Other secondary endpoints

Ten (50%) of the 20 patients treated with SVPE experienced transient hypotension during SVPE, which was corrected by infusion of 200-300 mL crystalloid saline (Fig. 1). Minor bleeding through the CVC insertion site (excluding at the time of insertion) was observed in 10/20 patients (50%; Fig. 1); these bleeds required a pressure pack. Reduction of the anticoagulant dose along with a pressure pack was required in 3/20 patients, who all had a prolonged prothrombin time (PT). Three patients had single episode of haemorrhage through the urinary catheter: one was diagnosed with a CAUTI with normal coagulation profile, one had a prolonged PT, the other had sterile haematuria with normal PT. Overall, PT and activated partial thromboplastin time (aPTT) were prolonged in 4/20 patients and only PT was prolonged in 2/20 patients. Clotting time and bleeding time were not prolonged in any patient. One patient developed anaemia (haemoglobin, 8 gm/L) at the end of SVPE; this patient also had severe sepsis and required one unit of blood transfusion (patient 11, Fig. 1). CVC blockages were not observed in any SVPE-treated patients with GBS. One patient with increased clotting tendency who required an increased dose of low molecular weight heparin had shortened clotting time (CT) ($< 50\%$ of upper limit of normal), though PT was normal (patient 10, Fig. 1).

331 The neurological outcomes of the SVPE-treated patients with GBS at six months in terms of
332 neurological scores are given in Table 3. Median time to recover the ability to walk unaided was
333 4 weeks (Fig. 3). Fourteen (70%) of the 20 patients had an improvement in GBS disability score
334 of one or more grades at four weeks after the onset of SVPE. At one month, 12 patients (60%)
335 were able to walk unaided, two patients (10%) were able to walk aided and six (30%) patients
336 were bedbound, of whom three still required mechanical ventilation. At three months, 14 (70%)
337 patients were able to walk unaided, one (5%) could walk with aid and five (25%) patients were
338 bedbound. At six months, 14 (70%) patients were able to walk unaided, three (5%) could walk
339 with aid and three (15%) remained bedbound (Table 3).

341 *Other relevant clinical and laboratory findings*

342 Allergic/transfusion reaction to FFP was observed in four patients with GBS treated with SVPE
343 (Fig. 1). These transfusion reactions presented as an itchy erythematous skin rash (three patients),
344 fever (two patients), hypotension (one patient) following transfusion of FFP; all of these reactions
345 were managed with oral antihistamine (and intravenous saline in one patient) without further
346 complications.

348 The other documented haematological and biochemical abnormalities were hypo-albuminemia (n
349 = 4), thrombocytopenia (n = 6), hyponatraemia (n = 1), hypokalaemia (n = 3), hypomagnesaemia
350 (n = 1), hypocalcaemia (n = 3); (Table 2).

352 *Immunoglobulin dosage admitted by FFP*

353 During SVPE the median volume of FFP administered per GBS patient as replacement fluid was
354 6000 ml (range, 5000 ml to 6000 ml). Considering the normal plasma IgG level of 11.20 mg/ml

(range, 6.9 mg – 17.6 mg)³⁶, SVPE treated GBS patients received IgG dose of median 0.9 g/kg (range 0.6 g/kg – 1.3 g/kg).

Discussion

Principal findings

This study suggests SVPE may represent a safe and feasible alternative to conventional plasma exchange for patients with severe GBS in limited-resource settings. Of the 20 patients in this study, one (5%) experienced a SAE (severe sepsis due to probable CLABSI). The rate of SAE was not significantly higher than the hospital control group without GBS with a CVC, and no patients had a CVC-related thromboembolic event in patients with SVPE. We were able to remove the prespecified target volume (8 L) of plasma as the target primary endpoint of feasibility in 15/20 (75%) patients with GBS. Median plasma exchange volume and rate during SVPE were 8.4 L and 140 mL/kg, respectively. Minor adverse effects included transient hypotension during SVPE in 50% (10/20), minor haemorrhage from CVC insertion site in 50% (10/20), transfusion reaction to FFP in 20% (4/20), and hypo-albuminemia, anaemia and electrolyte imbalance in 20% (4/20) of patients. An improvement of at least one grade on the GBS disability score was observed for 14/20 (70%) patients at four weeks after the initiation of SVPE. No patients died.

Comparison with baseline hospital control patients and standard/modified PE

With respect to HAIs, no significant differences were observed in the frequency of CLABSI, severe sepsis, VAP or CAUTI between the SVPE-treated patients with GBS and 24 hospital control patients without GBS treated using a CVC in the same ICU or HDU (Fig. 2). However, antimicrobial agents were used more frequently, usually prophylactically, in the hospital control patients compared to the patients with GBS treated with SVPE ($p < 0.0001$; Fig. 2). The

probability of detecting microorganisms in clinical infections may have been reduced due to overzealous use of antibiotics in the hospital control patients. Early trials of PE in patients with GBS showed 34% of patients develop severe infections.^{7 11} Subsequently, another large trial documented septicaemia in 19% of patients.⁵ However, the rates of CLABSI were not reported.

A previous RCT on GBS from the US showed a beneficial effect with PE rate of 40-50 ml/kg/session, for 3 to 5 sessions in 7 to 14 days, which comes to a total PE volume of 120-250 ml/kg.⁷ The first French RCT on adult GBS patients showed beneficial effect of 4 PE sessions [2 plasma volume (3.5 L) per PE session] over 8 days and in range, 6 – 12 L plasma was removed per patient.⁴ Subsequent French RCT with PE dose escalation showed, 2 PE sessions [1.5 plasma volume per PE session] are beneficial in mild to moderate GBS cases but less effective than 4 PE sessions in severe GBS cases and 6 PE sessions are as effective as 4 PE sessions in severe cases of GBS.⁵ In this RCT the exact total plasma volume exchanged per patient was not mentioned, but the authors indicated that the rate of plasma exchange was 40-ml/kg body weight per PE session. As to that a 60-70 kg person should have an exchange of 2.4 L-2.8 L per session and the therapeutic range of plasma volume to be exchanged would be 5.6 L to 11.2 L ml (2 to 4 PE sessions).

During the piloting of the SVPE procedure we assessed that removal of 1 L of patient plasma could be feasible in a day. Therefore we defined our target plasma volume of 8 L to be removed in 8 days. The median total PE volume and rate in SVPE was 8.4 L and 140 ml/kg, which is at the lower range as compared to both the French and American RCT on PE for adult GBS patients. We were able to remove >120 mL/kg plasma in 80% of patients, which should provide a therapeutic effect.³⁷ Notably, the body weight of our patients may be lower than that of patients

in western countries. In addition, SVPE was complete within 8 days, shorter than the usual time required for a full session of PE (10 to 12 days).

Replacement fluid used in SVPE was FFP. We have several justifications in favour of using FFP instead of human albumin or other available colloidal solutions available in Bangladesh. First FFP is safe in terms of microbiological safety since stringent screening for viral and bacterial contamination was performed before infusion. Second, in contrast to human albumin and colloid solutions, FFP contains normal human IgG that could contribute to the beneficial immunotherapeutic effect in GBS. FFP was previously used as replacement fluid in large PE trials, quintessentially with the same volume (half the volume of replacement fluid) we used in SVPE.^{4 5} SVPE treated GBS patients received approximately half the amount of IgG from the FFP used as replacement fluid compared to the total IVIg doses traditionally used in GBS (2gm/kg). Third, FFP contains all human plasma proteins that helps preservation of plasma colloid osmotic pressure and prevents formation of oedema and hypotension. Lastly FFP is much cheaper than commercial human albumin.

In each day three units of FFP were transfused as replacement fluid after the last session of SVPE and in the initial two to three sessions, normal saline was used as replacement fluid. This was done to achieve the maximum immunotherapeutic effect of FFP as SVPE was not resumed before the next day and the IgG in FFP remained in the circulation overnight for a longer period of time (10 to 12 hours). However due to long half life of IgG, a substantial amount of IgG present in FFP were probably washed away due to repeated plasma removal both during SVPE and by conducting standard PE.

In GBS, treatment with modified methods of PE done previously, were device based and done on limited number of GBS patients. In one study on 25 GBS patients from India, daily removal of

small volume of plasma (10-15 ml plasma/kg body weight) for duration of median 3 days using traditional PE machine was shown to be clinically beneficial.³⁸ In another study from the same country, 12 GBS patients were treated with PE over 10 days using different PE-machine kit (REF627 kit from Haemonetics Corporation Limited on MCS+ machine) where authors claimed clinical improvement, however the main focus was on cost effectiveness and the total plasma volume exchanged per patient was not mentioned.³⁹ Nevertheless these methods are based on specific devices those are not in common practice, nor the trained personnel for these are available in the developing countries.

Important observations in terms of secondary endpoints were transient hypotension, transfusion reaction to FFP and minor bleeding through the CVC insertion site. Hypotension is a common complication during traditional PE that affects nearly half of patients.⁵ Spells of hypotension during SVPE were more frequent during the three to four days after initiation of SVPE, and could be easily corrected by rapid infusion of 300-400 mL saline (Fig. 1). The hypotension could possibly be explained by hypovolemia due to drawing blood or as a result of the compromised autonomic nervous system in patients with GBS. As SVPE proceeded, hypotensive spells were encountered less frequently despite drawing the same volume of blood, which may in part be explained by adaptation of the vasomotor system or recovery from autonomic dysfunction. Minor bleeding through the CVC insertion site occurred in 50% of patients and could be controlled by applying a simple pressure pack over the CVC insertion site in most cases; mild prolonged PT was noted in 30% (3/10) patients. However, spontaneous bleeding usually occurs if the PT is more than 2.5 times prolonged and PC is < 0.50 lac/ μ L.⁴⁰ Movement of the limb where the CVC was placed may have caused traction on the CVC and contributed to local bleeding in the other seven patients. Haematuria is not uncommon in patients with a UTI, as may have occurred in one SVPE treated patient; traumatic traction of the urinary catheter may cause haematuria in two

other catheterized SVPE-treated patient taking oral aspirin, who had haematuria and sterile urine. We also monitored the major organ function and biochemical status of the patients treated with SVPE. No patients experienced hepatic or renal impairment. One patient developed anaemia and hypoalbuminemia; this patient had severe sepsis, a common cause of anaemia and hypoalbuminemia in critically ill patients admitted to an ICU (patient 11, Fig. 1). Electrolyte imbalances were detected in 15% of the SVPE-treated patients with GBS, and were mild, subclinical and easily corrected.

The median reported durations to recovery of independent walking in patients with GBS in large-scale RCTs after PE are 53, 52 and 70 days^{4 5 7}; compared to 30 days in our patients treated with SVPE. Moreover, 60% of the patients with GBS treated with SVPE were able to walk independently at four weeks, whereas 20% of patients with GBS acquired independent walking ability at four weeks after traditional PE. However, these differences may possibly be due to the small sample size and variations in demographic and neurophysiological characteristics between cohorts. Finally, SVPE was completed in all 20 patients and no patients died.

Limitations of SVPE

SVPE is a time-consuming and labour-intensive procedure, which is a limitation. We used multiple thin-lumen tubing systems interconnected with a multichannel connector device, which may increase the chance of blood coagulating within the tubing system. Coagulation may require manipulation or replacement of the tubing to ensure free flow of blood and saline. Such handling could increase the chance of microbial contamination. A single continuous wide-lumen tubing system (SVPE kit) could resolve this problem. Most importantly, personnel conducting the SVPE procedure should maintain proper aseptic technique, which can sometimes be challenging in developing countries. Furthermore, other adaptations such as provision of a larger blood bag or

479 increasing the number of days for SVPE could be considered to increase the plasma exchange
480 rate.
481
482 *Clinical implications and future research*
483 Despite the limitations, our study showed SVPE is a safe and feasible treatment for GBS in a
484 resource-limited setting where IVIg or PE are either unavailable or unaffordable. Specifically, the
485 poorest 20% of the world's population (1.8 billion people) who typically earn less than 10 US\$
486 per day and who are not covered by a national health insurance system may benefit. Considering
487 the incidence of GBS is 2/100,000 in developing countries, approximately 40,000 patients could
488 potentially benefit from SVPE every year, worldwide. In the future, a multicentre RCT is
489 required to assess the clinical efficacy of SVPE for patients with GBS. If proven effective, SVPE
490 could be an affordable and easily available alternative plasma exchange technique in low-income
491 countries for patients with GBS and other disorders, who at present cannot afford standard PE
492 due to its high cost and unavailability.

501 **Declarations**

502 *Acknowledgements:* This research activity was funded by GBS/CIDP Foundation International,
503 USA and Fondation Mérieux, Lyon, France. The icddr,b acknowledges with gratitude the
504 contributions of the Government of Bangladesh, Global Affairs Canada (GAC), Swedish
505 International Development Cooperation Agency (Sida), and Department for International
506 Development, UK (DFID). Md Ekhlash Mia and Smrity Akhter assisted this study in a full-time
507 capacity. We are grateful to all of the neurologists from the NINS who referred their patients to
508 us and K. S. Fahim for his support in preparation of the diagrams in this article.

509

510 *Authors' contributions:* BI, PVD, BJ, QDM, ZI, and HPE conceived the study design and sample
511 size of the study. MV, MVJ, SR, and HPE contributed to the infection safety guidelines in the
512 study design. BI and QDM conducted the study and BI collected and analysed the data and
513 drafted the manuscript. All authors have critically revised the manuscript and have read and
514 approved the final manuscript.

515

516 *Funding:* This study was funded by two competitive research grants:

- 517 1. The GBS/CIDP Foundation International GBS grant (major contribution)
- 518 2. The Fondation Mérieux: Small Grants Program 2014 (partial contribution)

519

520 *Role of the funding source:* The funders had no role in study design, data collection, data
521 analysis, data interpretation, or writing of the report.

522

523

524 *Competing interests:* No investigators have any competing financial, professional or personal
525 interests that may have influenced the findings described in this manuscript to disclose.
526
527 *Ethics approval and consent to participate:* The Institutional Review Board (IRB) of the icddr,b,
528 comprised of an Ethical Review Committee (ERC) and Research Review Committee (RRC),
529 reviewed and approved this study protocol on 09/12/2015 (reference number: PR-15086, version
530 no 3).
531
532 *Patient consent:* Obtained.
533
534 *Data sharing:* Extra data can be accessed via the Dryad data repository at <http://datadryad.org/>
535 with the doi: 10.5061/dryad.55nb389
536
537 *Transparency:* The corresponding author affirms that the manuscript is an honest, accurate and
538 transparent account of the study being reported; that no important aspects of the study have been
539 omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have
540 been explained.

References

1. Willison HJ, Jacobs BC, and van Doorn PA. Guillain-Barre syndrome. *Lancet* 2016;388(10045):717-27.
2. Van Koningsveld R, Van Doorn PA, Schmitz PI et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. *Neurology* 2000;54(3):620-5.
3. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. *Medicine* 1969;48:173-215.
4. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. *Ann Neurol* 1987;22(6):753-61.
5. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. *Ann Neurol* 1997;41(3):298-306.
6. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Plasma exchange in Guillain-Barre syndrome: one-year follow-up. *Ann Neurol* 1992;32(1):94-7.
7. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. *Neurology* 1985; 35(8):1096-104.
8. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. *Lancet* 1984;1(8382):877-9.

565 9. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma
566 exchange in acute inflammatory polyradiculoneuropathy. *Lancet*
567 1984;2(8415):1296-9.

568 10. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for
569 Guillain-Barre syndrome. *Cochrane Database Syst Rev* 2014:Cd002063.
570 [http://cochranelibrary-
571 wiley.com/doi/10.1002/14651858.CD002063.pub6/epdf] Accessed 8 June
572 2018.

573 11. Chevret S, Hughes Richard AC, Annane D. Plasma exchange for Guillain-
574 Barré syndrome. *Cochrane Database Syst Rev* 2017; (2).
575 [http://cochranelibrary-
576 wiley.com/doi/10.1002/14651858.CD001798.pub3/epdf] Accessed 8 June
577 2018.

578 12. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter:
579 immunotherapy for Guillain-Barre syndrome: report of the Quality
580 Standards Subcommittee of the American Academy of Neurology.
581 *Neurology* 2003; 61(6):736-40.

582 13. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous
583 immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch
584 Guillain-Barre Study Group. *N Engl J Med* 1992; 326(17):1123-9.

585 14. Islam MB, Islam Z, Farzana KS, et al. Guillain-Barre syndrome in
586 Bangladesh: validation of Brighton criteria. *J Peripher Nerv Syst* 2016;
587 21(4):345-351.

15. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. *Neurology* 2010; 74(7):581-7.
16. Ishaque T, Islam MB, Ara G, et al. High mortality from Guillain-Barre syndrome in Bangladesh. *J Peripher Nerv Syst* 2017;22(2):121-126.
17. Islam MB, Islam Z, Rahman S, et al. Small volume plasma exchange for Guillain-Barre syndrome in resource poor settings: a safety and feasibility study. *Pilot Feasibility Stud* 2017;3:40.
18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. *Ann Neurol* 1990;27 Suppl:S21-4.
19. Centers for Disease Control and Prevention. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection) 2018; [https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf] Accessed 8 June 2018.
20. Hughes RA, Newsom-Davis JM, Perkin GD et al. Controlled trial prednisolone in acute polyneuropathy. *Lancet* 1978;2(8093):750-3.
21. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991;14(11):1103-9.
22. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry* 2006;77(8):973-6.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

611 23. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall
612 Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
613 *Neurology* 2011;76(4):337-45.

614 24. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in
615 catheter related bloodstream infections in Michigan intensive care units:
616 observational study. *Bmj* 2010;340:c309.

617 25. Flodgren G, Conterno LO, Mayhew A et al. Interventions to improve
618 professional adherence to guidelines for prevention of device-related
619 infections. *Cochrane Database Syst Rev* 2013;3:Cd006559.
620 [http://cochranelibrary-
621 wiley.com/doi/10.1002/14651858.CD006559.pub2/epdf] Accessed 8 June
622 2018.

623 26. O'Grady NP, Alexander M, Burns LA, et al. Summary of
624 recommendations: Guidelines for the Prevention of Intravascular Catheter-
625 related Infections. *Clin Infect Dis* 2011;52(9):1087-99.

626 27. Centers for Disease Control & Prevention. Urinary Tract Infection
627 (Catheter-Associated Urinary Tract Infection
628 [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and
629 Other Urinary System Infection [USI]) Events. 2018;
630 [https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf] Accessed 8
631 June 2018.

632 28. Centers for Disease Control & Prevention. Pneumonia (Ventilator-
633 associated [VAP] and non-ventilator-associated Pneumonia [PNEU])
634 Event. 2018;

- 635 [https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf] Accessed
 636 8 June 2018.
- 637 29. Centers for Disease Control & Prevention. Identifying Healthcare-
 638 associated Infections (HAI) for NHSN Surveillance. 2018;
 639 [https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsnc
 640 urrent.pdf] Accessed 8 June 2018.
- 641 30. Centers for Disease Control & Prevention. CDC/NHSN Surveillance
 642 Definitions for Specific Types of Infections. 2018;
 643 [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf]
 644 Accessed 8 June 2018.
- 645 31. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre
 646 syndrome with high-dose immune globulins combined with
 647 methylprednisolone: a pilot study. *Ann Neurol* 1994;35(6):749-52.
- 648 32. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of
 649 Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. *J*
 650 *Neurol Neurosurg Psychiatry* 2007;78(9):1012-3.
- 651 33. Stigler SM. The True Title of Bayes's Essay. *Statistical Science*
 652 2013;28(3):283-288.
- 653 34. Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of
 654 Bayesian clinical trials monitoring. *Stat Med* 1994;13(13-14):1371-
 655 83;discussion 1385-9.
- 656 35. Resnic FS, Zou KH, Do DV et al. Exploration of a bayesian updating
 657 methodology to monitor the safety of interventional cardiovascular
 658 procedures. *Med Decis Making* 2004; 24(4):399-407.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

659 36. Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of
660 immunoglobulins (IgG, IgA, IgM) in a general adult population and their
661 relationship with alcohol consumption, smoking and common metabolic
662 abnormalities. *Clin Exp Immunol* 2008;151(1):42-50. doi: 10.1111/j.1365-
663 2249.2007.03545.x

664 37. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS,
665 Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of
666 prognostic factors and the effect of plasmapheresis. *Ann Neurol*
667 1988;23(4):347-53.

668 38. Tharakan J, Jayaprakash PA, Iyer VP. Small volume plasma exchange in
669 Guillain-Barre syndrome: experience in 25 patients. *J Assoc Physicians*
670 *India* 1990;38(8):550-3.

671 39. Iyer RR, Shah PH, Roy SS, et al. Reducing the economic burden in
672 management of Guillain-Barre syndrome using modified plasmapheresis.
673 *Asian journal of transfusion science* 2016;10(2):118-21. doi:
674 10.4103/0973-6247.187940.

675 40. Izak M, Bussel JB. Management of thrombocytopenia. *F1000prime*
676 *reports* 2014;6:45. doi: 10.12703/p6-45.

677
678
679

Table 1: Demographic and clinical characteristics of the 20 patients with GBS included in this small volume plasma exchange (SVPE) study at entry

Characteristic	Value
Demography	
Sex [males: females (ratio)]	13:7 (1.85)
Age (years) [¶]	33 (18 - 55)
Body weight (kg) [¶]	60 (50 - 72)
Antecedent events [‡] (total)	18 (90%)
Diarrhoea	10 (50%)
Respiratory infection	5 (25%)
Fever	3 (15%)
Days from antecedent events to weakness [¶]	7 (3 - 30)
Days between onset of weakness to admission [¶]	7 (2-12)
Neurological deficits at entry	
Weakness in arms and legs	20 (100%)
Cranial nerve deficits	12 (60%)
Decreased deep tendon reflexes	20 (100%)
Sensory involvement	5 (25%)
GBS disability score [§]	4 19 (95%)
	5 1 (5 %)
Severity of weakness (MRC sum-score) [¶]	20 (0-29)
Autonomic dysfunction	11 (55%)

¶ Median (range); † increased protein level (> 45 mg/dL) in combination with CSF cell count < 50/μL; CSF = cerebrospinal fluid; NCS = nerve conduction study; ‡ symptoms of an infection in the four weeks preceding the onset of weakness; § GBS disability score (0 - 6) = 0: healthy state; 1: minor symptoms and capable of running; 2: able to walk 10 meters or more without assistance but unable to run; 3: able to walk 10 meters across an open space with help; 4: bedridden or chair-bound; 5: requiring assisted ventilation for at least part of the day; 6: dead.

689 Table 2: Treatment characteristics and complications associated with SVPE in the 20 patients
690 with GBS

Characteristic/complication	Value
Treatment characteristics	
Number of sessions of SVPE per patient ¶	30 (24 - 42)
Volume of plasma removed per patient ¶	8.4 (6.3 – 9.6)
Plasma exchange rate (mL/kg) ¶	140 (110-175)
Time between hospital admission and SVPE (days) ¶	8 (5-10)
Time between onset of weakness and start of SVPE (days) ¶	8 (5-10)
Need to stop SVPE due to poor hemodynamic tolerance	0/20 (0%)
Need for blood transfusion for anaemia	1/20 (5%)
Reduction of anticoagulant drug dose for bleeding	3/20 (15%)
Temporary withdrawal of antiplatelet drug for bleeding	4/20 (20%)
Increased anticoagulant drug dose to continue SVPE	1/20 (5%)
CVC blockade/replacement	0/20 (0%)
Complications during SVPE	
<i>Infection</i>	
Leukocytosis	7/20 (35%)
CLABSI §	6.25
VAP §	136.4
CAUTI §	40
Severe sepsis	1/20 (5%)
Antimicrobial agents used	6/20 (30%)
<i>Bleeding and coagulation</i>	
Bleeding from CVC insertion site	10/20 (50%)
Bleeding from mucosal area	3/20 (15%)
Prolonged BT (BT > 10 min)	0/20 (0%)
Prolonged CT (CT > 15 min)	0/20 (0%)
Prolonged PT (PT > 14 sec) ¶	6/20 (30%) [15-19 sec]

Prolonged aPTT (aPTT > 40 sec) ¶	3/20 (15%) [51-240 sec]
<i>Other complications</i>	
Saline responsive hypotension	10/20 (50%)
Anaemia (Hb < 8 gm/L)	2/20 (10%)
Thrombocytopenia (PC < 1.5 lac/μL) ¶	6/20 (30%) [0.79-1.3 lac/μL]
Jaundice (serum bilirubin > 1.2 mg/dL)	0/20 (0%)
Renal impairment (serum creatinin > 1.2 mg/dL)	0/20 (0%)
Hyponatraemia (serum Na ⁺ < 135 mEq/L)	1/20 (5%) [126 mEq/L]
Hypokalaemia (serum K ⁺ < 3.5 mEq/L) ¶	3/20 (15%) [2.6-3.2 mEq/L]
Hypoalbuminemia (serum albumin > 35 gm/L) ¶	4/20 (20%) [26-32 gm/L]
Hypocalcaemia (serum Ca ⁺ < 2.2 mmol/L) ¶	3/20 (15%) [1.89-1.98 mmol/L]
Hypomagnesaemia (serum Mg ⁺ < 75 mEq/L) ¶	1/20 (5%) [73 mEq/L]
Hypersensitivity/transfusion reaction to FFP	4/20 (20%)

691

692 ¶ Median (range); § rate per 1000 device days; CLABSI: central line-associated bloodstream
 693 infection; VAP: ventilator-associated pneumonia; CAUTI: catheter-associated urinary tract
 694 infection; CVC: central venous catheter; BT: bleeding time, CT: clotting time; PT: prothrombin
 695 time; APTT: activated partial thromboplastin time; FFP: fresh frozen plasma.

696

Table 3: Neurological outcomes of the 20 patients with GBS after SVPE

Clinical outcome	1 month	2 months	3 months	6 months
Cranial nerve involvement	7/20 (35%)	6/20 (30%)	4/20 (20%)	2/20 (10%)
Autonomic involvement	3/20 (15%)	3/20 (15%)	0/20 (0%)	0/20 (0%)
Sensory dysfunction	1/20 (5%)	1/20 (5%)	1/20 (5%)	1/20 (5%)
GBS disability score [¶]	0 = 0 1 = 3 2 = 9 3 = 2 4 = 3 5 = 3	0 = 1 1 = 6 2 = 6 3 = 1 4 = 5 5 = 1	0 = 1 1 = 7 2 = 6 3 = 1 4 = 5 5 = 0	0 = 2 1 = 7 2 = 5 3 = 3 4 = 3 5 = 0
MRC sum score [†] *	47 (0-60)	49 (0-60)	53 (6-60)	58 (22-60)
ONLS [‡] *	4 (1-12)	3 (0-12)	3 (0-12)	2 (0-10)
R-ODS [§] *	26 (0-41)	33 (0-45)	37 (0-45)	38 (0-46)

* Median (range); ¶ GBS disability score (0 - 6) = 0: healthy state, 1: minor symptoms and capable of running, 2: able to walk 10 meters or more without assistance but unable to run, 3: able to walk 10 meters across an open space with help, 4: bedridden or chair-bound, 5: requiring assisted ventilation for at least part of the day, 6: dead; † MRC sum score: Medical Research Council sum score; ‡ ONLS: Overall Neuropathy Limitation Scale²²; § R-ODS: Rash-built Overall Disability Score²³

Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS.

SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, ^A measured in litres, ●: spell of hypotension (systolic BP < 90 mm Hg), ○: CVC insertion site bleeding, ▲: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.

Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE ($n = 20$): twenty patients with GBS aged ≥ 18 -years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE ($n=20$): twenty-four patients aged ≥ 18 -years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * $p < 0.0001$.

Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.




Figure 1: Feasibility of SVPE and associated complications for the 20 individual patients with GBS. SVPE: small volume plasma exchange, HAI: hospital acquired infection, V: ventilator-associated pneumonia, B: central line-associated blood stream infection, U: catheter-associated urinary tract infection, A measured in litres, black dot: spell of hypotension (systolic BP < 90 mm Hg), empty drop: CVC insertion site bleeding, black triangle: hypersensitivity to fresh frozen plasma, shaded squares: pyrexia due to bacterial infection, dotted squares: pyrexia due to suspected viral infection, M: onset of mechanical ventilation, C: urinary catheterization.




Figure 2: Hospital-acquired infections and use of antibiotics in the 20 patients with GBS receiving SVPE compared to the 24 hospital control patients without GBS treated in an ICU with a CVC who did not receive SVPE.

■ SVPE (n = 20): twenty patients with GBS aged ≥ 18 -years-old who were bedbound (GBS disability score ≥ 4) received small volume plasma exchange (SVPE) within 2 weeks of the onset of weakness. □ Non-SVPE (n=20): twenty-four patients aged ≥ 18 -years-old with a diagnosis other than GBS who required a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period as the patients with GBS received SVPE; * $p < 0.0001$.





Figure 3: Kaplan-Meier estimate (with 95% confidence limits) of the cumulative incidence of restoration of independent walking ability in patients with GBS treated with SVPE.

Supplementary Figure: Hospital-acquired infections in the 20 patients with GBS treated with SVPE and the 24-hospital control patients without GBS.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

2017 CONSORT checklist of information to include when reporting a randomized trial assessing nonpharmacologic treatments (NPTs)*.
Modifications of the extension appear in italics and blue.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Title and abstract					
	1a	Identification as a randomized trial in the title	NA (Non-randomized)		
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4, 5	Refer to CONSORT extension for abstracts for NPT trials	3, 4, 5
Introduction					
Background and objectives	2a	Scientific background and explanation of rationale	6		
	2b	Specific objectives or hypotheses	6, 7		
Methods					
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7	When applicable, how care providers were allocated to each trial group	NA
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	No changes to methods after trial commencement		
Participants	4a	Eligibility criteria for participants	7, 8	When applicable, eligibility criteria for centers and for care providers	NA
	4b	Settings and locations where the data were collected	7		
Interventions†	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8	Precise details of both the experimental treatment and comparator	7, 8
	5a			Description of the different components of the interventions and, when applicable, description of the procedure for tailoring the interventions to individual participants.	9
	5b			Details of whether and how the interventions were standardized.	8, 9

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	5c.			Details of whether and how adherence of care providers to the protocol was assessed or enhanced	8, 9
	5d			Details of whether and how adherence of participants to interventions was assessed or enhanced	NA
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9		
	6b	Any changes to trial outcomes after the trial commenced, with reasons	No changes to trial outcomes after the trial commenced		
Sample size	7a	How sample size was determined	9	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	7b	When applicable, explanation of any interim analyses and stopping guidelines	10		
Randomization:					
- Sequence generation	8a	Method used to generate the random allocation sequence	NA (Non-randomized)		
	8b	Type of randomization; details of any restriction (such as blocking and block size)	NA (Non-randomized)		
- Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	NA (Non-randomized)		
- Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA (Non-randomized)		
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Blinding was not possible	If done, who was blinded after assignment to interventions (e.g., participants, care providers, those administering co-interventions, those assessing outcomes) and how	Blinding was not possible

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40-7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
	11b	If relevant, description of the similarity of interventions	7, 8		
	11c			If blinding was not possible, description of any attempts to limit bias	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10	When applicable, details of whether and how the clustering by care providers or centers was addressed	NA
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA		
Results					
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	11	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center	Single center study
	13b	For each group, losses and exclusions after randomization, together with reasons	No losses and exclusions after inclusion		
	13c			For each group, the delay between randomization and the initiation of the intervention	11
	new			Details of the experimental treatment and comparator as they were implemented	11-16
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7		
	14b	Why the trial ended or was stopped	NA (Trial completed)		
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.	NA
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	11-12		

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40–7.

Section/Topic Item	Checklist item no.	CONSORT item	Page no	Extension for NPT trials	Page no
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12-16		
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA		
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15		
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	12-15		
Discussion					
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20-21	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group	NA
Generalizability	21	Generalizability (external validity, applicability) of the trial findings	16-20	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial	16-20
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	16-20		
Other information					
Registration	23	Registration number and name of trial registry	4		
Protocol	24	Where the full trial protocol can be accessed, if available	Manuscript reference no: 17		
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	22		

*Additions or modifications to the 2010 CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials

†The items 5, 5a, 5b, 5c, 5d are consistent with the Template for Intervention Description and Replication (TIDieR) checklist

Cite as: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of Internal Medicine*. 2017 Jul 4;167(1):40-7.

Table: Required documents of the safety and feasibility study of the small volume plasma exchange (SVPE) for Guillain-Barré syndrome patients for the World Health Organization Trial Registration Data Set

	Item/Label	Description
1	Primary Registry and Trial Identifying Number	Clinicaltrials.gov NCT02780570
2	Date of Registration in Primary Registry	May 23, 2016
3	Secondary Identifying Numbers	International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Protocol Number: PR-15086, Version no. 3, Date: 09/12/2015
4	Source(s) of Monetary or Material Support	GBS/CIDP Foundation International Fondation Mérieux: (Small Grants Program 2015)
5	Primary Sponsor	GBS/CIDP Foundation International
6	Secondary Sponsor(s)	Fondation Mérieux: (Small Grants Program 2014)
7	Contact for public queries	MD. BADRUL ISLAM Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam

		Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
8	Contact for scientific queries	MD. BADRUL ISLAM Principal Investigator (PI) Email: bislamdmch@gmail.com Telephone no: +880 1712 89 0172 Postal address: Dr. Badrul Islam Research trainee and PhD Fellow Laboratory Sciences and Services Division (LSSD) Icddr,b Dhaka, Bangladesh
9	Public title	Small volume plasma exchange for Guillain-Barré syndrome
10	Scientific title	Small volume plasma exchange for Guillain-Barré syndrome in low-income countries: a safety and feasibility study
11	Countries of Recruitment	Bangladesh
12	Health condition(s) or problem(s) studied	Guillain-Barré syndrome (GBS)
13	Interventions	<u>Small Volume Plasma Exchange (SVPE)</u> A loading dose of low-molecular weight heparin (1.5 mg/kg) will be given subcutaneously at least two hours

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

before initiation of SVPE; the same dose will be administered once daily or divided into two equal doses daily for eight days or until SVPE is completed. Whole blood (7 mL/kg body weight) will be drawn from the central venous catheter into the blood transfusion bag in each session. The blood bag will be hung beside the patient for 2.5 h on a saline stand and left uninterrupted to allow plasma and blood cells to separate. The blood cells will be infused back into the patient and plasma will be discarded and replaced with fresh frozen plasma and colloid solution alternately (in equal volumes) via the closed-circuit SVPE kit illustrated in. In case of excessive clotting (bleeding time reduction of > 50% of baseline for that patient), aspirin (600 mg) will be administered orally at least two hours before the next SVPE session and continued thereafter at 150 mg orally/day until SVPE is completed. One blood bag will be used each day, with a total of six sessions/day. A total of 48 sessions will be performed over eight days, removing approximately 8000 mL plasma in total.

Central venous catheterized patients without GBS

To compare the safety of SVPE in patients with GBS in the context of the background risk of central line-associated blood stream infection (CLABSI) at the study intensive care (ICU) and high-dependency care (HDU) units, the incidence of CLABSI will be assessed in a control group of adult patients with a diagnosis other than GBS admitted to the same ICU and HDU units in the same period of time the patients with GBS will be enrolled for SVPE. We will assess the rate of CLABSI in

		patients aged ≥ 18 -years-old requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units.
14	Key Inclusion and Exclusion Criteria	<p><u><i>Inclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old fulfilling the diagnostic criteria for GBS of the National Institute of Neurological and Communicative Disorders and Stroke (NINDS) 2. Unable to walk unaided for more than 10 meters (GBS disability score ≥ 3) 3. Presented within 2 weeks of the onset of weakness 4. Unable to afford standard treatment with IVIg or PE. <p><u><i>Exclusion criteria for SVPE in GBS patients</i></u></p> <ol style="list-style-type: none"> 1. Patients with severe or terminal concomitant illness 2. Evidence of healthcare-associated infection on admission (except for aspiration pneumonia) 3. Previous history of severe allergic reaction to properly matched blood products and pregnant women will be excluded from the study. <p><u><i>Inclusion criteria for patients without GBS</i></u></p> <ol style="list-style-type: none"> 1. Patients aged ≥ 18-years-old 2. Requiring a CVC for > 2 to ≤ 8 calendar days after admission to the same ICU and HDU units in the same period of time the patients with GBS enrolled for SVPE. <p><u><i>Exclusion criteria for patients without GBS</i></u></p>

		<div>1. Patients with healthcare-associated infection present on admission (except aspiration pneumonia)</div> <div>2. Pregnant women</div>
15	Study type	<div><u>Type of the study</u>: Interventional</div> <div><u>Method of allocation</u>: Non-randomized</div> <div><u>Masking</u>: Non-masked</div> <div><u>Assignment</u>: Parallel arm</div> <div><ul style="list-style-type: none">SVPE in patients with GBSRate of CLABSI in patients without GBS</div> <div><u>Purpose</u>: Safety and feasibility of SVPE</div>
16	Date of first enrolment	February 20, 2016
17	Target sample size	<div>SVPE in patients with GBS = 20</div> <div>Rate of CLABSI in patients without GBS = ≥ 20</div>
18	Recruitment status	<div>Completed:</div> <div><ul style="list-style-type: none">Twenty cases of GBS have been successfully treated with SVPE and 24 control cases without GBS have been recruited.</div>
19	Primary Outcome(s)	<div><u>Primary outcome of safety</u>:</div> <div><div>1. Number of patients with GBS treated with SVPE developing severe sepsis or septic shock due to central line associated blood stream infection (CLABSI) as per standard guideline (Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection); CDC Device-associated Module, BSI. January 2017)</div><div>2. Occurrence of venous thrombosis in the limb</div></div>

		<p>where the CVC is placed. Venous thrombosis will be assessed according to Wells criteria (<i>Philip S. Wells et al. Evaluation of d -Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis; N Engl J Med 2003;349:1227-35</i>)</p> <p><u>Primary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Ability to remove at least eight litres of plasma by SVPE over eight days.
20	Secondary Outcome(s)	<p><u>Secondary outcome of safety:</u></p> <ol style="list-style-type: none"> 2. Relative risk of CLABSI due to SVPE compared to CLABSI in control patients without GBS treated using a CVC 3. Hemodynamic instability during the SVPE procedure (variations in systolic blood pressure greater than 30 mmHg or sudden bradycardia involving a reduction in heart rate by more than 20 beats per min within 30 min of starting SVPE or an increase in heart rate above 120 beats per min) 4. Development of anaemia (Hb <7 gm/dL) or serious haemorrhage requiring blood transfusion. <p><u>Secondary outcome of feasibility:</u></p> <ol style="list-style-type: none"> 1. Rate of CVC occlusion during the SVPE procedure 2. The healthcare personnel's acceptability and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		<p>satisfaction with the SVPE procedure and any unanticipated events compromising the SVPE procedure as assessed using a standard questionnaire.</p> <p>3. Neurological outcome will be assessed in terms of improvement in GBS disability score and MRC sum score at discharge and up to 4 weeks after entry.</p>
--	--	--